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ABSTRACT 
 Elevated plasma concentrations of lipoprotein(a) (Lp(a)) have been identified as a 
causal risk factor for calcific aortic valve disease (CAVD) and coronary heart disease 
(CHD). Relationships have recently been identified for genetic factors, such as single 
nucleotide polymorphisms (SNPs) in the LPA gene, specifically r10455872 and rs3798220, 
that have been correlated with increased Lp(a) plasma levels and risk of cardiovascular 
disease (CVD). Apo(a) bears striking homology with the zymogen plasminogen and 
possesses several similar structural features. A key feature shared between these proteins 
is the presence of multiple repeats of a kringle domain, which possesses the ability to bind 
to exposed lysine residues with high affinity. Apo(a) contains several copies of a 
plasminogen like KIV domain, one of which, KIV10, has been implicated in many 
proinflammatory processes in vitro. It has been hypothesized that the proinflammatory 
potential of Lp(a)/apo(a) is derived from the ability to be covalently modified by an 
oxidized phosphatidylcholine (oxPC) moiety. The work in this dissertation assesses the 
mechanism by which the oxPC moiety on apo(a) stimulates interleukin-8 (IL-8) production 
in macrophages. Targeted mutagenesis was used to determine a role for the KIV10 strong 
lysine binding site (sLBS) in the covalent addition of the oxPC moiety on apo(a) and 
identified histidine 33 of KIV10 as the site of covalent oxPC modification. Furthermore, 
characterization of the I4399M variant of apo(a), resulting from the rs3798220 SNP, from 
a perspective of its distinct structural and functional properties, revealed roles for the 
polymorphism on the structure and permeability of purified fibrin and plasma clots. The 
enhanced prothrombotic potential of this variant may be a result of an oxidized methionine 
residue, as identified by mass spectrometry. The identification of distinct functional 
 vii 
properties associated with the oxidative modification of Lp(a)/ apo(a) offers insights into 
its proatherosclerotic and prothrombotic potentials. 
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General Introduction 
  
	
 
 
 
 
 
2 
1.1 LIPOPROTEIN(a) 
Lipoprotein(a) (Lp(a)) was discovered in 1963 by Kåre Berg and constitutes a 
distinct class of lipoprotein particle found within the human plasma.1, 2 Lp(a) contains a 
lipoprotein moiety that is essentially indistinguishable from low density lipoprotein (LDL); 
and contains a cholesteryl ester and triglyceride rich core, a cholesterol/phospholipid outer 
monolayer) as well as apolipoprotein B100 (apoB100). However, Lp(a) is clearly 
distinguished from LDL by the presence of a unique glycoprotein, apolipoprotein(a) 
(apo(a)), that is covalently linked to apoB100 by a single disulfide bond (Figure 1.1).3, 4 The 
apo(a) moiety is a hydrophilic component due to its immense level of glycosylation with 
carbohydrates accounting for approximately 28% of the total mass of the molecule, and 
also lacks the large hydrophobic sequences usually observed in lipoproteins.5 In 1987, 
analysis of the human liver apo(a) cDNA sequence identified a striking similarity of apo(a) 
to the fibrinolytic plasma proenzyme plasminogen.6 Although the physiological function(s) 
of Lp(a) have not yet been fully elucidated, studies within the past 8 years have identified 
Lp(a) as a causal risk factor for coronary heart disease (CHD) [reviewed in ref. 7].  There 
is now evidence to suggest that Lp(a) may be the strongest genetic risk factor for CHD 
[Reviewed in ref. 8]. Recently, a causal relationship was described between elevated 
plasma Lp(a) levels and calcific aortic valve disease (CAVD) 9, 10 
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Figure 1.1 Representation of the structure of Lp(a). 
Lipoprotein(a) (Lp(a)) is a distinct lipoprotein class that is similar to LDL in lipid 
composition and presence of apolipoproteinB-100 (apoB-100), but is distinguished from 
LDL by the presence of apolipoprotein(a) (apo(a)). The LDL-like moiety is composed 
of a triglycerides (TG) and cholesteryl esters (CE) core, surrounded by an outer 
monolayer of phospholipids (PL) and free cholesterol (FC). Apo(a) consists of multiple 
copies of a plasminogen-like kringle IV (KIV) domain, followed by a single copy of 
each of the plasminogen-like kringle V (KV) and a protease (P) domains. KIV domains 
in apo(a) can be further classified into 10 distinct subtypes (KIV1 to KIV10) based on 
amino acid sequence with the number of identically repeated KIV2 domains varying in 
the population from 3 to >30. Lysine binding sites (LBSs) in KIV7 and KIV8 play a key 
role in non-covalent association with two lysine residues in the amino-terminal region 
of apoB-100. This initial non-covalent interaction between apo(a) and apoB-100 
facilitates disulfide bond formation between a free cysteine in KIV9 of apo(a) and apoB-
100.4 Adapted from reference 4.	
	
	
	
 
 
 
 
 
4 
Although the duality of the structure of this molecule, with similarities to both LDL 
and plasminogen, suggests that Lp(a) can elicit both proatherogenic and prothrombotic 
effects within the vasculature, there have been many potential pathophysiological roles 
proposed for Lp(a) that cannot be attributed to either the LDL or plasminogen-like 
components alone.  
 Circulating levels of plasma Lp(a) vary widely within the population, from nearly 
undetectable to greater than 100 mg/dL. The primary determinant of Lp(a) levels is the 
LPA gene itself, attributing for ~90% of Lp(a) plasma concentration.11 The size of the LPA 
gene, as determined by the number of sequences encoding the KIV2, accounts for 
approximately 69% of this variation, while 22% of the genetic variability in plasma Lp(a) 
levels is attributed to cis-acting sequences in the gene that are yet to be fully understood 
(reviewed further in Section 1.1.4).11 Relationships have recently been identified for single 
nucleotide polymorphisms (SNPs), rs10455872 and rs3798220, in the LPA gene.12 In 
general, an inverse correlation exists between apo(a) size and circulating Lp(a) levels, with 
small isoforms present in much higher concentrations than larger isoforms.13, 14 This is 
explained at least in part by the inability of larger isoforms to be secreted from hepatocytes 
at the same rate as smaller isoforms.14 It was determined that due to the complex folding 
required by multiple kringle domains, more time is required to properly fold an apo(a) 
molecule that contains a larger number of KIV domains. This results in an increase in 
endoplasmic reticulum (ER) retention time leading to ER assisted degradation, and thus 
lower amounts of secreted protein.15 It is important to note that plasma levels of Lp(a) are 
dictated primarily by their rate of production and not by the efficiency by which they are 
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removed from circulation.16 The specific pathways for Lp(a) catabolism are controversial, 
and the extent to which they contribute to Lp(a) plasma levels in both normal and disease 
states remains unclear.17 
New drug therapies developed to specifically lower Lp(a) levels are currently under 
investigation. Antisense oligonucleotide (ASO) therapy targeting apo(a) is currently in 
Phase II clinical trials.18 All currently available methods of lowering plasma Lp(a) levels 
also affect levels of other lipoproteins as well, as reviewed in Section 1.1.7.  Thus, it has 
been difficult to assess whether lowering Lp(a) plasma concentrations reduces risk for 
CHD or other atherothrombotic disorders. A comprehensive understanding of the 
pathophysiological molecular mechanisms through which Lp(a) contributes to the 
progression of atherogenesis is currently lacking.19 This has precluded the development of 
therapeutic strategies aimed at reducing the harmful effects of Lp(a) in the vasculature. 
1.1.1 Structure of Lp(a) 
 Lipoprotein(a) presents as a unique lipoprotein particle identical to LDL with the 
exception of the unique glycoprotein apolipoprotein(a). Apo(a) bears striking homology to 
the human plasma zymogen plasminogen and possesses many of the same key features.2 
Plasminogen, in its proenzyme form, contains a short tail domain (T), followed by five 
sequential copies of a structural domain known as a kringle. These kringles vary in amino 
acid sequence from one another, and are annotated as kringle 1 (KI) to kringle 5 (KV). 
Following the kringle domains is a trypsin-like serine protease domain (P), which can be 
cleaved by urokinase plasminogen activator (uPA) or tissue-type plasminogen activator 
(tPA) resulting in the active fibrinolytic enzyme plasmin (Figure 1.2). Apo(a) contains ten 
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subtypes of a plasminogen-like kringle IV (KIV) domain, each present in a single copy, 
with the exception of apo(a) KIV2 which can be present in a variable number of identically 
repeated copies (from less than 3 to greater than 30 identical copies; Figure 1.2).These 
kringle domains are annotated as kringle IV subtypes one through ten (KIV1-KIV10), and 
are connected in tandem by serine-, threonine-, and/or proline-rich inter-kringle 
polypeptide linkers.20 Carboxyl-terminal to the KIV domains, apo(a) possesses domains 
that are highly similar to the plasminogen KV and protease domains (Figure 1.2). The 
protease-like domain in apo(a) has been rendered inactive by amino acid substitutions that 
convert the Arg-Val cleavage motif, recognized by plasminogen activators, to a Ser-Ile 
sequence, as well as a 9 amino acid deletion near the domain terminus.21  
1.1.2 Lysine-binding properties of apo(a)  
 Kringle domains are present in many important proteins in the coagulation and 
fibrinolysis cascades, such as plasminogen, prothrombin, tPA, and Factors VII, IX, and X. 
In the case of plasminogen, the high affinity of kringle domains to exposed lysine residues 
allows plasminogen to interact with its ligands, such as fibrin. These binding interactions 
serve to act as a means to accelerate the activation of plasminogen to plasmin, and allow 
plasmin to act on its fibrin substrates.22 The possession of lysine binding kringle domains 
is essential for the ability for plasmin to be generated and to dissolve fibrin clots. These 
structural kringle motifs are defined by a tri-looped structure consisting of approximately 
80 amino acids, containing three invariant intramolecular disulfide bonds and are largely 
considered to function as protein binding domains.23 The kringle domains within apo(a) 
vary in amino acid sequence and thus can possess distinct functional features. For example, 
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Figure 1.2 Structural similarities between plasminogen and apo(a). 
Plasminogen consists of an amino terminal tail sequence (T) followed by five kringle 
domains (KI-KV) and a serine protease domain (P). Apo(a) contains a number of 
repeated domains which are highly similar to that of plasminogen kringle IV (KIV), 
followed by single copies of a plasminogen kringle V (KV) and protease-like (P) 
domains. Kringle IV domains of apo(a) can be grouped into 10 distinct types on the basis 
of amino acid sequence with each present in a single copy except for KIV type 2 (KIV2). 
The number of KIV2 domains ranges from 3 to greater than 30 identically repeated copies 
which gives rise to the Lp(a) isoform size heterogeneity observed in the population. 
Unlike plasminogen, the protease domain of apo(a) is catalytically inactive. The weak 
lysine binding sites (LBS) and strong LBS of apo(a) (indicated with circles and asterisks 
respectively) are important for many interactions between apo(a) and biological 
substrates. The cysteine (SH) present in KIV9 of apo(a) is required for disulfide bond 
formation to the C-terminal region of apoB-100.2 Adapted from reference 4. 
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apo(a) KIV5-8 each possess “weak” lysine binding properties based on their ability to bind 
to the lysine analog e-aminocaproic acid (e-ACA). The weak lysine binding sites (LBS) in 
KIV types 7 and 8 have been shown to mediate the non-covalent association of apo(a) with  
apoB100 that precedes disulfide bond formation between the unpaired cysteine in apo(a) 
with apoB-100.24, 25 The apo(a) KV domain also contains a weak lysine binding site and 
may play roles in endothelial cell tube formation and fibrin binding.26-28 The KIV10 domain 
possesses the greatest similarity with plasminogen KIV and contains a relatively strong  
lysine binding site (sLBS).29 This feature of KIV10 has been implicated in the ability of 
apo(a) to bind to exposed lysine residues on different substrates, such as fibrin and cell 
surface receptors and has been implicated in potential prothrombotic functions of apo(a).30 
Additionally, the sLBS in apo(a) has been implicated in vascular cell function.31-36 
The structure of the lysine binding site has been well defined and generally consists 
of a hydrophobic trough that forms an indentation on the surface of the kringle; this trough 
is lined with hydrophobic amino acids and contains both a cationic and an anionic cluster 
at either end.37 Overall, it has been determined that in apo(a) KIV10 the lysine binding 
pocket requires seven specific amino acids composing the hydrophobic trough (Trp60, 
Phe62 and Trp70 ), cationic centre (Asp54 and Asp56) and anionic centre (Arg35 and Arg69),  
in order to maximally bind to lysine or lysine analogs (Figure 1.3).24, 29 Due to differences 
in the amino acid sequences of each apo(a) kringle domain, there are different theoretical 
and reported affinities for lysine and lysine analogues for each domain.26, 29 For example, 
the KIV5 LBS shares much homology to plasminogen KI but lacks a cationic centre and is 
predicted to have a reduced affinity for lysine.38 X-ray crystallographic modelling of KIV7 
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revealed a smaller LBS when compared to KIV10, resulting from mutations of the critical 
residues Asp56 and Tyr62 in the LBS to Glu and Phe respectively.39, 40 The Asp56 à Glu 
substitution is also present in KIV5-8. A functional analysis of the KIV7 binding domain 
reported a 10-fold decrease in the ability to bind lysine when compared to KIV1029; these 
differences in affinity to lysine underlie important functional differences that have been 
reported in these apo(a) KIV domains.41 KIV9 does not contain the necessary requirements 
for an intact LBS and possesses very low affinity for lysine.42 However this domain is 
unique in that it contains the only unpaired cysteine residue in the entire apo(a) molecule.43 
Using site directed mutagenesis, it was determined that this residue is responsible for the 
disulfide bond formation with the apoB100 component of LDL.3   
Each KIV sequence also includes an interkringle region that bridges each distinct 
domain. These polypeptide linkers are approximately 30 amino acids in length and are the 
location of the potential O-linked glycosylation sites on apo(a) due to the high Ser/Thr 
content of these sequences.20 There is also at least one N-linked glycosylation site within 
each KIV domain.44  Together, the O-and N-linked carbohydrates contribute approximately 
28% of the mass of an apo(a) molecule, are rich in sialic acid, are heterogeneous in total 
carbohydrate content and are important for secretion of apo(a).5, 44-46  
The complex nature of the structure of Lp(a) allows it to be a multi-ligand binding 
protein. In particular, the lysine binding potential of the apo(a) moiety has been implicated 
in many pathophysiological processes, both antifibrinolytic and proatherosclerotic.47, 48  
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1.1.3 Species Distribution of LPA 
 The gene encoding apo(a), LPA, resides on chromosome 6q26 and originated as a 
consequence of a gene duplication and remodeling event of PLG, the gene encoding 
plasminogen.6, 49 The PLG gene is ubiquitous across all species, however LPA appeared 
late in primate evolution following the divergence of New and Old World monkeys 
approximately 80 million years ago.49 As such, Lp(a) is only present in humans, apes, and 
Old World monkeys. The European hedgehog also contains an Lp(a)-like particle. 
However, hedgehog apo(a) is composed of multiple repeating copies of a plasminogen-like 
KIII domain.49 This likely represented an independent PLG duplication event, distinct from 
the one that gave rise to human Lp(a).49 
  Analysis of the non-human primate LPA gene has yielded many insights into how 
sequence variations in the apo(a) KIV10 sequence can influence the lysine binding function. 
It is apparent that during the evolution of Lp(a) in apes and monkeys, the lysine binding 
properties of KIV10 were lost as a result of mutations distinct to each species; this is 
summarized in Table 1.1. A comparative analysis of rhesus monkey apo(a) cDNA with 
human liver cDNA revealed a similar structure with a series of plasminogen-like KIV 
domains immediately followed by a proteolytically inactive plasminogen-like protease 
domain.50 As such, rhesus monkey Lp(a) lacks the KV domain. It was also identified that 
rhesus monkey apo(a) lacks a functional KIV10 LBS as a result of a Trp70 à Arg mutation 
in the lysine binding pocket.31 Interestingly, this polymorphism has also been reported to 
be present in approximately 2% of the human population.51 It was later determined that 
cynomologous monkeys share almost identical apo(a) domain organization with that of  
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Figure 1.3 The Structure of the lysine binding site in apo(a) KIV10 
The lysine binding site in apo(a) KIV10 consists of seven critical amino acids collectively 
forming a hydrophobic depression in the surface of the domain with cationic and anionic 
centers. The following amino acids have been designated as critical for optimal lysine 
binding function; Arg35, Asp54, Asp56, Trp60, Phe62, Arg69, and Trp70. Amino acids 
composing the; hydrophobic trough are indicated in fuschia; cationic centre are indicated 
in blue; and anionic centre in red. 
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rhesus monkeys, in that they both lack KV and possess the same LBS destabilizing 
mutation.52 Analysis of baboon apo(a) also reported a significantly reduced ability to bind 
lysine-Sepharose and partially degraded fibrin; this was speculated to be due to 
conformational changes arising from the lack of a KV domain in these animals.26 Unlike 
rhesus monkey apo(a), baboon apo(a) has all KIV10 amino acids required for lysine 
binding; interestingly, a Trp to Arg polymorphism has been reported at position 70, which 
corresponds to a minor allele in baboons.26 The lack of ability of baboon KIV10 to bind to 
lysine despite the presence of an intact LBS highlights a potential role for KV in providing 
a conformation of the protein that facilitates the lysine binding function of KIV10. In 
another study, chimpanzee apo(a) was assessed for its ability to bind to intact and plasmin-
degraded fibrin. It was determined that an Asp56 à Asn mutation disrupts the sLBS in 
KIV10.53 This mutation is also present in gorilla.52 The orangutan is the only reported 
species to maintain all of the amino acids required for the sLBS as well as a KV domain 
although  Lp(a) from this species has not been isolated and studied.52 It is intriguing that 
all species of Old World monkeys and apes, with the exception of the orangutan, have 
converged on a similar motif of inactivation of the KIV10 lysine binding ability, the 
advantages that may result from this remain to be determined. 
1.1.4 Determinants of Plasma Lp(a) Concentration 
With plasma Lp(a) levels ranging so widely within the population there has been much 
debate about whether synthesis, assembly, or clearance pathways ultimately dictate Lp(a) 
concentration. Apo(a) is synthesized and secreted primarily in hepatocytes.54 The 
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Table1.1 Comparison of the structure and function of multiple species of apo(a) 
 
 
Table 1: Comparison of the structure and function of the KIV, V and protease-like domains 
of human apo(a) with apo(a) from Old World monkeys and apes A. Summary of the 
properties of KIV, KV and protease-like domains present in various species of apo(a). The 
potential of these variants to bind fibrin is a measure of their lysine binding ability. Species 
that have been directly assessed for their ability to bind to lysine or lysine analogs are 
annotated with an asterisk. B. Summary of the differences in amino acid sequence of the 
lysine binding site in humans, Old World monkeys, and apes 
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determinants of the level of Lp(a) in the plasma can be seen at the level of transcription, 
secretion, assembly, and catabolism. 
With respect to the synthesis of apo(a), relatively little is known about factors that 
can modulate LPA expression. A number of studies have reported the ability of sex 
hormones to modulate Lp(a) levels. For example, in men with prostate cancer and receiving 
high dose estrogen therapy, Lp(a) levels were lowered by approximately 50%.55 Similar 
effects on Lp(a) levels have been reported in postmenopausal women on estrogen 
replacement therapies, albeit to a lesser extent (~15-50% lowering).56-58 A subsequent 
study showed that estrogen/tamoxifen treatment in transgenic apo(a) mice lowered hepatic 
LPA mRNA levels, as well as corresponding plasma apo(a) concentations.59 Although the 
mechanism by which estrogens can lower apo(a) synthesis is unknown (no estrogen 
response elements have been identified in the LPA promoter) it has been hypothesized to 
be an indirect effect caused by the gene expression changes caused by estrogen.60 Since the 
LPA promoter does contain interleukin 6 (IL-6) sensitive sites, it is possible that there may 
be some cytokine regulation of apo(a) encoding mRNA.61 Wade et al. reported an 
approximately 5-fold enhancement in LPA reporter gene activity in HepG2 cells when 
exposed to IL-6.62 A negative farnesoid X receptor (FXR) response element was also 
detected in the promoter region of the gene.63 It is possible that bile acids can bind to this 
sequence and downregulate apo(a) mRNA levels, though this is yet to be investigated. 
Several single nucleotide polymorphisms (SNPs) and other sequence variations, 
whether inside or adjacent to the gene, have been shown to effect LPA gene size and 
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potentially plasma Lp(a) concentration. Such sequence variants are a pentanucleotide 
repeat polymorphism (TTTTAn) in the 5’-flanking region, though there is no influence for 
transcriptional regulation through this motif64, 65, and several SNPs that exist within the 
gene sequence.66, 67 Clarke and colleagues have recently identified an association with 
SNPs rs3798220 and rs10455872, with elevated Lp(a) levels and CHD.12  Several null LPA 
alleles have also been reported, that result in sequence truncation, thus not giving rise to an 
apo(a) protein.68, 69  
The involvement of cis-acting sequences in the transcription of LPA mRNA 
remains to be thoroughly investigated, with the exception of the effect of the quantity of 
KIV2 repeats within the polypeptide sequence. Once translated, depending on the number 
of repeating KIV domains, apo(a) can be subjected to ER retention and possibly targeted 
for ER assisted protein degradation. Using steady state radiolabeling of primary baboon 
hepatocytes, White et al. determined that post-translational processing of apo(a) is a 
significant factor in Lp(a) production.70, 71The ultimate result of these studies was that 
smaller apo(a) molecules are synthesized and secreted at a faster rate than larger isoforms.72 
Interestingly, in individuals that are heterozygous for apo(a) isoform size, dominance is 
not always associated with the small apo(a) allele. Recent evidence suggests that size of 
the apo(a) allele not only effects plasma levels of that corresponding isoform, but also the 
levels of the other expressed apo(a) molecule.73, 74 
 The vast majority of apo(a) in plasma is present in Lp(a) particles, with very low 
levels of free apo(a) detectable in plasma.75 This has been interpreted to suggest either rapid 
clearance of free apo(a), or highly efficient Lp(a) particle formation. Lp(a) assembly occurs 
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though a two-step mechanism, the first of which is the association of the weak LBS in 
apo(a) KIV types 7 and 8 with surface-exposed lysine residues in the amino terminus of 
apoB100.76, 77 There remains controversy, however, as to the location of covalent Lp(a) 
formation. Although there is a large body of evidence to suggest that the process of Lp(a) 
assembly occurs extracellularly, there are several studies that report the identification of 
covalent Lp(a) particles intracellularly.78-80 In one report using baboon hepatocytes, it was 
suggested that Lp(a) can be assembled on the cell surface.81 Support for extracellular 
assembly of Lp(a) has been provided by studies showing that an oxidase activity present 
in the medium of cultured hepatoma cells can significantly enhance covalent Lp(a) 
formation.82 In in vitro studies, in the absence of this enzymatic activity, spontaneous 
covalent linkage of the apo(a) and apoB-100 components of Lp(a) progresses extremely 
slowly despite the efficiency of the initial non-covalent interaction.82 It has also been 
reported that apo(a) supports a more open conformation when bound to lysine analogs, 
making it a better substrate for covalent bond formation.82 As such, lysine-dependent 
binding of non-covalent apo(a)-apoB-100 complexes to cell surface receptors such as 
plasminogen receptors may represent a plausible mechanism by which apo(a) can adopt a 
conformation that accelerates covalent association with apoB-100.  Taken together, it can 
be hypothesized that non-covalent interactions occur intracellularly, but covalent bond 
formation requires the cell surface and extracellular oxidase activity for optimal covalent 
Lp(a) formation. 
 The clearance of Lp(a) from the circulation has been under investigation for 
decades.19 Several studies have reported a major role for the liver in the clearance of 
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Lp(a)83; a possible role for the kidney in Lp(a) catabolism has also been proposed. The 
latter stems from studies reporting that patients with renal disease have significantly 
elevated Lp(a) levels.84, 85 This work was further addressed in an in vivo study reporting 
that the increases observed in Lp(a) plasma levels in hemodialysis patients were solely due 
to a decreased catabolic rate.79  
In a powerful isotopic labelling study in humans, it was determined that Lp(a) levels 
are determined at the level of production rather than clearance, as there was no difference 
in the catabolic rates of large and small isoforms yet it is well established that they are 
synthesized at different rates.16 It has been speculated over the years that Lp(a) catabolism 
can occur through different receptors, which is in keeping with the duality of its structure. 
The role of the low density lipoprotein receptor (LDLR) in Lp(a) catabolism has been a 
recurring question in the field of Lp(a) research, with evidence both for and against its 
involvement.19 Evidence suggesting strongly against a role for the LDLR in Lp(a) 
clearance is the lack of ability of statins to significantly modulate Lp(a) levels.86 Statins 
are HMG-CoA reductase inhibitors that cause an increase in the hepatic cell surface 
abundance of the LDLR, resulting in a significant decrease in plasma LDL levels.87 Since 
statin therapy has little effect on Lp(a) levels, this has been interpreted to suggest that the 
LDL moiety of Lp(a) does not interact with the LDLR, perhaps due to steric hindrance by 
apo(a). It has been shown that exogenous apo(a) can effectively compete for the clearance 
of radiolabeled Lp(a) in mice. This suggests that an apo(a) receptor is primarily responsible 
for Lp(a) catabolism.83 However, transgenic LDLR overexpressing mice were able to clear 
Lp(a) much more rapidly than wildtype, suggesting that the LDL moiety of Lp(a) may be 
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a ligand for this receptor.88 The role of the LDLR has recently been under investigation 
once again in the context of the development of inhibitors of proprotein convertase 
subtilisin/kexin type 9 (PCSK9).89 PCSK9 is a furin-like enzyme which is secreted in an 
inactive form, primarily from the liver.90 It has been demonstrated that PCSK9 can bind to 
the LDLR and target it for intracellular degradation.91 As such, increasing LDLR levels by 
inhibition of PCSK9 has become a viable therapeutic strategy to significantly lower plasma 
LDL in vivo (see section 1.1.5).92 In addition to lowering of plasma LDL levels by up to 
70%, PCSK9 inhibitors have been found to consistently lower Lp(a) levels by 
approximately 30%.93  Evidence from our group94 and others92 suggest that under 
conditions of PCSK9 inhibition, the combination of low levels of competing LDL with a 
very high LDL receptor number result in the ability of the LDLR to internalize and degrade 
Lp(a). This has been a point of controversy in the field, particularly since some have failed 
to show a relationship in clinical studies between PCSK9-mediated LDL lowering and 
Lp(a) lowering, suggesting no role for the LDLR in Lp(a) catabolism.95  
Under normal physiological conditions, the majority of Lp(a) is likely cleared 
through a receptor(s) that recognizes and binds to apo(a). In this regard, there have been 
reports of the existence of different receptors with the ability to bind Lp(a). In early studies, 
Tam et al. reported the presence of both low and high affinity apo(a)/Lp(a) receptors on 
the hepatic cell surface, with the low affinity component corresponding to plasminogen 
receptors that are capable of binding to the apo(a) component of Lp(a) in an ε-ACA-
dependent manner 96 Recently it was reported that scavenger receptor-BI (SR-BI) deficient 
mice had significantly lower rates of Lp(a) clearance. However, >60% of Lp(a) was cleared 
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from circulation within 24 hours, thus only a minor role was determined for SR-BI.97 
Furthermore it was reported that the ability of Lp(a) to be a ligand for SR-BI is mediated 
by the presence of oxidized phospholipids (oxPLs) on Lp(a), rather than through its protein 
components.98 With strong evidence for multiple receptors that can contribute to Lp(a) 
catabolism, the identification of the primary route for Lp(a) clearance in vivo remains to be 
determined. It is also worthwhile to note that roles for specific receptor pathways may vary 
in different physiological/pathophysiological settings. 
1.1.5 The Role of Inflammation in Atherosclerosis and Atherothrombosis  
Atherosclerosis is a progressive disease that is characterized by the accumulation 
of lipids and fibrous components within the walls of large arteries.99 Atherosclerotic 
diseases are the leading cause of death in the industrialized world.100 Atherogenesis is a 
complex pathophysiological process driven by responses to inflammation. The initiation 
of atherosclerotic plaque formation is caused by local inflammation in response to damage 
to the endothelial cell (EC) layer of the artery. Endothelial injury can be triggered by 
consuming a high saturated-fat diet, smoking, hypertension, mechanical trauma, 
hyperglycemia, obesity, or insulin resistance.101 This ultimately leads to cellular stress and 
endothelial cell dysfunction.102 The initial injury can also play a longer, sustained role in 
plaque development, which is primarily mediated by endothelial cells (ECs) as well as 
smooth muscle cells (SMCs), platelets, lymphocytes, monocytes, and macrophages. This 
is followed by the release of a broad array of cytokines, growth factors, proteases, and 
reactive oxygen species (ROS) from this group of cells within a developing lesion.103  
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Under normal conditions, ECs are anti-coagulant, anti-inflammatory, and function 
as a permeability barrier between the subendothelial space and the flowing blood in the 
lumen of the vessel.104 The endothelium serves many homeostatic functions such as nitric 
oxide (NO) production and resistance to the adhesion of other cells.105 However, EC 
damage can result in a proinflammatory state of the ECs and leaking of the components of 
blood into the intimal space. This damage usually occurs in areas that are prone to 
hemodynamic strain, such as the branch points of arterial vessels.106 In a proinflammatory 
state, ECs will begin to upregulate chemokines, cytokines, and cell adhesion molecules 
(CAMs) such as vascular cell adhesion molecule 1 (VCAM-1), P-Selectin, E-Selectin, and 
intracellular cell adhesion molecule 1 (ICAM-1).102 These CAMs, particularly VCAM-1, 
allow for the recruitment and attachment of leukocytes to the arterial wall. Oxidized LDL 
(oxLDL) can be internalized by the lectin-like oxidized LDL receptor (LOX-1) that is 
expressed throughout the vasculature of hypertensive, diabetic, and dyslipidemic 
individuals.107 LOX-1 is also expressed on SMCs, monocytes and macrophages and has 
been proposed as a potential biomarker for cardiovascular diseases.108 Oxidized LDL 
(oxLDL)  can either directly or indirectly increase CAM expression; the latter occurs 
through decreasing endothelial nitric oxide synthase (eNOS) expression and nitric NO 
levels, which can also be an effector of CAM expression via NF-κB.109  
The secretion of chemokines such as monocyte chemoattractant protein-1 (MCP-
1) and interleukin-8 (IL-8) by intimal cells (ECs and VSMCs) causes migration of the 
leukocytes through inter-endothelial junctions and into the subendothelial space.106 
Cytokines, namely macrophage-colony stimulating factor (M-CSF), induces 
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differentiation of resident leukocytes into macrophages.110 During differentiation, 
epigenetic remodeling of macrophage DNA results in an upregulation of pattern-
recognition receptors, such as scavenger receptors and toll-like receptors (TLRs).111, 112 
Scavenger receptors, such as scavenger receptor A (SRA) and CD36,  are capable of 
internalizing a broad range of ligands including cell fragments, bacterial endotoxins, and 
oxLDL. The cholesterol taken up from oxLDL is either mobilized from the macrophages 
or deposited in lipid droplets within these cells.112 In a case where lipid mobilization is 
impaired or if circulating cholesterol is high, extensive lipid deposition will transform 
macrophages into foam cells. Native LDL is not taken up rapidly enough for this to 
occur.113 However, exposure to the oxidative waste of vascular cells (ie/ reactive oxygen 
species (ROS)) within the intima can promote oxidation, lipolysis, and aggregation of LDL 
allowing it to function as a ligand for more receptors, such as scavenger receptor 1A and 
LOX-1, and thus is more rapidly internalized.114 The formation of foam cells is the major 
event that characterizes an early atherosclerotic lesion, as these cells become lipid enriched 
and accumulate a fatty streak will progress on the vessel lumen.115 Over time, foam cells 
die and contribute to the formation of a necrotic core, a hallmark of late stage 
atherosclerotic lesions.114  
 Macrophages within lesions also contribute to the formation of an atherosclerotic 
plaque through the secretion of cytokines that promote the migration and proliferation of 
smooth muscle cells from the medial layer.102 Decreased NO levels resulting from these 
cytokines also promotes platelet aggregation.116 At the same time components of the blood, 
such as von Willebrand factor, promote platelet activation leading to release of platelet 
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derived growth factor (PDGF) that can further stimulate migration and proliferation of 
medial SMCs.117 Activated platelets also stimulate transforming growth factor beta (TGF-
β) secretion which stimulates interstitial collagen synthesis by SMCs. The combination of 
smooth muscle cell migration and extracellular matrix (ECM) protein deposition 
contributes to the formation of the fibrous cap.110 The fibrous cap serves as a barrier 
between the lipid-rich thrombogenic material in the plaque and the coagulation proteins 
within the flowing blood.  
Over time, the secretion of interstitial collagenases and matrix metalloproteinases 
(MMPs) is stimulated in macrophages, SMCs, and ECs by exposure of these cells to 
inflammatory ligands such as tumour necrosis factor alpha (TNF-α) and decreased NO 
levels.118, 119 Due to the production of ECM proteins, secretion of macrophage proteases, 
and calcification of advanced lesions, the plaque will become unstable and will eventually 
rupture. Release of the thrombogenic material, namely the pro-coagulant tissue factor, in 
the necrotic core will stimulate the activation of the coagulation cascade resulting in the 
formation of an acute thrombus that can  occlude the vessel.110 The reduced blood flow can 
manifest as acute angina, myocardial infarction, an embolism, or a stroke.  
1.1.5.1	The	pro-atherogenic	effects	of	LDL/Lp(a)	on	vascular	cells		
 As described above, the initial steps in the progression of atherosclerosis are 
dependent on the interaction between the ECs, monocytes and macrophages within the 
arterial wall.120, 121 The expression of cell adhesion molecules was found to be critical for 
the adherence of mononuclear cells to the vessel wall. It is well documented that LDL is 
able to increase VCAM-1 and E-Selectin expression, however oxidation of LDL 
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dramatically increases its ability to promote the expression of these molecules and ICAM-
1 and P-Selectin expression as well.122 Treatment of human umbilical vein endothelial cells 
(HUVECs) with Lp(a) has been reported to enhance the expression of all of the 
aforementioned CAMs, as well as PDGF.123-126 Specifically, it was the apo(a) component 
of Lp(a) that was reported to trigger ICAM-1 expression in HUVECs.123 Adhesion of 
monocytes to ECs was also reported to be stimulated through the binding of Lp(a) – in a 
lysine-dependent manner – to the β-integrin Mac-1. This Lp(a)-Mac-1 binding event was 
also shown to promote tissue factor secretion in THP-1 cells.34 Lp(a)/apo(a) has also been 
shown to contribute to monocyte recruitment through enhancing secretion of chemokines 
I-309 and interleukin-8 (IL-8) from cultured macrophages.127, 128  
Aside from CAM expression, a role for apo(a) has been defined in various other 
aspects of endothelial dysfunction. Treatment of HUVECs with recombinant apo(a) (r-
apo(a)) leads to cytoskeletal rearrangement, which in turn results in a loss of cell-cell 
contact and increased HUVEC monolayer permeability.36 The same system was later used 
to assess the role of apo(a) in inflammatory processes, as treatment of ECs with r-apo(a) 
was able to increase prostaglandin synthesis by means of stimulating the nuclear 
translocation of β-catenin.35 Lp(a), in many ways, can participate in the atherosclerotic 
process in a manner similar to LDL. Like LDL, Lp(a) can be readily oxidized within the 
lesion and taken up by macrophages to form foam cells, allowing it to contribute to lesion 
development.129 
Oxidized lipids have been shown to accelerate the onset of inflammatory processes 
in vascular cells.130 Lp(a) has been shown to be the preferential carrier of oxidized 
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phospholipids (oxPL), when compared to LDL.131 The apo(a) component of an Lp(a) 
particle also has an oxidized phospholipid moiety, which has been reported to induce 
apoptosis in endoplasmic reticulum (ER) stressed macrophages through a CD36 and TLR2 
dependent manner, the same receptors used to initiate inflammatory responses by 
oxLDL.132 These reports illustrate a clear role for Lp(a)/apo(a) in contributing to 
endothelial dysfunction and localized vascular cell inflammation, key steps in the initiation 
of atherosclerotic plaque formation.  
Endothelial and smooth muscle cell migration are important steps in the formation 
and neovascularization of the fibrous cap in a mature plaque. Lp(a)/apo(a) is able to 
stimulate EC growth and migration by diminishing the pool of transforming growth factor-
β (TGF-β) generated by HUVECs. The ability of apo(a) to mediate this effect was shown 
to be dependent on the presence of the LBS in KIV10 of apo(a), through binding to the  
integrin αVβ3 on the cell surface.133 However, Lp(a) can inhibit in vitro EC tube formation 
by inhibiting the conversion of plasminogen to plasmin on the cell surface.28 Similarly, 
apo(a) was able to stimulate SMC migration and proliferation by inhibiting the TGF- β, 
with a critical role defined for the inhibitory potential KIV9 domain on pericellular plasmin 
formation.134 Transgenic rabbits expressing a human r-apo(a) were found to have a distinct 
SMC phenotype prone to increased proliferation.135 Furthermore, apo(a) has been shown 
to competitively inhibit pericellular plasminogen activation on the surface of ECs, 
monocytes and macrophages in vitro, in a KIV10 and KV dependent manner.31 In the 
clinical setting, 90% and 31% of macrophages and SMCs, respectively, co-localized with 
Lp(a) in the coronary atheromas of patients.136 The ability of Lp(a) to promote 
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inflammatory states in SMCs, ECs, monocytes and macrophages in both in vitro and in 
vivo by initiating distinct cell signaling processes proves that Lp(a) has strong 
proinflammatory potential. Taken together, these data strongly suggest a role for 
Lp(a)/apo(a) in the initiation and development of an atherosclerotic plaque. 
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Figure 1.4  The effects of lipoprotein(a) on vascular cell phenotype. 
Lp(a) has been reported to induce chemoattractant activity of circulating monocytes and 
to increase endothelial cell permeability. This may allow circulating monocytes to bind 
to endothelial cells, and to migrate into the vessel intima. Within the intima Lp(a) can 
become oxidized and contribute to the formation of macrophage foam cells, thus 
initiating the process of atherogenesis. Lp(a) has also been shown to increase smooth 
muscle cell migration and proliferation and, interfere with fibrinolysis in the vasculature, 
owing to its ability to inhibit plasminogen activation on the cell and fibrin surfaces. 
	
	
	
	
	
	
	
	
	
	
 
 
 
 
 
27 
	1.1.5.2	The	prothrombotic	and	antifibrinolytic	effects	of	Lp(a)/apo(a)	
 Despite the remarkable homology between apo(a) and plasminogen, the direct role 
for Lp(a)/apo(a) in the thrombotic complications of atherosclerosis remains controversial. 
Though there is a growing body of evidence from in vitro studies to show that Lp(a) has 
procoagulant and antifibrinolytic effects, direct evidence for corresponding effects in vivo 
is currently lacking.  
The initial reports of a possible prothrombotic role for Lp(a) were based on the 
ability of apo(a) to inhibit the binding of plasminogen to the cell surface receptors of ECs 
and monocytes.137, 138 Recently it was reported that apo(a) and Lp(a) were not only able to 
inhibit the binding of plasminogen to the surface of ECs, monocytes and macrophages, but 
also that apo(a) could directly inhibit tPA-mediated plasminogen activation on the cell 
surface.31 This effect was diminished in the presence of lysine analog ε-ACA and 
dependent on the sLBS in KIV10 as well as the KV domain of apo(a), underscoring a role 
for the lysine binding ability of apo(a) in this context. In addition, synthesis of plasminogen 
activator inhibitors (PAIs) is significantly increased in cultured ECs and male human 
monocytes when exposed to Lp(a), representing a mechanism by which apo(a) can limit 
plasmin generation.139, 140 These findings implicate a role for Lp(a) in atherothrombosis, in 
the context of mural thrombus formation, cell migration, and angiogenesis.  
More directly relevant to thrombotic disorders is the evidence that Lp(a)/apo(a) can 
inhibit tPA-mediated plasminogen activation in fibrin clots, thus attenuating fibrinolysis.33 
It has also been shown that Lp(a)/apo(a) can inhibit  plasminogen activation by inhibiting 
the conversion of Glu-plasminogen to its more readily activatable Lys-plasminogen 
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form141; inhibition of Glu- to Lys-plasminogen conversion prevents a positive feedback 
mechanism that is required for maximal plasmin generation. Apo(a) can inhibit the binding 
of plasminogen to its substrate fibrin and can also form a quaternary complex with 
plasminogen, tPA, and fibrin that has a significantly reduced turnover rate when compared 
to the ternary complex lacking apo(a).33, 142 In vivo models have supported these findings 
by showing attenuation of thrombolysis in rabbit jugular vein and transgenic apo(a) mouse 
models.143, 144 It has also been shown that Lp(a) can enhance local thrombogenic potential 
by binding to and inactivating tissue factor pathway inhibitor (TFPI), a potent inhibitor of 
the tissue factor-initiated coagulation cascade.145, 146 This could result in the unregulated 
activity of pro-thrombotic tissue factor upon plaque rupture. This evidence suggests that 
Lp(a) may possess roles in thrombus formation, though it is unclear if Lp(a) can directly 
promote clot formation or prevent lysis in vivo. 
1.1.6 Lp(a) as a causal risk factor for vascular diseases 
 Lipoprotein(a) poses unique challenges to researchers who are striving to 
understand the contribution of this complex lipoprotein to the development of CVD. One 
of the greatest challenges is that the gene encoding apo(a), LPA, is only present in humans, 
apes and Old World monkeys147 Without the ability to study human apo(a) in well 
characterized animal models for atherosclerosis, it is difficult to assess the 
pathophysiological roles of apo(a)/Lp(a) in vivo. Additionally, the measurement of plasma 
Lp(a) has been complicated by sensitivity to isoform size that has been shown in virtually 
all commercially available assays.148 The method published by Marcovina and 
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colleagues149 is considered to be the gold standard in the field and uses a 5-point calibrator 
system standardized traceable to an international reference material.  
 There have been many case-control studies which have consistently reported over 
more than 3 decades that elevated Lp(a) is a risk factor for CHD. Unfortunately, however, 
this type of study design cannot distinguish a causal role for Lp(a) in disease as opposed to 
a disease marker.150, 151 Genetic studies less than a decade ago have provided evidence for 
a causal role for Lp(a) in CHD.  In 2009, a Mendelian randomization study assessed genetic 
variation in the LPA gene by quantifying the number of sequences encoding KIV2 domains 
in the LPA  gene, and showed that the number of KIV2-encoding sequences was inversely 
related to Lp(a) plasma levels and risk for myocardial infarction.150 The design of this study 
eliminated selection bias and reverse causation, therefore making it possible to assess a 
causal role for Lp(a) in CHD. Genome-wide association studies have also determined that 
the size of the LPA gene is a major determining factor for CHD risk.152, 153 Additional 
evidence for a causal role of Lp(a) in CHD came from  a study by Clarke and colleagues 
in which two single nucleotide polymorphisms (SNPS) were identified in the LPA gene 
that are associated with increased Lp(a) levels and significantly increased risk for CHD.12 
SNPs were found to account for 36% of Lp(a) plasma levels in this study. The two SNPs 
are rs10455872, an intronic polymorphism, and rs3798220 which results in an Ile to Met 
substitution at the 4399 amino acid position in the protease-like domain of apo(a). For both 
SNPs, the association with risk was accounted for by their association with Lp(a) levels.12  
Recently, the intronic SNP was found to be associated with aortic valve 
calcification and stenosis, although this has yet to be further investigated.154, 155 Though, 
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the exact molecular mechanisms for a role for Lp(a) in CAVD have not been explored, 
with the exception of the recent discovery that Lp(a) can be a carrier of autotaxin in the 
plasma.156 Prior to the study by Clarke and colleagues, the rs10455872 variant had been 
correlated with severe CAD and increased Lp(a) plasma levels.157 The latter study also 
reported a strong correlation between this SNP and small apo(a) isoform sizes. The 
rs3798220 SNP was later investigated in a randomized trial of low-dose aspirin therapy. It 
was determined that women with the rs3798220 SNP had significantly higher Lp(a) levels 
and a 2-fold increased risk for cardiovascular disease.158 This study further showed that in 
carriers of SNP, cardiovascular risk was lowered by over two-fold in response to the low-
dose aspirin therapy compared to individuals without this polymorphism.158 This variant 
has also been correlated with increased oxidized phospholipid content on the LDL 
component of Lp(a), possibly increasing the atherogenic potential of Lp(a) in  individuals 
with this SNP.159 In 2014, a study reported that elevated Lp(a) levels were correlated with 
reduced clot permeability and increased lysis times. Interestingly, polymorphism carriers, 
for the I4399M Lp(a) SNP, had ethnic-dependent variations in plasma clot permeability 
and lysis times, with Caucasians presenting with less permeable clots that were more 
resistant to lysis.160 Although the basis for these observations were not explored in this 
study, it does highlight a potential functional role for this Lp(a) variant in thrombotic and/or 
fibrinolytic complications independent of its association with elevated Lp(a) levels.   
It has been established that small isoform sizes of Lp(a) promote risk for CHD, but 
not independent of levels. A systematic review of 40 different studies (meta-analysis), 
showed that individuals with smaller apo(a) isoforms (less than 22 KIVs) have a 2-fold 
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higher risk of CHD and ischemic stroke than those with larger isoforms.161 However, this 
remains to be a controversial topic in the field since it is not clear whether small isoform 
sizes of Lp(a) can confer risk independently of levels.  
There has been controversy as to whether Lp(a) is a risk factor for venous 
thromboembolism (VTE). Several small studies have reported that high plasma 
concentrations of Lp(a) are a risk factor for VTE in both adults and children.162-166 Recently 
it was reported that low KIV2 repeat number and elevated Lp(a) levels are significantly and 
independently associated with VTE.166 This study directly contradicts a large Danish  
genetic study of >41,000 individuals, that reported that Lp(a) is a causal risk factor for 
atherosclerosis but not venous thrombosis.167 In fact, the vast majority of recent studies 
report that there is no association between genetically elevated Lp(a) levels and venous 
thrombosis.168, 169 Though there is evidence for and against a role for Lp(a) in venous 
thrombotic disorders, the more recent, larger genetic studies almost exclusively discount a 
causal role for Lp(a) in venous thrombosis.  
Taken together, the growing body of evidence from genetic studies shows that 
Lp(a) is a causal, independent risk factor for CHD, as well as other vascular diseases 
including CAVD (Figure 1.5). However, the mechanism by which Lp(a) contributes to 
vascular disease processes remains unclear. It is possible that the ability of Lp(a) to 
promote CVD may stem from its ability to be a carrier for proinflammatory oxidized 
phospholipids in plasma. This will be discussed in Section 1.2 in detail.  Further 
investigation into the mechanisms of Lp(a) function may identify new strategies for the 
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development of therapeutics aimed at reduced the harmful effects of Lp(a) in the 
vasculature.  
1.1.7 Therapeutic strategies to lower plasma Lp(a) levels 
 Currently, there are no available pharmaceutical treatments designed to specifically 
lower plasma Lp(a) levels. This has made it challenging to assess prospectively the effect 
of lowering of Lp(a) on cardiovascular outcomes. Statins, while very effective for LDL 
lowering, have little or no effect on Lp(a) levels.86 Therapies that have been shown to lower 
Lp(a) by up to 30% also have effects on other components of the lipid profile including 
triglycerides, HDL and LDL. These include niacin170, 171, and mipomersin172.  
PCSK9 inhibitors (monoclonal antibodies against proprotein convertase 
subtilisin/kexin type 9) have also been shown to lower Lp(a) levels by approximately 
30%93, 173, 174 and are highly effective LDL-lowering agents.148,175 The mechanism by 
which PCSK9 inhibitors lower Lp(a) is controversial. Since PCSK9 functions to lower the 
number of low density lipoprotein receptors (LDLR) on the hepatocyte surface, removing 
PCSK9 from the system will increase LDLR numbers, this suggests that increased Lp(a) 
clearance -caused by PCSK9 inhibitors- is due to an increase in LDLR. This in turn, allows 
the LDLR to bind to its substrate LDL promoting rapid clearance of LDL cholesterol. 
Romagnuolo and colleagues, determined that Lp(a) (and not apo(a)) can be a ligand for the 
LDLR and that exogenous PCSK9 treatment of HepG2 cells can not only result in the 
expected decrease in LDLR but also a decrease in Lp(a) internalization.94 However, this 
was only true in a situation where LDL levels were low and LDLR levels were elevated. 
In a study of 10 clinical trials, it was further shown that Lp(a) is a poor competitor for the 
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LDLR in the presence of LDL unless LDLR levels are significantly increased, in which 
case Lp(a) is a significant ligand for the receptor.92 There is currently a growing body of 
early phase study evidence showing a decrease in CVD risk as a direct result of  this 
therapeutic option.176 However, since the decrease in plasma Lp(a) observed is at best  
~30%, this study concluded that the LDLR is not the preferred route for Lp(a) clearance 
and another receptor(s) play a larger role in Lp(a) catabolism.94  
Injectable antisense compounds that are specifically designed to target apo(a) are 
now in Phase II trials; results of the Phase I study showed that this compound can lower 
plasma Lp(a) levels by > 85% percent.18, 177 This compound has the potential to be used in 
clinical trials designed specifically to look at cardiovascular outcomes in response to 
extreme Lp(a) lowering. A new ASO that is targeted to the KIV2 subunit of apo(a) is 
currently under investigation. The ASO is conjugated to a liver specific glycan, for targeted 
RNA silencing in hepatocytes. Anti-apo(a) ASO, now known as ISIS-APO(a)Rx, therapy 
was able to reduce apo(a) by 86% in a 12K-apo(a) transgenic mouse model.180 In a phase 
I study in normal volunteers, ISIS-APO(a)Rx was able to reduce plasma Lp(a) levels and 
associated oxPL by 89 and 93% respectively.18 Another approach designed to specifically 
lower Lp(a) is Lp(a)-specific apheresis.178 In a small study of 30 individuals with normal 
LDL levels that underwent Lp(a) apheresis treatments for 18 months a 73% reduction in 
plasma Lp(a) levels was reported, along with a significant regression in coronary 
atherosclerosis.179 Though effective, Lp(a) apheresis is an invasive, costly procedure and 
on that basis is likely not feasible as a long term treatment option. 
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Figure 1.5  The multiple mechanisms of Lp(a) pathogenicity 
Lp(a) has been shown to function through both proatherogenic and prothrombotic 
mechanisms as shown in in vitro and in vivo studies.  Lp(a) may promote atherogenesis 
through its ability to modulate vascular cell phenotype or potentially through stimulating 
inflammation through its covalent oxPC moiety. Lp(a) may elicit prothrombotic effects 
through its ability to inhibit plasminogen activation, fibrinolysis, and due to its homology 
to plasminogen. 
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1.2 OXIDIZED PHOSPHOLIPID MODIFICATION OF LIPOPROTEIN(a) – 
NEW INSIGHTS INTO Lp(a) FUNCTION. 
1.2.1 Formation and Structure of Oxidized Phospholipids  
 Glycerophospholipids are a class of lipid molecule found in many eukaryotic 
systems. They are composed of a glycerol backbone with the addition of two fatty acid 
residues and a phosphate-containing polar head group. A phospholipid (PL) that contains 
a fatty acid chain that has multiple sites of unsaturation is known as a polyunsaturated fatty 
acid (PUFA). PUFAs are prime candidates for oxidation due to the weaker carbon-
hydrogen bonds found within the methylene groups in between double bonds. Oxidation 
of these molecules, through enzymatic or non-enzymatic means, can result in several 
distinct biologically active products, such as lysophospholipids. The mechanisms of non-
enzymatic PUFA oxidation are well understood and usually require the presence of a free 
radical or ROS (Figure 1.6). Free radicals can be generated from exogenous sources such 
as ionizing radiation, UV-light, and smoking, or endogenous sources such as NADPH 
oxidase and the electron transport system in mitochondria. Radicals abstract a hydrogen 
atom from the bisallyic methylene found in unsaturated fatty acid carbon chains, forming 
a carbon-centered radical. This radical is prone to interact with molecular oxygen and will 
form a peroxyl radical. The formation of these peroxygen radicals is the first step in a  
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Figure	1.6		Oxidation	of	polyunsaturated	fatty	acid-containing	phospholipids.	
There are two main methods of PUFA oxidation; enzymatic and non-enzymatic. Non-
enzymatic lipid oxidation requires the initiation of the lipid peroxidation reaction by a 
reactive oxygen species or radical. Either oxidation mechanism results in the formation 
of a hydroperoxide molecule that will rapidly decompose into reactive carbonyls, such 
as aldehydes or ketones. These reactive carbonyls can covalently modify DNA, proteins, 
or other lipid molecules.  
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canonical lipid peroxidation chain reaction, which terminates in the generation of oxPL. In 
contrast, enzymatic formation of oxPL is executed by a class of enzymes known as 
lipoxygenases (LOXs). The function of a LOX is to introduce molecular oxygen into 1,4-
pentadiene motifs within a PUFA, creating a hydroperoxide molecule similar to the 
intermediates found in the lipid peroxidation reaction. Most of these enzymes recognize 
unesterified fatty acids. However, the 12/15-LOX group of enzymes is capable of oxidizing 
PL-esterified fatty acids. In fact, these enzymes have been shown to oxidize PL-PUFA 
substrates within the cell membrane and lipoprotein particles.181, 182 Interestingly, 15-LOX 
produces (S)-isomers of PL-esterified hydroperoxides which have been found using chiral 
chromatography to be enriched in early atherosclerotic lesions.183 Since non-enzymatic 
oxidation of lipids generates a racemic mixture of hydroperoxides, it is tempting to 
hypothesize an initial role for 15-LOX in in vivo atherogenesis.183 It is important to note 
that advanced atherosclerotic lesions showed no enrichment in a specific enantiomer, 
suggesting a dominant role for non-enzymatic lipid oxidation as the lesion progresses.183 It 
has also been reported that some members of the cytochrome P-450 family (classes 2C and 
2J) can oxidized free PUFAs, which can then be esterified into oxPL.184 Regardless of the 
mechanism of formation, peroxyl radicals and hydroperoxides can be further oxidized and 
fragmented in an arbitrary manner that leads to the formation of a wide spectrum of oxPLs 
with many unique functional groups. In particular, γ-hydroxy-α,β-unsaturated oxPLs 
containing terminal aldehydes have been shown to possess many different biological 
activities, including binding to macrophage CD36 and the induction of inflammatory 
effects in ECs.185, 186 These oxPL species are also found to be enriched in plasma in cases 
of hyperlipidemia and atherosclerosis.187 In addition, these oxPLs have been shown to form 
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protein adducts that have been detected as lipid-protein covalent complexes in vivo.188 It 
has been reported that oxPL molecules that contain terminal aldehydes or α,β-unsaturated 
carbonyl groups can react with nucleophilic amino and thiol groups. This makes amino- 
and sulfhydryl-containing amino acids such as lysine, arginine, histidine, and cysteine 
potential targets for the formation of Michael adducts or Schiff bases.189, 190 
1.2.2 Biological relevance of oxidized phospholipids in the vasculature 
 There is a significant body of data demonstrating a role for oxidized lipids as 
pathogenic molecules and indicators of disease. Specific to atherogenesis, oxidized-LDL 
is an example of the ability of lipid oxidation to influence changes in physiological 
processes, ultimately leading to pathogenic outcomes.122, 191-193 Peroxidation of oxPLs can 
result in the generation of reactive molecules that form adducts with other lipids and protein 
molecules, thereby altering the normal physiology of signaling molecules and inducing 
immune responses.194 Classic examples of such oxPLs are malondialdehyde (MDA), 4-
hydroxynonenal (4-HNE), and 1-palmitoyl-2-(5'-oxo-valeroyl)-sn-glycero-3-
phosphocholine (POVPC).195, 196 It has been reported that several species of 
immunoglobulin, mainly IgG and IgM, can specifically detect these oxidized lipid products 
in oxLDL.197, 198 These anti-oxLDL antibodies have been shown to be present in mouse 
models of atherosclerosis, as well as in humans with CVD.199, 200 Recent studies report that 
individuals with higher levels of anti-oxLDL IgM antibodies had lower incidences of 
atherosclerosis, a result not observed for similar IgGs.201 One of the cornerstones in the 
field of oxPLs and atherosclerosis was the discovery of an endogenous anti-oxPL IgM 
which was named E06. This antibody was derived from the spleen of LDLR-/- mice and is 
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able to bind to copper- oxidized LDL.202 Intense characterization of this autoantibody led 
to the determination that it was specific to oxPLs that possessed a phosphocholine head 
group, and cannot recognize unoxidized PC residues.203, 204 Sequencing of the heavy and 
light chain of E06 indicated that the antibody’s variable region was 100% identical to the 
previously reported T15 human IgA that was crystalized with its ligand phosphocholine.205 
The E06 antibody was later determined to be able to histochemically stain atherosclerotic 
lesions, aside from is ability to bind to oxLDL and apoptotic cells. 206 E06 has become an 
important tool for characterizing the role of oxPLs in atherogenesis.207  
 Oxidized phospholipids (and oxPL-conjugated molecules) have also been shown to 
be ligands for various cellular receptors. The relationship of oxPLs with the scavenger 
receptor CD36 has been well characterized over the years, and has been shown to be 
important for the clearance of oxLDL by macrophages.208 This has been reported as a 
crucial step in the progression of atherogenesis in vivo.209, 210 Further study pointed to the 
requirement for a fragmented γ-hydroxy-α,β-unsaturated fatty acid in the sn-2 position of 
the PL for the covalent modification of proteins. This moiety was subsequently shown to 
covalently attach to Lys164  and Lys166 of apoB100, by the formation of a Schiff base.211 
Binding of oxPL to CD36 has also been shown to activate platelets, by initiating JNK2 and 
MKK4 kinase signaling cascades.212 Furthermore, these molecules have been shown to 
initiate signaling through vascular endothelial growth factor receptor-2 (VEGFR2), toll-
like receptor-4 (TLR4), prostaglandin receptors, and peroxisome proliferator-activated 
receptors (PPARs).212-215 As such, several signaling pathways can be initiated by exposure 
of cells to oxPLs; these pathways are involved in promoting monocyte chemotactic activity 
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and tissue factor expression in non-endothelial cells, as well as maintaining endothelial cell 
monolayer properties [reviewed in reference 215].  
 Overall, the accumulation of decades of evidence has resulted in the identification 
of oxidized phospholipids as proinflammatory molecules. Platelet activating factor (PAF)-
like molecules, diacyl oxidized phospholipids, are able to significantly increase monocyte 
adhesion through the activation of β1-integrin and P-selectin on ECs.216, 217 OxPLs have 
also been reported to stimulate expression and secretion of IL-8 and monocyte chemotactic 
protein-1 (MCP-1) in cultured ECs, linking the oxidation of lipids to atherogenesis.213 
PAF-like oxPLs and lysophosphatidic acid have also been shown to directly activate 
platelets and promote adhesion.218 Pro-inflammatory ROSs have also been reported to be 
stimulated by oxPAPC, but not by native PAPC, in human and bovine aortic ECs, a process 
that could further promote oxidation and plaque formation.219 Due to the various 
pathogenic mechanisms described, the potential for oxPLs to promote atherogenesis and 
enhance disease progression is clear and significant. 
1.2.3 Oxidized phospholipids and lipoprotein(a) 
 Lipoprotein(a) has been proposed to initiate and contribute to atherothrombosis 
through a myriad of different potential mechanisms, as reviewed in Section 1.1.5 (Figure 
1.5). Over the past decade evidence has accumulated suggesting that the pathogenicity of 
Lp(a) may be in part due to the presence of oxidized phospholipids on the Lp(a) particle.220 
In 2003, a study by Edelstein et al. determined that there are lysine-phosphatidylcholine 
adducts on the apo(a) component of Lp(a).221 This work used the PC binding E06 IgM 
antibody to map the oxPC moiety to the carboxyl-terminal domains of apo(a), using 
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elastase digestion fragments, and thus determining that fragments including KIV5-PD and 
KV-PD reacted with E06. It was determined that the oxPC moiety on apo(a) was located 
on the KV domain, as rhesus monkey apo(a) did not react with E06 and lacks a KV 
domain.221 Furthermore, this study speculated that the oxPL moiety was the product of the 
formation of a Schiff base between the reactive aldehyde group of the oxidized 
glycerophosphocholine and lysine residues Lys12 and Lys42 of KV. Evidence for the 
involvement of lysine residues in coordinating the OxPL moiety was two-fold: two 
residues/mol of apo(a) were not able to be modified by 2,4,6-trinitrobenzene sulfonic acid. 
Specifically, Lys12 and Lys42 in the apo(a) KV domain were identified by computational 
modeling.221 This was the first study to characterize a covalently-linked oxPL modification 
on the apo(a) component of Lp(a).  
An E06 sandwich ELISA was developed that could be used to screen plasma 
samples for the quantification of oxPL on apoB containing lipoproteins.222 Plasma from 
high-expressing apo(a)/apoB100 double transgenic mice was found to have elevated levels 
of oxPL associated with their Lp(a) protein, where LDL from these mice (or from apoB100 
mice) did not.223 Using the same sandwich E06 ELISA technique, a group of >500 patients 
was assessed for Lp(a) levels and oxPL:apoB100  levels, and was subjected to coronary 
angiography. Elevated Lp(a) levels correlated with higher amounts of oxPL:apoB100 and 
this was associated with incidence of obstructive coronary artery disease.224 Similar results 
were reported from the Bruneck study where oxPL:apoB100  levels and Lp(a) levels were 
strongly associated with each other and with the incidence and progression of carotid and 
femoral atherosclerosis.225 In a follow up study it was determined that increasing 
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lipoprotein-associated phospholipase A2 (Lp-PLA2) activity enhanced CVD risk and that 
apoB100-associated oxPL could predict cardiovascular events independent of Framingham 
Risk Score (FRS) information.226  
The repeated correlation of high Lp(a) levels with elevated oxPL:apoB100 suggests 
that the oxPL associated with the LDL component of Lp(a) may be a source of 
proatherogenic potential. Indeed, data from the Dallas Heart Study confirmed this finding 
and reported a correlation between small isoform sizes and increased oxPL:apoB100, which 
is consistent with the inverse correlation between Lp(a) levels and isoform size.220 
However, none of the studies to this point could differentiate which apoB100-containing 
lipoprotein class actually carried the oxPL. Five years after the discovery of oxPL on Lp(a), 
Bergmark et al. characterized the distribution of oxidized phospholipids on apoB100-
containing lipoproteins using coimmunoprecipitation and ultracentrifugation experiments. 
First, it was determined that apo(a) pulldown decreased plasma E06 reactivity by 85%. 
Immunoblotting of ultracentrifugation fractions found that nearly all E06 positive fractions 
contained Lp(a), but not other lipoproteins.131 Using organic extraction, approximately 
50% of Lp(a)-associated lipids could be extracted and therefore were non-covalently 
associated. In addition, in vitro transfer studies showed that oxLDL donates oxPL to Lp(a), 
rather than to LDL. These data clearly identify Lp(a) as a preferential carrier of oxPL 
compared to other plasma lipoproteins.131  
Further studies aimed to assess whether oxPL were associated with the apo(a) or 
LDL-like moieties of Lp(a). Using a gentle reduction technique, Lp(a) can be dissociated 
into apo(a) and the LDL-like lipoprotein (referred to as Lp(-a)). Using this technique, it 
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was determined that the apo(a) component of Lp(a) was able to react with the T15 anti-PC 
antibody, but Lp(-a) was not.227 This study also showed no correlation between plasma 
Lp(a) levels or the number of KIV2 repeats with the extent of oxPL modification of apo(a). 
Based on this evidence it was speculated that the oxPL on apo(a) might be derived from 
cellular origin, as a post-translational modification, and not picked up from the plasma pool 
of free oxPL, though the mechanism of oxPC modification of Lp(a) has yet to be 
confirmed.227 Though there was no effect of the KIV2 polymorphism on extent of oxPL 
modification of apo(a), it was found that carriers of the rs3798220 SNP (I4399M apo(a) 
variant) had increased oxPL:apoB100.159 This relationship was particularly strong for 
smaller isoforms of Lp(a) (<21 KIV2 repeats), suggesting that the increase in CAD risk for 
I4399M carriers could be due not only to the increased Lp(a) levels that are associated with 
the presence of this SNP, but also to the elevated oxPL on Lp(a).  
Interestingly, plasminogen was also found to contain oxPC moieties, and these 
remained present on plasmin after activation by uPA.228 In lipoprotein-deficient fractions 
of human and monkey plasma, plasminogen was a significant carrier of oxPC indicating 
that plasminogen is a second major source of plasma oxPC in addition to Lp(a).229 The 
relevance of the oxidized phospholipid on plasminogen is largely unknown. It was 
observed that oxPC levels on circulating plasminogen acutely increased following 
myocardial infarction.229 A functional effect of oxPC on plasminogen function was shown 
in 2012, when removal of the oxPC on plasminogen (by treatment with PLA2) was able to 
significantly prolong the lysis time of fibrin clots.229 These data indicate that plasminogen 
may have oxPL-related pathophysiological roles in myocardial infarction and 
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atherothrombosis. Interestingly, the presence of oxPC seems to make plasminogen a more 
effective fibrinolytic agent, while the presence of oxPC on Lp(a) seems to promote vascular 
disease. 
Only recently has the oxidized phospholipid on apo(a) been assessed directly from 
the perspective of structure and function. Leibundgut et al. screened Lp(a) from humans 
and five different primate species. Of note, the apo(a) from each of these species differs 
from human with respect to apo(a) KIV10 sequence and/or the presence of KV. Only human 
Lp(a) samples were positive for oxPC on apoB or apo(a) using E06 immunoblotting, where 
all primate species were negative for oxPC, consistent with the initial Edelstein study on 
rhesus monkey apo(a).52, 221 However, the initial conclusion by Edelstein et al. of the oxPL 
moiety being present on the KV domain was contradicted by the fact that chimpanzee and 
gorilla Lp(a) do possess a KV domain but are E06 non-reactive. This lead to a 
comprehensive screening of more than 28 different recombinant human apo(a) variants, 
truncations, and isoforms in order to pinpoint a domain(s) of apo(a) that harbours the oxPC 
moiety. Figure 1.7 shows representative E06 (anti-PC) immunoblotting of all recombinant 
variants, Lp(a) and plasminogen. The data demonstrated that only apo(a) variants that 
contain components of the carboxyl-terminal portion are reactive with E06 (compare KIV1-
4 to 6K, Fig. 1.7). In fact, systematic deletion of kringle domains in the carboxyl-terminal 
domain indicated that the presence of KIV10 is required for E06 reactivity.52 Interestingly, 
the only variant that contained KIV10 but lacked immunoreactivity to E06 was 17KΔAsp56, 
which contains all components of apo(a) but mimics the defective sLBS seen in gorilla and  
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Figure	1.7		Mapping	the	domain	of	oxPL	modification.	
A. Schematic of recombinant apo(a) proteins. B. Immunoblotting of various r-apo(a) 
constructs and human plasminogen with E06 for PC-oxPL and an anti-apo(a) antibody. 
Individual constructs are explained in detail in figure 2. Arrows indicate where E06 
activity is not present. In these immunoblots oxPL are denoted to reflect only E06-
detectable oxPL and not all oxPL. Figure adapted with permission from reference 52. 
A 
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chimpanzee species (see section 1.1.3). The presence of KV was clearly dispensable for 
E06 reactivity in the human apo(a) deletion variants (Fig. 1.7). Rhesus monkey 
apo(a),lacking a KV domain, also has a Trp70àArg mutation in KIV10, which has a similar 
destabilizing effect on the sLBS. Transgenic mice expressing wild-type apo(a) contained 
oxPL, while mice expressing the DAsp56 apo(a) variant lacked oxPL.52 In conclusion, this 
study determined that an intact, sLBS-containing KIV10 domain is required for E06 
reactivity. Coupled with the lack of requirement for KV for E06 reactivity, the data strongly 
suggest that KIV10 harbours the oxPL moiety, not KV. The exact amino acid(s) modified 
by the oxPC moiety and the role of the sLBS in the mechanism of oxPC addition remains 
to be explained. The evidence in favour of a role for the oxidized phospholipids on Lp(a) 
in cardiovascular pathophysiology is strong, but the molecular mechanisms underlying the 
harmful effects of the covalent oxPC modification on apo(a) are still currently under 
investigation. A study by Seimon et al. recently reported the first direct functional role for 
the oxPC on apo(a) in an atherosclerotic process, in which Lp(a)/apo(a) was shown to 
induce apoptosis in ER-stressed macrophages.132 Using a combination of trypsin and 
phospholipase A2 treatments, they reported that removal of the oxPL from apo(a) abolished 
its ability to exert pro-apoptotic effects. The ability of the oxPL on apo(a), and other lipids 
in the study, to elicit apoptosis was determined to be dependent on TLR2/CD36 
heterodimer mediated intracellular signaling.132 These data suggest that the oxPL 
associated with apo(a) promote macrophage apoptosis within a developing atherosclerotic 
lesion, representing one mechanism linking oxPL on apo(a) to atherosclerosis. Given the 
strong correlation of the oxidized phospholipids on Lp(a) with incidence of CVD, it is 
clearly crucial to determine the various mechanisms by which the oxPC moiety on apo(a) 
directly influences the progression of disease. 
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1.3 RATIONALE AND OBJECTIVES 
 While elevated plasma Lp(a) levels have been documented to be a causal risk factor 
for cardiovascular diseases, the mechanisms of how Lp(a) contributes to atherothrombotic 
disorders are still not fully described. It is only in understanding these molecular processes 
that we can hope to develop appropriate therapeutic treatments aimed at preventing the 
pathogenic effects of Lp(a).  
 The identification of a correlation between elevated levels of oxidized 
phospholipids on Lp(a)/apo(a) and the incidence of coronary heart disease illuminates a 
new potential mechanism by which Lp(a) elicits its effects on the vasculature. It is 
important that the determinants of this oxidative modification be investigated; only by 
understanding the mechanism of oxPC addition to apo(a) can we develop the tools required 
for efficient study of its role in cardiovascular diseases. For instance, it has been shown 
that removal of the strong LBS in KIV10 decreases the proatherosclerotic effects of apo(a) 
in a transgenic mouse model230; since this LBS may also be required for oxPC addition, it 
is not clear if it is the LBS itself or the oxPC (or perhaps both) that is the entity causing 
harm. 
 It is well documented that oxidized lipid products play a progressive role in 
inflammation and atherosclerosis. The potential for the oxPC moiety on apo(a) to have 
effects on the atherogenicity of Lp(a) has not been intensively examined. Careful dissection 
of the known mechanisms of how apo(a) can influence vascular cells is required in order 
to determine if any of these roles are due, at least in part, to oxidative modification of 
apo(a). Understanding the link between LPA polymorphisms and their relation to 
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physiological processes, as well as the influence of the oxPL modification, is necessary for 
the development of appropriate pharmaceutical interventions.  
 We hypothesize that Lp(a)/apo(a) possesses an oxidized phosphocholine-derived 
modification on the KIV10 domain of apo(a), adducted to a specific amino acid residue, 
and that the strong lysine binding site within this domain is critical in this process. 
Furthermore, we hypothesize that there are numerous effects of oxidative modification of 
apo(a) reflecting the influence of pro-inflammatory processes related to disease 
progression. 
In order to investigate these hypotheses, the objectives of this dissertation are: 
1. To characterize, at the primary sequence level, the oxidized phosphocholine 
modification of apolipoprotein(a); 
2. To elucidate the mechanism of lipoprotein(a) induced interleukin-8 expression in 
macrophages; 
3. To determine the structural and functional effects of the rs3798220 (I4399M) single 
nucleotide polymorphism. 
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2.1 Summary  
 Elevated plasma levels of lipoprotein(a) (Lp(a)) have been identified as an 
independent and causal risk factor for coronary heart disease and calcific aortic valve 
stenosis. Lp(a) is an enigmatic lipoprotein that contains a moiety indistinguishable from 
low density lipoprotein (LDL) as well as the unique glycoprotein apolipoprotein(a). We 
have shown that apo(a) contains a covalent oxidized phosphocholine (oxPC) adduct on the 
KIV10 domain, and that perturbation of the strong lysine binding site in this kringle results 
in a lack of covalent oxPC addition. Since apo(a) from Old World monkeys and apes lacks 
covalent oxPC modification, sequence comparison with human apo(a) potentially offers 
insights into the identify of amino acids in human apo(a) that contain oxPC. In the current 
study, we constructed mutations in a KIV10KV di-kringle apo(a) species that contains 
covalent oxPC modification. All residues that are either substituted in primate apo(a) or 
that can act as acceptors for covalent oxPC addition were assessed using site-directed 
mutagenesis. The resulting variants were then subjected to immunoblotting analysis with 
E06, an IgM antibody that detects the presence of oxPC containing a phosphocholine head 
group. Each variant was also assessed for lysine-binding ability using lysine-Sepharose 
affinity chromatography. Our analysis has led to the identification of the His33 residue as 
the site of covalent OxPC addition in apo(a). Mutation of this residue to an alanine results 
in loss of OxPC modification of this variant, with concomitant retention of its lysine 
binding ability. In the current study we have also identified the presence of non-covalently 
associated oxPC present on the apo(a) component of Lp(a). Interestingly, the extent of non-
covalently-bound OxPC species appears to be reduced in the apo(a) variant containing a 
mutation in the strong lysine binding site in KIV10. Taken together, the ability to assess the 
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individual contributions of the lysine binding site and oxPC modification of apo(a) kringle 
IV type 10 will provide useful tools to advance our understanding of the mechanisms by 
which Lp(a) contributes to atherothrombotic diseases.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
 
 
 
 
 
70 
2.2 Background 
 Elevated plasma levels of lipoprotein(a) (Lp(a)) have been identified as an 
independent and causal risk factor for coronary heart disease and calcific aortic valve 
stenosis.1 Lp(a) is an enigmatic lipoprotein that is indistinguishable from low density 
lipoprotein (LDL), both in the composition of lipids and the presence of apolipoprotein 
B100 (apoB100). However, Lp(a) also contains the hydrophilic glycoprotein 
apolipoprotein(a) (apo(a)) that makes Lp(a) a unique class of lipoprotein.2 The apo(a) 
component of Lp(a) is structurally similar to the plasma zymogen plasminogen. The LPA 
gene, encoding apo(a), originated from a duplication event of the plasminogen gene that 
occurred late in evolution and as such is only expressed in humans and Old World 
monkeys.3 Apo(a) comprises ten domains with high sequence similarity to plasminogen 
kringle IV, denoted KIV1-KIV10. Each domain is present in a single copy with the 
exception of KIV2 which can vary from <3 to >30 copies, giving rise to Lp(a) isoform size 
heterogeneity within the population.4 Apo(a) also contains plasminogen-like KV and 
protease domains although the apo(a) protease domain is proteolytically inactive.5 
Plasma Lp(a) levels vary widely within the human population, from less than 0.1 
to greater than 100 mg/dL. Approximately 20% of individuals globally have elevated Lp(a) 
levels (defined clinically as >50 mg/dL).6 However, determination of Lp(a) levels is not a 
routine procedure, due to challenges inherent in the measurement of this lipoprotein and 
lack of viable strategies for lowering of Lp(a) levels in the clinic. Additionally, the 
beneficial effect of Lp(a) lowering on clinical outcomes has not been establishment due to 
lack of agents designed to specifically lower Lp(a). 
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Lp(a). has been shown to stimulate atherthrombotic processes including endothelial 
cell (EC) cytoskeletal remodelling and proliferation7, inhibition of plasminogen 
activation8, and stimulation of monocyte chemotactic activity.9; these effects have been 
primarily attributed to the apo(a) component of Lp(a). Evidence generated within the past 
decade supports independent and potentially additive atherogenic effects of oxidized 
phosphocholine (oxPC) associated with Lp(a).10 In this regard, a growing body of data has 
documented the presence of both covalent and non-covalent oxPC associated with plasma 
Lp(a). It has been determined that Lp(a) is a major class of oxPC-containing lipoprotein 
and that oxidized LDL (oxLDL) can donate oxidized lipids to Lp(a), thus has been named 
the preferential carrier of oxPC in the plasma.11 Oxidized phospholipids have many well-
documented pathophysiological effects and have been designated as damage-associated 
molecular patterns (DAMPs), eliciting many proinflammatory and proatherogenic effects 
in the vasculature. Several clinical studies have reported a strong correlation between the 
levels of Lp(a) and the oxPC content of apoB-containing lipoproteins; this was further 
associated with increased cardiovascular disease risk.12-14 It is tempting to hypothesize that 
the effect of Lp(a) in atherogenesis may arise, at least in part, from the proinflammatory 
effects of oxPC present on this lipoprotein. 
Understanding the association of oxPC with Lp(a) is critical for determining the 
exact role for this moiety on Lp(a) pathogenicity. The current understanding of the 
determinants of oxPC binding to Lp(a) was established through two main studies. The first 
of these studies, by Edelstein and colleagues, clearly demonstrated that the oxPC on Lp(a) 
is covalently associated with the apo(a) moiety of the molecule.15 The study identified the 
lipid moiety on apo(a) as an oxidized phosphatidylcholine (oxPC), as it can be detected by 
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the E06 IgM autoantibody that is specific for oxPC-containing epitopes.16 The E06-reactive 
epitope was determined to be present within the C-terminal region of apo(a). Rhesus 
monkey apo(a) lacks oxPC. Since this species lacks a KV domain, this was interpreted to 
suggest that oxPC modification of apo(a) occurs on KV.15 Edelstein and colleagues 
speculated that the oxPC moiety was added to critical lysine residues in KV through Schiff 
base formation. Recently, a more comprehensive study screened several species of Old 
World monkeys and apes and determined that there was no E06 reactivity in any apo(a) 
from any of these species regardless of the presence or absence of the KV domain.17 
Furthermore, the investigators used human recombinant apo(a) variants containing 
systematic deletions analyzed by western blotting using E06 to deduce the location of the 
oxPC moiety. Using this approach, apo(a) KIV10 was identified as the site of oxPC 
addition. However, since all non-human primate apo(a) contains this domain yet lacks E06 
reactivity, it was hypothesized that there may be a critical role for the lysine binding 
function of KIV10 for oxPC modification. Interestingly, only human apo(a) KIV10 contains 
a strong binding site (sLBS) in KIV10. The lysine binding activity of apo(a) has been 
implicated in many of the effects of Lp(a) on vasculature, such as endothelial cell 
monolayer permeability and prostaglandin synthesis.7, 18 As such, it can be hypothesized 
that the lysine-dependent pathogenic effects of Lp(a) may be due to oxPC present on apo(a) 
KIV10.  
In the present study we undertook a targeted mutagenesis approach to identify 
potential sites of oxPC addition on apo(a).  Identification of these site(s) will allow us to 
assess the contribution that the oxidized phospholipid moiety on apo(a) makes to the 
pathogenic effects of Lp(a).  
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2.3 Experimental Methods 
 
2.3.1 Construction, expression, purification and characterization of recombinant 
apo(a)  
 Expression plasmids encoding sequences spanning the entire KIV10 domain, and 
KIV10 plus KV domains were generated by amplification of the pRK5haKIV10-P plasmid 
from the apo(a) signal sequence to the end of either KIV10 or KV, using primers sets A and 
B, or A and C respectively (Supplementary Table 2.1).19 Bold face lower case letters in 
primers B and C indicate the mutations introduced to generate an AgeI restriction digest 
site. PCR reactions were carried out in a BioRad CFX96 thermocycler using Q5 High-
Fidelity DNA Polymerase (New England Biolabs) under the following conditions: 
denaturation at 98°C (10 sec), annealing at 62°C (30 sec), and elongation at 72°C (20 sec), 
for a total of 40 cycles. The PCR product was digested with EcoRI-HF and AgeI-HF, (New 
England Biolabs); the pcDNA™4/myc-His was also digested with these enzymes, 
liberating the myc-tag. This reaction yielded a 438bp and 678bp fragment for KIV10 and 
KIV10KV respectively. The fragments were agarose gel-purified and ligated with the vector 
at 16°C overnight using T4 DNA ligase (Invitrogen) to create the plasmids 
pcDNA4C.KIV10.His and pcDNA4C.KIV10KV.His. 
Plasmids were transfected into HEK293 cells using MegaTran1.0 at 10 µg 
DNA/100mm plate and subjected to selection with 150 µg/mL Zeocin at 48 hours post-
transfection, until a viable population was observed. Recombinant apo(a) was purified from 
the conditioned medium (CM) of stably-expressing cell lines. The CM was adjusted to 0.5 
M NaCl containing, 0.2 mM β-mercaptoethanol, 5 mM imidazole, and 2% glycerol, pH 8.0, 
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and applied to a Ni2+- Sepharose excel (GE Healthcare) column; the column was washed and 
eluted with 12 mM and 300 mM imidazole respectively. Eluted samples were concentrated 
with PEG-20,000 (Sigma) and dialyzed against HEPES-buffered saline (HBS: 20 mM 
HEPES and 150 mM NaCl, pH 7.4). Concentrations were determined using bicinchoninic 
acid assay (BCA assay; Pierce) with BSA as a standard. Purity of KIV10KV and KIV10 was 
assessed by SDS-PAGE followed by silver staining.   Variants of KIV10 and KIV10KV (see 
Supplementary Table 2.1) were generated using the Quikchange II Site Directed 
Mutagenesis kit (Agilent) or the Q5 Site Directed Mutagenesis Kit (New England Biolabs), 
as per manufacturer’s instructions, using primer pair sets shown in Supplementary Table 
2.1. 
 
2.3.2 Cell Culture 
 Human embryonic kidney (HEK293) cells were cultured in Minimal Essential 
Medium (MEM, Gibco) supplemented with 10% FBS (Gibco) and 1% antibiotic-
antimycotic (Gibco). THP-1 acute monocytic leukemia cells (ATCC# TIB-202) were 
cultured in RPMI-1640 medium adjusted to contain 4.5 g/L glucose in 10 mM HEPES pH 
7.4 containing a 1.0 mM sodium pyruvate, and supplemented with 10% (v/v) fetal bovine 
serum (ATCC), 1% (v/v) antibiotic-antimycotic, and 50 µM β-mercaptoethanol (complete 
medium). THP-1 monocyte cells were subcultured to a density of 4 × 105 cells/mL and 
their density did not exceed 1 × 106 cells/mL. All cells were grown in a humidified 
atmosphere (5% CO2, 95% room air) at 37˚C. THP-1 monocytes were differentiated by the 
addition of complete growth medium enriched with 100 nM phorbol 12-myristate 13-
acetate (PMA). Differentiated cells were plated in a 24-well plate at a density of 8 × 105 
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cells/mL (1 mL per well) and grown under the same conditions as for the THP-1 monocytes 
for 72 h. At this time, differentiated THP-1 cells were incubated with serum-free complete 
medium for 16 h after which time the medium was replaced with serum-free complete 
medium containing 500 nM of recombinant apo(a) variants KIV10KV, KIV10, or mutant 
variations of the former; the cells were incubated with the various protein additions for 12 
hours.  
 
2.3.3 Assessment of the presence of a covalent oxidized phospholipid moiety on 
apo(a)  
 SDS–PAGE was performed using 12% polyacrylamide gradient gels. Proteins were 
then transferred to a PVDF membrane (Millipore) in transfer buffer (25 mM Tris, 192 mM 
glycine, 10% (v/v) methanol). Blots were blocked in E06 blotting buffer (TBS buffer 
containing 1% BSA, 0.3 mM EDTA and 0.2% sodium azide) for 1 h, and then incubated 
with primary EO6 antibody (1:400) for 18 hours at 4°C. The membranes were washed with 
blotting buffer and incubated with an anti-IgM horseradish peroxidase conjugated 
secondary antibody (Sigma; 1:7500) for1 hour followed by a final wash in E06 blotting 
buffer.  Immunoreactive bands were visualized using SuperSignal West Femto Maximum 
Sensitivity Substrate (Thermo Scientific) with a FluorChem Q Gel Imaging System (Alpha 
Innotech).20 The same blots were then washed 5 times with 1X NET (150 mM NaCl, 5 mM 
EDTA, 50 mM Tris pH 7.4, and 0.05% Triton X-100) and blocked in 6% (w/v) non-fat 
milk in 1X NET for at least 1 h at room temperature. Blots were then incubated with a 
primary polyclonal sheep anti-Lp(a) antibody (1:15000) for at least 4 hours, washed three 
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times, and incubated with a rabbit anti-sheep HRP-conjugated secondary (1:7500) (GE 
Healthcare, USA). Blots were imaged as described above. 
 
2.3.4 Lysine Binding Assay  
Assessment of the lysine-binding ability of recombinant apo(a) proteins was 
performed using a modified lysine-Sepharose chromatography protocol.21 Briefly, two mL 
of lysine-Sepharose resin (GE Healthcare) was equilibrated with wash buffer (0.5 M NaCl, 
2.7mM KCl, 8 mM Na2HPO4, 1.46 mM KH2PO4; pH 7.4). Approximately 15 µg of protein 
was diluted approximately 20-fold with PBS and applied to the column. The column was 
then subjected to 6 X 1 mL washes. Fractions (1.5mL) were collected from gradient elution 
of the column with 0.1 µM to 200 mM of the lysine analog ε-aminocaproic acid (ε-ACA) 
in wash buffer. Fractions were assessed for the presence of recombinant apo(a) protein by 
immunoblotting analysis, using a polyclonal anti-Lp(a) antibody as previously described. 
Proteins were defined as being positive for lysine binding by their ability to remain bound 
to the lysine-Sepharose column in the presence of ε-ACA concentrations greater than 
1mM. 
 
2.3.5 Modeling of the Apo(a) KIV10 domain 
The Molecular Operating Environment (MOE) program22 was used for the modelling 
and input preparation for all molecular dynamics (MD) simulations, and analysis of the 
results obtained. All MD simulations were run using the NAMD program.23 The X-ray 
crystallographic structure of the wild-type kringle IV 10/M66 variant of human 
apolipoprotein(a) with ε-aminocaproic acid bound (PDB ID: 3KIV) was used as a starting 
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template for all subsequent enzyme structures in the current study.24 In particular, the 
His33Ala mutant was obtained from the wild-type enzyme via in silico mutagenesis using 
MOE.22 Missing hydrogens were added using the default protocols in MOE22 followed by 
spherical solvation around the boundaries of the protein to 6 Å. This solvated structure was 
then minimized using the Amber 12:EHT molecular mechanics (MM) forcefield.25, 26 
The minimized structure was then subjected to MD simulation with no restraints applied 
to the atoms of the complex except the wall restraint that was applied to the spherical water 
droplet to ensure retention of the water sphere. The MD began with a simulated annealing 
in which, at a constant volume and pressure, the temperature was gradually raised from 
150 to 300 K over 150 ps. This was followed by the production run for 4850 ps at a 
temperature of 300 K. 
The root mean squared deviation (RMSD) of the lysine binding site in apo(a) KIV10 (the 
selected residues used were Arg35, Asp54, Asp56, Trp60, Phe62, Arg69, and Trp70) was 
monitored and examined by cluster analysis to generate 10 clusters in the context of H33A, 
and 8 clusters in the wild-type form. The average structure of the highest cluster was 
selected and minimized using the Amber 12:EHT MM forcefield.25, 26 The calculated 
RMSDs also provided a statistical measurement of the deviation of the binding site of the 
mutant from that of the wild-type form. 
 
2.3.6 Extraction and characterization of non-covalently bound phosphocholine 
containing lipids on apo(a)  
The lipids were extracted from KIV10KV and KIV10KVΔAsp56 by the method 
previously described by Folch et al. with some modifications.27, 28 The lipid extracts were 
stored in 2:1 chloroform:methanol, flushed with nitrogen and then capped and stored at -
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80°C until analysis. The internal standard mixture spiked into each sample prior to 
extraction consisted of 1,2-dinonanoyl-sn-glycero-3-phosphocholine (09:0 P C), 1-
heptadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine (17:0 LPC) and 1,2-
diarachidonyl-sn-glycero-3-phosphocholine (20:0 PC).29 The oxidation products of PC 
were divided into two groups: fragmented (aldehydes and carboxylates), and non-
fragmented (hydroxides, hydroperoxides).  
The separation of oxidized PCs was carried out using reverse-phase (RP) 
chromatography as reported previously.28, 30-33 Briefly, lipid extracts were reconstituted in 
RP solvent A (described below) immediately prior to injection. Thirty microliters of the 
sample was injected onto an Ascentis Express C18 HPLC column (15 cm × 2.1 mm, 2.7 
µm; Supelco Analytical, Bellefonte, Pennsylvania, USA) with separation accomplished 
using a Prominence UFLC system from Shimadzu Corporation (Canby, Oregon, USA).  
Elution was performed by linear gradient of solvent A (acetonitrile/water, 60:40 v/v) and 
solvent B (isopropanol/acetonitrile, 90:10, v/v) with both solvents containing 10 mM 
ammonium formate and 0.1% formic acid. The time program used was as follows: initial 
solvent B at 32% until 4.00 min; switched to 45% B; 5.00 min 52% B; 8.00 min 58% B; 
11.00 min 66% B; 14.00 min 70% B; 18.00 min 75% B; 21.00 min 97% B; 25.00 min 97% 
B; 25.10 min 32% B until the elution was stopped at 30.10 min. A flow rate of 260 µl/min 
was used for analysis, and the column and sample tray were held at 45°C and 4˚C, 
respectively.  
The HPLC system was coupled to a 4000 QTRAP® triple quadrupole mass 
spectrometer system with a Turbo V electrospray ion source from AB Sciex (Framingham, 
Massachusetts, USA). For phosphatidylcholine, the detection was carried out in positive 
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ion mode by MRM of 84 transitions using a PC-specific product ion (184.3 m/z, Da) which 
corresponds to the cleaved phosphatidylcholine. The MRM settings were as follows: 
declustering potential=125, entrance potential=10, collision energy=53, collision cell exit 
potential=9 and dwell time= 50 msec. 34, 35 
  The instrument was tuned by direct infusion of poly(propylene glycol) (PPG) in 
both positive and negative modes and external mass calibration was performed at regular 
intervals. The retention time window in MRM was set to detect peaks of significance within 
60 seconds of confirmed retention time and data was collected utilizing Analyst® Software 
1.6 (AB Sciex). Multi-quant® Software 2.1 (AB Sciex) was used to compare peak areas of 
internal standards and unknown analytes to quantitate the results.   
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2.4 Results 
 
2.4.1 Identification of potential sites of covalent oxPC addition to the KIV10 and KV 
domains 
 In order to identify amino acids that can contain covalently-bound oxPC species, 
we undertook a site-directed mutagenesis approach. Oxidized phospholipids containing 
terminal aldehyde groups are the most reactive. As such, we exploited known mechanisms 
of covalent amino acid – aldehyde linkage. All amino acids which could form a Schiff base 
(arginine and lysine) or Michael adduct (histidine and cysteine) were considered candidates 
for oxPC addition. These residues were systematically mutated to an alanine, or glutamine 
in cases where a conservative mutation was thought to be appropriate. In this way all 
candidate lysine, arginine, and histidine residues were mutated. Cysteine residues were 
ruled out as candidate amino acids as all cysteine residues in apo(a) KIV10KV are involved 
in invariant disulfide bonds that are required to form the kringle structure. Additional 
mutations of Asp56 to Ala or Glu and Trp70 to Ala, respectively, were generated to further 
assess the requirement of an intact lysine binding site for covalent oxPC addition. These 
mutations were made based on the chimpanzee (Asp56 à Asn) and rhesus monkey (Trp70 
à Arg) KIV10 domains, which lack lysine binding ability, or by the apo(a) KIV7 weak 
lysine binding site (Asp56 à Glu). Figure 2.1 shows a representative structure of the 
KIV10KV.his protein, with all candidate amino acids shaded in grey.  
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Figure	2.1	Candidate	amino	acids	for	covalent	oxPC	addition	in	KIV10KV.	
Truncated apo(a), KIV10KV.his, was subjected to site directed mutagenesis to identify 
residue(s) required for oxPC addition. Critical amino acids were also mutated to assess 
the requirement for the strong lysine binding site for oxPC modification. The amino acids 
highlighted in grey are the amino acids that were systematically mutagenized. 
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2.4.2 Determination of covalent oxPC modification by E06 immunoblotting 
 Variants of the apo(a) KIV10KV construct were subjected to immunoblotting with 
the E06 antibody to identify the presence of covalently linked oxPC. Site directed 
mutagenesis of candidate residues in KIV10 revealed a clear role for the strong lysine 
binding site, as lysine binding deficient mutants Asp56 à Ala and Trp70 à Ala were all 
negative for the covalent oxPC modification (Figure 2.2A). The Asp56 à Glu variant 
retained E06 reactivity, albeit to a significantly reduced extent. All other apo(a) KIV10 
domain variants were positive for E06 immunoreactivity, with the exception of the His33 
à Ala variant. All variants generated in the KV domain of the KIV10KV variant (KV Lys 
à Ala substitutions) retained E06 immunoreactivity (Figure 2.2B). Screening of the apo(a) 
KIV10 domain alone revealed the presence of covalent oxPC modification, albeit to a lesser 
degree than that observed using KIV10KV (Figure 2.2C). No E06 immunoreactivity was 
observed using on the KIV10ΔAsp56 variant; this was also observed using the 
KIV10KVΔAsp56 variant. 
 
 
 
 
 
 
 
 
  
	
 
 
 
 
 
83 
	
Figure 2.2 Covalent oxPC modification of apo(a) KIV10 and KIV10KV assessed by 
E06 immunoreactivity 
Detection of covalent oxPC was detected by immunoblotting of apo(a) variants (see Fig. 
2 1) with the E06 antibody. Total apo(a) protein was detected using a sheep polyclonal 
anti-apo(a) antibody. Lysine binding was assessed based on elution profiles of the apo(a) 
variants from a lysine-Sepharose column. Panel A. Apo(a) variants with candidate 
mutations in the lysine binding site of apo(a). Apo(a) kringle IV10 (SK) was also 
subjected to this analysis. Panel B. Analysis of candidate histidine and arginine residues 
oxPC in KIV10. Panel C. Analysis of candidate lysine residues oxPC in KV. 
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2.4.3 Assessment of the lysine binding properties of E06-negative apo(a) variants 
 To further our analysis of the relationship between oxPC binding and the presence 
of a functional lysine binding site in KIV10, we next examined the ability of apo(a) variants 
that are E06-negative by western blotting to bind to lysine-Sepharose columns. Subjecting 
wild-type KIV10KV and KIV10 to lysine-Sepharose chromatography followed by a gradient 
elution with the lysine analog ε-ACA revealed the ability of these proteins to bind to lysine 
(Figure 2.3). Both Asp56 à Ala variations of KIV10KV and KIV10 were eluted in the wash 
fractions; the Asp56 à Glu and Trp70 à Ala variants of KIV10KV also did not bind to the 
lysine column. Finally the His33 à Ala variant bound to the lysine-Sepharose column in a 
comparable manner to that observed for the KIV10KV and KIV10 wildtype proteins. As 
such, the His33 à Ala variant of KIV10KV does not contain covalent oxPC but retains 
lysine binding properties comparable to wild-type apo(a).  
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Figure 2.3 Assessment of lysine binding properties of E06 non-reactive apo(a) 
variants. 
Lysine binding ability was assessed by applying 15 µg of each apo(a) variant to a lysine 
Sepharose column, followed by washing to remove non-specifically bound protein, and 
gradient elution using lysine analog ε-ACA to remove specifically-bound protein. 
Fractions were collected and analyzed by SDS-PAGE followed by anti-apo(a) blotting 
using a sheep polyclonal antibody. 
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Table 2.4 Summary of the investigation of covalent oxPC modification of apo(a) 
using site-directed mutagenesis of candidate residues in KIV10 and KV. 
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2.4.4 Computational assessment of KIV10 and KIV10 H33A 
 Using a molecular dynamic simulation approach, we modelled the human KIV10 
domain of apo(a) in complex with the lysine analog ε-ACA, both with and without the 
His33 mutation. This was performed to determine if there is a structural basis for the lack 
of oxPC addition to this residue. Analysis of the KIV10 domain allows for the observation 
of the His33 in its native environment (Figure 2.4). We observed that His33 does not appear 
to be within significant proximity of any amino acids that could participate in hydrogen 
bonding or salt bridge interactions. An overlay of the KIV10 and KIV10 H33A domains 
shows a lack of major changes in secondary structures or  overall conformation as a result 
of the His33 àAla substitution. 
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Figure 2.4 Computational assessment of KIV10 and KIV10 H33A. 
A molecular dynamic simulation of KIV10 (green) complexed with ε-ACA (ligand not 
shown) was modeled and overlayed with a KIV10 variant containing a His33 à Ala 
mutation (blue). Models are representative of the average conformation of the respective 
domains over a 5 ns simulation. The position of His 33 is shown on the overlay of the 
wildtype KIV10 domain (green His 33 visualized). 
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2.4.5 Identification of non-covalent oxPC species on apo(a) 
 Using organic extraction, the non-covalently bound oxPC on KIV10KV or 
KIV10KVΔAsp56 were removed from their respective proteins and subjected to reverse 
phase chromatography in tandem with mass spectrometry using a multiple reaction 
monitoring approach in positive ion mode for 184.3m/z. This specific mass to charge ratio 
is indicative of the phosphocholine head group that is present on a subset of lipids that is 
of interest (Fig. 2.5A) The top 5 most abundant lipid species are shown in Figure 2.5B and 
include POVPC (1-palmitoyl-2-(5'-oxo-valeroyl)-sn-glycero-3-phosphocholine), PONPC 
(1-palmitoyl-2-(9'-oxo-nonanoyl)-sn-glycero-3-phosphocholine), PGPC (1-palmitoyl-2-
glutaryl-sn-glycero-3-phosphocholine), PAzPC (1-palmitoyl-2-azelaoyl-sn-glycero-3-
phosphocholine), and KDdia-PC (1-palmitoyl-2-(4-keto-dodec-3-ene-dioyl)-
phosphatidylcholine). Amounts shown in Figure 2.5 are in ng oxPC per ng of protein. 
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						A.	
	
						B.	
	
Figure 2.5 Apo(a) KIV10KV contains non-covalently associated oxidized 
phosphatidyl choline species. 
A. Assessment of oxPC species that associate with the KIV10KV and KIV10KV D56A 
variants was conducted by extensive lipid extraction of the recombinant proteins 
followed by mass spectrometry. For phosphatidylcholine, detection was carried out in 
positive ion mode by MRM using a PC-specific product ion (184.3 m/z, Da) which 
corresponds to the cleaved phosphorylcholine head group. The top five most abundant 
species are represented in nanograms of oxPC per nanogram of protein, and are also 
represented as a schematic diagram in B. 
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Figure 2.6 Sequence comparison of human and primate KIV10, with insights to 
function. 
Differences between human, ape, and Old World monkey apo(a). The sequences of 
KIV10 from the indicated species are aligned with human KIV10 as well as plasminogen 
(Plg) KIV. Substitutions relative to human KIV10 are shaded in grey, and the invariant 
cysteine residues involved in disulfide bond formation are shaded in black. Also shown 
are the residues (asterisked) of the functional lysine binding site. Summarized are the 
LBS activity based on amino acid sequence and the presence of KV, as well as the ability 
to bind fibrin and be recognized by E06. 
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2.5 Discussion 
 Lipoprotein(a) has been established as a causal risk factor for cardiovascular 
disease and calcific aortic valve stenosis.36 The evidence for a pathophysiological role of 
Lp(a) is significant yet the mechanisms by which Lp(a) elicits its effects within the 
vasculature still remain unclear. Since its discovery in 2003 by Tsimikas and colleagues, 
the association of E06 reactive phospholipid species and Lp(a) has been proposed to be 
involved in the atherogenicity of Lp(a).37, 38 The finding that the apo(a) moiety of Lp(a) 
possesses a covalently linked oxPC molecule, as indicated by E06 immunoblotting, 
highlighted a novel structural element to the apo(a) glycoprotein.15 This finding provides 
additional rationale for the apo(a) component of the Lp(a) protein complex to be considered 
atherogenic, a title usually associated with the LDL-like moiety. The identification of a 
proinflammatory post-translational modification on apo(a) can potentially offer 
explanation to some of the proinflammatory effects associated with apo(a) on vascular 
cells, such as increased prostaglandin synthesis18 and upregulation of cell adhesion 
molecules in endothelial cells39, processes that are not yet fully understood. The exact 
molecular mechanisms by which this modification contributes to the proinflammatory and 
proatherogenic potentials of Lp(a) have only recently begun to be described. 
 The domain on apo(a) that harbours the oxidized phospholipid moiety has been 
previously investigated with the aid of non-human primate Lp(a), as well as several 
recombinant apo(a) variants. However, the location of the moiety on the primary sequence 
of apo(a) has yet to be determined. In this study, we subjected a recombinant human apo(a) 
variant to targeted alanine mutagenesis in order to deduce key structural features on the 
KIV10 and KV domains that are required of oxPC modification of apo(a). Initial studies by 
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Edelstein et. al., suggested that the covalent oxPC moiety on apo(a) was present on either 
Lys12 or Lys42 of the KV domain.15 This deduction was predicated by experiments 
performed on elastase fragments of human apo(a), with added insights from studies on 
rhesus monkey apo(a). Early studies hypothesized that the ability of apo(a) to induce IL-8 
expression in macrophages was a product of the oxPC moiety.40 Using a series of 
pancreatic and leukocyte elastase fragments it was determined that the oxPC moiety was 
present in the carboxyl-terminal portion of apo(a), as fragments 2 (KIV5-P) and 7 (KV-P) 
reacted with E06. Analysis of rhesus monkey apo(a), which lacks KV, suggested that KV 
was the domain harbouring the oxPC moiety as this variant does not react with the E06 
antibody.15 However, optimal IL-8 stimulating ability was not possessed by fragment 7, 
suggesting the absence of an immunogenic oxidized phospholipid on fragment 7.40 This 
was explored in detail in a later publication from our group and collaborators using human 
recombinant apo(a) variants, several of which entirely lacked the KV domain. In contrast 
to the report of Edelstein et al., our study showed that proteins lacking KV (17KΔV, 
17KΔVP, and KIV5-10) could possess E06 immunoreactivity.17 The battery of recombinant 
variants unveiled the importance of the KIV10 domain since all variants that lacked a KIV10 
domain possessed no immunoreactivity to E06.  
In order to further characterize the domains critical for oxPC addition in the present 
study, we first constructed a small apo(a) truncation including only the KIV10 exclusively, 
or the KIV10 and KV domains of apo(a) (Figure 2.1). Using these small apo(a) truncations 
we are able to confirm that these domains of apo(a) harbor the sequences giving E06 
immunoreactivity, thus an oxidized phospholipid moiety (Figure 2.2A). These results 
conclusively define KIV10 as the carrier of covalent oxPC modification. 
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The finding of a relationship between KIV10 lysine binding ability and oxPC 
addition raises two key questions. First: is lysine binding by this kringle actually required 
for addition of oxPC? Second: when assessing the elimination of certain pathogenic effects 
of apo(a) when the KIV10 LBS is mutated (for example evoking EC dysfunction in vitro7 
or atherogenesis in transgenic mice in vivo41), are these effects due to loss of lysine binding 
or loss of oxPC addition or both? Our current study provides a definitive answer to the 
first, while also providing a way forward to address the second. Utilizing several mutants, 
in the context of KIV10KV, we have demonstrated that mutation of human apo(a) at critical 
lysine binding residues Asp56 and Trp70 is able to block the ability of apo(a) to be modified 
by oxPC (Figure 2.2A). This result also is in agreement with the lack of E06 
immunoreactivity observed previously in rhesus monkey apo(a), as this species possesses 
a Trp70 à Arg substitution.15 Furthermore, using a more conservative Asp56 à Glu variant 
it can be observed that a significant reduction in the intensity of an E06 reactive band is 
present on this mutant, in contrast to the loss of E06 reactivity seen with the former lysine 
binding mutant. The conservative mutation mimics the key difference underlying the 
relatively weak lysine binding site present in human KIV7.21 Subjecting these variants to a 
lysine-Sepharose binding assay can confirm that these E06 unreactive proteins have no 
affinity for lysine, as Asp56 and Trp70 mutants elute from the resin without the addition 
of the lysine analog ε-ACA, whereas the non-mutated for remains about to the resin until 
the concentration of ε-ACA exceeds 100mM (Figure 2.3). However, even the weak lysine 
binding site variant, Asp56 à Glu, did not possess the ability to bind to lysine-Sepharose. 
This is potentially due to the use of 0.5 M NaCl in the wash buffer, which was used to 
prevent the non-specific interaction of the lysine-Sepharose and the glycans on apo(a). A 
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single KIV10 containing this mutation has been previously reported to possess lysine 
binding ability, albeit with 10-fold less affinity.21 In the context of bacterially purified 
KIV10, the D56E variant was able to withstand 0.15 M NaCl washes and up to 20 mM ε-
ACA, whereas wildtype eluted at 200 mM ε-ACA.21 The designation of this variant as a 
mutant with an intermediate ability to bind lysine provides support to the idea that lysine 
binding is important for the modification of this domain. The significant decrease in the 
ability of this variant to react with E06, without total abolishment of immunoreactivity, 
suggests an intermediate ability to be modified by phosphorylcholine containing oxPC. 
The extent of E06 reactivity positively correlates with the ability of apo(a) variants to bind 
lysine giving insights to the possible mechanism of oxPC addition. The realization of the 
importance of the lysine binding properties of apo(a) as a requirement for oxPC addition, 
allows for proper interpretation of the results seen in ape and Old World monkey apo(a) 
and may give insight into where the modification may be derived from. The interaction of 
apo(a) with various ligands in a manner dependent on the sLBS in KIV10, is well 
documented with ligands such as fibrin42, collagen43, and cell surface receptors.44, 45 The 
mechanism of oxPC addition to apo(a) is yet to be determined, however it is possible that 
the lysine binding properties of apo(a) may allow for apo(a) to interact with cell surface 
receptors and bring it into proximity of sources of oxidized phospholipids, such as the cell 
membrane. 
The location of the oxPC moiety on the primary sequence of apo(a) has been a key 
research question. The early reports of the oxPC modification on apo(a) suggested Lys12 
and Lys42 on KV as candidates of oxPC addition, based on the availability of these amino 
acids to participate in Schiff base formation.15 Mutation of Lys12/42 in combination was 
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found to have no effect on the ability of mutant apo(a) to react with the E06 antibody 
indicating that these two residues are not involved in oxPC addition.17 Aldehyde containing 
oxidized phospholipids are known to form adducts with thiol and amido containing amino 
acid side chains such as lysine, cysteine, histidine, and arginine.46 In this study we 
generated of 17 candidate proteins (derived from KIV10KV) in order to unambiguously 
determine the specific amino acid location of the covalent oxidized phosphocholine 
modification on apo(a). Figure 2.2C indicates that no lysine mutation made in KV was able 
to prevent the oxPC modification of apo(a), as determined by E06 immunoreactivity 
(Summarized in Table 2.1). This is in agreement with direct proof that the KV domain does 
not harbor the E06 reactive lipid moiety.17 In KIV10, we examined residues His3, His31, 
Arg32, His33, and Arg35. Figure 2.2B reveals that His3, His31, Arg32, and Arg35 all retain 
reactivity to the E06 anti-phosphocholine antibody. However, the His33 à Ala variant did 
not possess any reactivity to E06, indicating that it lacks an oxPC moiety. Furthermore, 
subjecting this variant to lysine-Sepharose chromatography proved that this mutation has 
no effect on the ability of KIV10 to bind to lysine (Figure 2.3), as it binds to a similar 
apparent affinity as the non-mutated protein. In addition, we used molecular dynamic 
simulations of the KIV10 domain in the absence and presence of the His33 mutation and 
found no significant changes in the structure of the lysine binding domain, or the entire 
KIV10 in general (Figure 2.4). In fact, a close look at the coordination sphere surrounding 
His33 reveals that it is most likely not involved in any hydrogen bonding or salt bridge 
interactions, and is thus available for participation in a Michael addition reaction with 
phospholipid containing an oxidized fatty acyl chain terminating in a free aldehyde. We 
have, therefore, identified the long-sought location of the covalent oxPC modification of 
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apo(a). Moreover, we have managed to decouple the oxPC addition to KIV10 from its lysine 
binding function, a summary can be seen in Figure 2.6. Therefore, the identification of 
His33 as the site of oxPC modification will allow for the determination of which pathogenic 
processes that the oxPC modification of apo(a) stimulates.  
 Previous studies on the roles of oxPC in apo(a) elicited processes have highlighted 
the role specifically for the E06 reactive phospholipid in inflammatory processes. A recent 
study was able to block the apo(a) induced inflammatory response in human macrophages 
using an E06 blocking approach, by 50%.47 Though E06 has a robust effect as a blocking 
agent, studies that used treatment of apo(a) with phospholipase A2 were able to almost 
blunt the effect of oxPC on inflammatory processes entirely.9, 48 This suggests that there 
are E06-unreactive pro-inflammatory oxPC on apo(a). Using a lipid extraction of KIV10KV 
and the associated Asp56 variant, we used a mass spectrometry approach and identified 
several species of oxPC that were non-covalently associated with apo(a) (Figure 2.6).  The 
results from the organic extraction of the E06 negative Asp56 variant, revealed almost a 
50% decrease in all of the detected oxPC species indicating that the lysine binding ability 
of apo(a) may also play a role in the ability to associate with non-covalent oxidized 
phospholipids. However, it can be noted that E06 remains able to identify a significant 
proportion of the oxPC on apo(a), as the wildtype apo(a) variant possessed greater than 
50% more detectable lipid species. It should be noted, however, that the roles of these non-
E06-detectable oxPC are unknown, since it is E06 reactivity that has been correlated to 
vascular risk in patients. 
In conclusion, this study is the first report of a variant of apo(a) that lacks the ability 
to be modified by E06 reactive oxidized phosphocholine while retaining its ability to bind 
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to lysine through KIV10. We have identified His33 within KIV10 as the long-sought site of 
oxPC addition. In addition, we have confirmed the association between the lysine binding 
ability of apo(a) and the ability for apo(a) to be modified by oxPC. The determination of 
the presence of non-covalent oxPC and the identification of the site of covalent oxPC 
addition will serve as valuable information in the elucidation of the roles for apo(a) in pro-
inflammatory processes within the vasculature, and specifically which of those roles are 
elicited by atherogenic oxPC. 
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Supplementary Table 0.1: Oligonucleotide primers used in this study   
Primer Sequence Rationale 
A 5’-TCCACTCCCAGGTCCAACTGCACCT-3’ 
Amplifies 
EcoRI 
restriction site 
before KIV10 
B 5’-CAAAaccggtGTCTTGTTCAGAAGG-3’ 
AgeI 
restriction site 
after KIV10 
C 5’- GAaccggtACAGAGAGGATATCACAGTAGTCA -3’ 
AgeI 
restriction site 
after KV 
D 5’-GTCCGGCAGTGCTACgcTGGTAATGGCCAGAG-3’ KIV10 H3A 
E 5’-CTCTGGCCATTACCAgcGTAGCACTGCCGGAC-3’ KIV10 H3A 
F 5’-CATGACACCAgcCCGGCATCAG-3’ KIV10 H31Ac 
G 5’-GATGACCAAGATTGACATG-3’ KIV10 H31Ac 
H 5’-CATGACACCACACCaGCATCAGAGGACCC-3’ KIV10 R32Q 
I 5’-GGGTCCTCTGATGCtGGTGTGGTGTCATG-3’ KIV10 R32Q 
J 5’-GGAATCCAGATGCCGcTACAGGCCCTTGGTG-3’ KIV10 D56A 
K 5’-CACCAAGGGCCTGTAgCGGCATCTGGATTCC-3’ KIV10 D56A 
L 5’-CAGATGCCGAaACAGGCCCTT-3’ KIV10 D56Ec 
M 5’-GATTCCTGCAGTAGTTCATTGTC-3’ KIV10 D56Ec 
N 5’-CAGCATCAGGgcGGAGTACTGC-3’ KIV10 W70Ac 
O 5’-GGGTCCATGGTAAAACAC-3’ KIV10 W70Ac 
P 5’-CTGTATGTTTGGGAATGGgcAGGATACCGGGGCAAGAAG-3’ KV K7A 
Q 5’-CTTCTTGCCCCGGTATCCTgcCCCATTCCCAAACATACAG-3’ KV K7A 
R 5’-GGAAAGGATACCGGGGCgcGAAGGCAACCACTGTTA-3’ KV K12A 
S 5’-TAACAGTGGTTGCCTTCgcGCCCCGGTATCCTTTCC-3’ KV K12A 
T 5’-AAGGATACCGGGGCAAGgcGGCAACCACTGTTACTG-3’ KV K13A 
U 5’-CAGTAACAGTGGTTGCCgcCTTGCCCCGGTATCCTT-3’ KV K13A 
V 5’-AGCACGTTCATTCCAGGGACAAATgcATGGGCAGGTCTG-3’ KV K42A 
W 5’-CAGACCTGCCCATgcATTTGTCCCTGGAATGAACGTGCT-3’ KV K42A 
Z 5’-ATAAATGGGCAGGTCTGGAAgcAAATTACTGCCGTAACCCTG-3’ KV K48A 
AA 5’-CAGGGTTACGGCAGTAATTTgcTTCCAGACCTGCCCATTTAT-3’ KV K48A 
BB 5’-GAATCCAAGAgcACTTTTTGACTACTGTGATATC-3’ KV K70c 
CC 5’-ATTGTGTAGCACCAGGGAC-3’ KV K70c 
DD 5’- ATGACTTCCAAGCTGGCCGTGGCT-3’ IL-8 
EE 5’- TCTCAGCCCTCTTCAAAAACTTCTC-3’ IL-8 
FF 5’- AGAGAGAGGCCCTCAGTTGCT-3’ GAPDH 
GG 5’- TTGTGAGGGAGATGCTCAGTGT-3’ GAPDH 
a Lower case letters indicate mutated sequences. 
b Plasmids containing KIV10 R36Q, KIV10 H33A, KIV10 R69Q mutations in the context of KIV10KV were 
synthesized by Genscript®. 
c Primers were designed for the generation of a linear blunt-ended product consistent with the Q5 site 
directed mutagenesis system (New England Biolabs). 
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3.1 Summary 
Elevated lipoprotein(a) (Lp(a)) levels are a causal risk factor for coronary heart 
disease. Accumulating evidence suggests that Lp(a) can stimulate cellular inflammatory 
responses through the kringle-containing apolipoprotein(a) (apo(a)) component. Here, we 
report that recombinant apo(a) containing 17 kringle-IV domains (17K) elicits a dose-
dependent increase in IL-8 mRNA and protein expression in THP-1 and U937 
macrophages. This effect was blunted by mutation of the lysine binding site in apo(a) 
KIV10, which results in the loss of oxidized phospholipid (oxPL) on apo(a). Trypsin-
digested 17K had the same stimulatory effect on IL-8 expression as intact apo(a) while 
enzymatic removal of oxPL from apo(a) significantly blunted this effect. Using siRNA to 
assess candidate receptors, we found that CD36 and TLR2 may play roles in apo(a)-
mediated IL-8 stimulation. Downstream of these receptors, inhibitors of MAP kinases JNK 
and ERK1/2 abolished the effect of apo(a) on IL-8 gene expression. To assess roles of 
downstream transcription factors, luciferase reporter gene experiments were conducted 
using an IL-8 promoter fragment. Apo(a) induced expression of this reporter construct was 
eliminated by mutation of IL-8 promoter binding sites for either NF-κB or AP-1. Our 
results provide a mechanistic link between oxPL modification of apo(a) and stimulation of 
proinflammatory intracellular signaling pathways.   
 
 
  
  
	
 
106 
 
3.2 Background 
Atherosclerosis is the leading cause of death in the industrialized world.1 The 
initiation of the development of an atherosclerotic lesion involves the activation of various 
vascular cell types, with macrophages playing a central role in this process as key mediators 
of the chronic inflammatory response.2 Upon damage to the vessel wall, endothelial cells 
secrete chemoattractants that can interact with monocytes and promote their directional 
migration, thereby recruiting these cells to the site of the developing lesions where they 
become differentiated into macrophages. Activated macrophages secrete a number of pro-
inflammatory cytokines including interleukin (IL)-1β, IL-6, IL-8, and tumor necrosis factor 
α (TNFα) that contribute to lesion progression.3, 4 
Elevated plasma concentrations of Lp(a) have been identified as a risk factor for 
vascular diseases such as peripheral vascular disease, stroke and coronary heart disease.5-7 
Lp(a) consists of a lipoprotein particle identical to low density lipoprotein (LDL) in both 
lipid composition as well as the presence of apolipoproteinB-100. However, Lp(a) is a 
unique lipoprotein class owing to the presence of the large glycoprotein apolipoprotein(a) 
(apo(a)) that is covalently linked to apoB-100 via a single disulfide bond.8 Apo(a) bears 
striking homology to the human plasma zymogen plasminogen and contains 10 distinct 
domains each homologous to the plasminogen KIV sequence. Each of the 10 apo(a) KIV 
domains is present in a single copy with the exception of KIV type 2 (KIV2) which can 
range from 3 to >30 identical copies in plasma Lp(a).9 Apo(a) also contains single copies 
of carboxyl-terminal domains that closely resemble the kringle V (KV) and pro-protease 
domains of plasminogen. Apo(a) KIV types 5-8 (KIV5-8) each possess a weak lysine 
binding site (LBS)10, several of which are responsible for the initial non-covalent 
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interaction of apo(a) and apoB-100 prior to covalent bond formation.11 KIV type 10 
(KIV10) is characterized by a strong LBS, which plays a role in apo(a)-mediated inhibition 
of plasminogen activation on fibrin and cell surfaces and binding of apo(a) to plasminogen 
receptors on the cell surface.12-14 
 Within the vascular milieu, the apo(a) component of Lp(a) has been reported to 
mediate a number of potential pro-inflammatory effects. In cultured vascular endothelial 
cells, Lp(a)/apo(a) has been shown to induce expression of the cell adhesion molecules 
ICAM, E-selectin and VCAM.15, 16 Lp(a)/apo(a) also promote the assembly of actin stress 
fibers resulting in cell contraction and increased endothelial cell permeability.17 
Lp(a)/apo(a) has been implicated in pro-inflammatory processes through its ability to bind 
to the integrin Mac-1 on endothelial cells, resulting in the Mac-1-dependent promotion of 
monocyte adhesion and transendothelial migration.18 The apo(a) component of Lp(a) has 
been shown to induce gene expression in THP-1 macrophages, including the upregulation 
of IL-8 expression; this effect was mapped to the carboxyl-terminal half of the apo(a) 
protein, with a role for the KV domain suggested.19 However, definitive identification of 
the apo(a) sequences required for this response, as well as elucidation of the mechanisms 
underlying it, have not been accomplished to date.  
 In recent years much attention has been paid to the oxidized phospholipid (oxPL) 
modification of Lp(a) and the extent to which it underlies the proatherogenic properties of 
this lipoprotein.20-22 It has been shown that, compared to LDL, Lp(a) is a preferential carrier 
of oxPL in plasma23, and that the modification consists of a lysine-phosphatidyl choline 
adduct that may reside within the apo(a) KV sequence.24 More recently, it has been 
demonstrated that oxPL addition to apo(a) requires the strong LBS in KIV10, while apo(a) 
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species lacking the KV domain were reported to contain oxPL to an extent comparable to 
full-length apo(a).25 OxPL modification of apo(a) was demonstrated to induce apoptosis in 
macrophages undergoing endoplasmic reticulum (ER) stress26; this response could be 
maintained upon trypsin digestion of the oxPL-containing apo(a) suggesting that the intact 
protein sequence was not required. In the same study, it was shown that the pro-apoptotic 
effects of apo(a) and Lp(a) were mediated by a TLR2/CD36–dependent signaling 
pathway.26 Taken together, the data suggest that oxPL modification of apo(a) facilitates 
interaction of apo(a)/Lp(a) with CD36 and macrophage toll-like receptors that, in turn, 
activate cellular pathways responsible for apoptosis in the context of sustained ER stress. 
This pathway may underlie, in part, the ability of Lp(a) to promote the development of 
atherosclerotic plaque vulnerable to rupture and subsequent atherothrombotic events. 
In the current study we sought to identify the cellular mechanisms by which apo(a) 
can induce a different pro-atherosclerotic mechanism: namely, induction of interleukin-8 
expression in macrophages. 
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3.3 Experimental Methods 
 
3.3.1 Expression, purification and characterization of recombinant apo(a) and 
plasma-derived Lp(a) 
 Plasmids encoding a 17-kringle-containing form of recombinant apo(a) (17K r-
apo(a)), as well as 17KΔLBS10 (containing an Asp → Ala substitution at amino acid 
position 57 that abolishes the strong LBS in the KIV10 domain) and 17KΔV (containing a 
deletion of the KV domain) were constructed and expressed in human embryonic kidney 
(HEK 293) cells as previously described.12, 27, 28 All r-apo(a) species were purified from the 
conditioned medium (CM) of stably-expressing cell lines by lysine–Sepharose (GE 
Healthcare) affinity chromatography as previously reported.12, 28 Purified proteins were 
assessed for purity by SDS-PAGE followed by silver staining, and the absence of 
endotoxin was verified using the ToxinSensor Chromogenic LAL Endotoxin Assay Kit 
(GenScript) as per the manufacturer’s protocol.  
 Lp(a) was purified from the plasma of a healthy volunteer with an apo(a) isoform 
containing 16 KIV domains using a previously described protocol.14 Purified Lp(a) 
concentrations were determined by bicinchoninic acid assay (Pierce) using BSA as a 
standard. The integrity of the purified Lp(a) was assessed by SDS-PAGE (under either 
reducing or non-reducing conditions) followed by silver staining.  
Assessment of the presence of an oxidized phospholipid moiety on purified 
recombinant apo(a) variants and purified Lp(a) was performed by western blotting as 
previously described using E06 IgM (Avanti Polar Lipids) which is specific for the 
phosphorylcholine head group of oxidized phospholipids. Total apo(a) protein was 
detected using an anti-apo(a) monoclonal antibody.   
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3.3.2 Cell Culture 
 THP-1 acute monocytic leukemia cells (ATCC# TIB-202) were cultured in RPMI-
1640 medium adjusted to contain 4.5 g/L glucose, 10 mM HEPES pH 7.4 and 1.0 mM 
sodium pyruvate, and supplemented with 10% (v/v) fetal bovine serum (ATCC), 1% (v/v) 
antibiotic-antimycotic (Gibco), and 50 µM β-mercaptoethanol (complete medium). U937 
histiocytic lymphoma cells (ATCC# CRL-1593.2) were cultured in RPMI-1640 medium 
adjusted to contain 1.0 mM sodium pyruvate, and supplemented with 10% (v/v) fetal 
bovine serum and 1% (v/v) antibiotic-antimycotic. All cells were grown in a humidified 
atmosphere (5% CO2, 95% room air) at 37˚C. THP-1 monocytes were differentiated by the 
addition of complete growth medium enriched with 100 nM phorbol 12-myristate 13-
acetate (PMA). U937 cells were differentiated following the same protocol, except that 250 
nM PMA was used.29 Differentiated cells were plated in a 24-well plate at a density of 8 × 
105 cells/mL (1 mL per well) and grown under the same conditions as for the THP-1 
monocytes for 72 h. At this time, differentiated THP-1 or U937 cells were incubated with 
serum-free complete medium for 16 h after which the medium was replaced with fresh 
serum-free complete medium containing treatments such as apo(a), Lp(a), and/or ε-ACA 
at the concentrations indicated in the Figure Legends; the cells were incubated with the 
treatments for 12 hours. In some experiments THP-1 cells were treated with specific 
inhibitors (Cayman Chemical) to assess downstream effectors according to the 
manufacturer’s specifications as outlined in Supplemental Table 1. 17K r-apo(a) was added 
to the cells at a final concentration of 500 nM either concurrently or following treatment 
with the respective inhibitors; cells were then incubated for 12 hours. 
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3.3.3 Trypsin and Phospholipase A2 (PLA2) Treatment of Apo(a) 
 In some experiments, 17K r-apo(a) (42 µg) was subjected to treatment with 0.21 
µg Trypsin Gold (Promega) for one hour at 37°C followed by quenching of the reaction by 
the addition of 0.4 µg soybean trypsin inhibitor (STI). Treatment of 17K r-apo(a) with 
PLA2 was based on a protocol modified from Seimon et al.26 Briefly, 17K r-apo(a) (42 µg) 
was dialyzed in Tris buffer (0.05 M Tris pH 7.4, 0.15 M NaCl), after which 10 U of PLA2 
(Sigma) supplemented with 5 mM CaCl2 was added and the reaction incubated for one 
hour at 37°C. Following PLA2 incubation some samples were further subjected to trypsin 
digestion as described above. After application of the reaction mixtures to THP-1 
macrophages, the final apo(a) concentration in the medium was 500 nM in all cases.  
 
3.3.4 Transfection of siRNA 
Following 48 hours of PMA stimulation, THP-1 macrophages (seeded as described 
above) were transfected with CD36 siRNA, TLR2 siRNA, or scrambled control siRNA 
(Santa Cruz Biotechnology) each at a final concentration of 80 nM as per the 
manufacturer’s protocol. The transfection mixture was incubated with the cells for 10 h 
followed by the addition of an equal volume of complete medium for 12 hours, and then 
incubated in serum-free complete medium for an additional 12 hours prior to 12 hours of 
apo(a) treatment (performed as described above). Cells were harvested and assayed 48 
hours post transfection. Percent knockdown was determined using quantitative real-time 
PCR (qRT-PCR) analysis (see below), using primers pairs K/L and M/N (Supplemental 
Table 2) for CD36 and TLR2, respectively.  
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3.3.5 Quantitative Real Time PCR 
THP-1 macrophage lysates were collected after apo(a) treatment using RLT Plus 
buffer (Qiagen) supplemented with 1% (v/v) 2-mercaptoethanol. Total RNA was isolated 
from the lysates using the RNeasy Plus kit (Qiagen) as per the manufacturer’s protocol. IL-
8 gene expression was assessed by qRT-PCR utilizing primer pair A/B (Supplemental 
Table 2) and normalized to GAPDH using primer pair C/D (Supplemental Table 2). All 
DNA primers utilized in this study were synthesized by Integrated DNA Technologies. 
Reactions were assembled in triplicate using the iTaq™ Universal SYBR® Green One-
Step Kit (BioRad) according to the manufacturer’s protocol and performed on a BioRad 
CFX 96 Thermal Cycler. Relative quantification of IL-8 mRNA was determined by 
normalization of the threshold cycle for each sample with that of GAPDH from the same 
reaction well, using BioRad CFX Manager Software Version 3.1 (Bio-Rad). All mRNA 
expression data are reported as a fold-increase compared to the control sample from cells 
not treated with apo(a). 
 
3.3.6 IL-8 Protein Quantification in Conditioned Medium 
 CM was harvested from the THP-1 macrophages at the time of lysate preparation. 
The amount of IL-8 protein in the CM was measured in triplicate using a human IL-8 
ELISA Kit (Invitrogen) according to the manufacturer’s protocol after a 1/1000 dilution of 
CM.  
3.3.7 Generation of IL-8 Reporter Constructs 
Genomic DNA was extracted from THP-1 monocytes using the QIAamp DNA 
Blood Midi Kit (Qiagen) according to the manufacturer’s protocol. A functional promoter 
	
 
113 
 
fragment of the human CXCL8 gene was generated by amplification of the (-162) to (+54) 
sequence of CXCL8 from the genomic DNA using primer pair E/F (Table 3.1); Primer E 
introduces an XhoI restriction site and Primer F overlaps with a native HindIII site. PCR 
reactions were carried out in a BioRad CFX96 thermocycler using Q5 High-Fidelity DNA 
Polymerase (New England Biolabs) under the following conditions: denaturation at 98°C 
(10 sec), annealing at 62°C (30 sec), and elongation at 72°C (20 sec) for a total of 40 cycles. 
The PCR product was digested with HindIII-HF and Xho1, (New England Biolabs); the 
pGL3 Basic firefly luciferase reporter vector (Promega) was also digested with these 
enzymes. The promoter fragment was agarose gel-purified and ligated with the vector at 
16°C overnight using T4 DNA ligase (Invitrogen) to create the plasmid -162 IL-8. ∆NFκB 
and ∆AP-1 variants were generated by site-directed mutagenesis of -162 IL-8 using the 
QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies) with the mutagenic 
primer pairs G/H and I/J (Table 3.1), respectively. 
  
3.3.8 Dual-Luciferase Assays 
THP-1 monocytes were transfected with either empty pGL3 Basic plasmid, the -
162 IL-8 reporter construct or mutant constructs, together with pRL-TK renilla luciferase 
control plasmid (Promega) using Lipofectamine LTX (Invitrogen). After 48 hours, THP-1 
monocytes were seeded into 24-well plates (8x105 cells/well) and differentiated into 
macrophages as described above. Quantification of luciferase activity of transfected THP-
1 macrophages was performed using the Dual-Glo® Luciferase Assay System (Promega), 
as per the manufacturer’s protocol. Firefly luciferase activity was divided by the renilla 
luciferase activity to correct for differences in cell number and transfection efficiency; 
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corrected luciferase activities are expressed relative to that from cells transfected with the 
-162 IL-8 construct and not treated with apo(a).  
 
3.3.9 Statistical Methods 
 Statistical analyses were performed with the use of SPSS software, version 22.0 
(SPSS Inc., Chicago, Illinois). Comparisons between samples were performed by one-way 
ANOVA using a Tukey post-hoc analysis. Statistical significance was assumed at p < 0.05.  
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3.4 Results 
3.4.1 The apo(a) component of Lp(a) stimulates IL-8 gene expression and protein 
secretion from THP-1 macrophages in a dose-dependent manner 
 We incubated THP-1 cells – differentiated into macrophages by PMA treatment – 
with 350 nM of LDL, 17K r-apo(a), or Lp(a) and assessed IL-8 gene expression using qRT-
PCR (Fig. 3.1A). Treatment with apo(a) was shown to stimulate IL-8 gene expression by 
8.4-fold compared to untreated control. The increase in IL-8 gene expression by Lp(a) was 
comparable to that observed for apo(a), while LDL treatment of the cells resulted in no 
significant increase in IL-8 gene expression (Fig. 3.1A). Treatment with apo(a) or Lp(a) 
resulted in a corresponding increase in IL-8 protein secretion into the conditioned medium 
while no appreciable increase was observed following LDL treatment (Fig. 3.1B). The 
effect of 17K on IL-8 mRNA expression was dose-responsive between 100 and 1000 nM 
17K (corresponding to ~2.5 - 25 mg/dL) (Fig. 3.1C). Likewise, a dose-dependent effect of 
17K on IL-8 protein secretion from THP-1 macrophages was observed (Fig. 3.1D).  
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Figure	 3.1	 The	 apo(a)	 component	 of	 Lp(a)	 stimulates	 IL-8	 expression	 in	 THP-1	
macrophages	
A. THP-1 macrophages were treated with 350 nM of each of LDL, 17K recombinant 
apo(a), or Lp(a) for 12 hours; control cells lacked apo(a). Total cellular RNA was then 
extracted for each condition and analyzed by real-time qRT-PCR using primers specific 
for IL-8 and GAPDH. IL-8 mRNA levels were normalized to GAPDH. The abundance 
of IL-8 mRNA is expressed relative to that in the untreated cells (Control). B. 
Conditioned medium harvested from treated cells in A was assayed for IL-8 protein 
expression using a human IL-8 ELISA kit. C. THP-1 macrophages were treated with a 
range of concentrations of 17K r-apo(a) (100 nM – 1000 nM) for 12 hours and IL-8 
mRNA abundance was measured as above. The abundance of IL-8 mRNA is expressed 
relative to that in the cells not exposed to apo(a). D. Conditioned medium harvested from 
treated cells in C was assayed for IL-8 protein expression using a human IL-8 ELISA 
kit. In all cases, the data represent the means ± s.e.m. of at least three independent 
experiments each conducted in triplicate. *: p < 0.05 and **: p < 0.01 versus Control. 
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3.4.2 Apo(a) stimulation of IL-8 production in THP-1 macrophages requires the 
lysine-binding site in apo(a) KIV10 domain 
 To assess the mechanism by which apo(a) stimulates IL-8 expression, the role of 
lysine-dependent interactions and the contribution of specific domains in apo(a) to the 
effect was assessed. The addition of the lysine analogue ε-aminocaproic acid (ε-ACA) did 
not affect the ability of 17K to increase IL-8 expression (Fig. 3.2A). On the other hand, 
using a recombinant apo(a) variant lacking the intact strong lysine binding site (LBS) in 
KIV10 (17KΔLBS10; Fig. 3.2A), we found that treatment with this apo(a) variant 
significantly blunted (by 70%) the ability of apo(a) to induce IL-8 gene expression. To 
explore a role for the KV domain of apo(a) we utilized a recombinant variant of 17K apo(a) 
lacking this domain (17KΔV; Fig. 3.2A). Treatment of THP-1 macrophages with 17KΔV 
did not result in a significant change in IL-8 mRNA induction compared to treatment with 
17K (Fig. 3.2A). As in our previous work, immunoblotting of these r-apo(a) species using 
the anti-oxPL antibody E06 revealed that both 17K and 17KΔV as well as Lp(a) contain 
oxPL while the 17KΔLBS10 lacks detectable oxPL (Fig. 3.2B). 
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Figure	3.2	Role	of	lysine-dependent	interactions	on	the	ability	of	apo(a)	to	stimulate	
IL-8	gene	expression	in	THP-1	macrophages.	
A. THP-1 macrophages were treated with 500 nM each of 17K, 17KΔLBS10, or 17KΔV 
recombinant apo(a), and/or 200 mM ε-ACA in serum free medium for 12 hours. IL-8 
mRNA levels were quantified by real-time qRT-PCR using primers specific for IL-8 and 
GAPDH. IL-8 mRNA levels were normalized to GAPDH and the relative abundance of 
IL-8 mRNA was expressed relative to the untreated control. The data represent the 
means ± s.e.m. of at least three independent experiments each conducted in triplicate. 
***: p < 0.001 versus Control; †: p < 0.05 versus 17K. B. Immunoblotting of plasma 
purified Lp(a) and 17K r-apo(a) variants was performed using an E06 antibody specific 
for oxidized phosphocholine. A monoclonal anti-apo(a) antibody (α-apo(a)) was used to 
detect total apo(a) protein. 
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3.4.3 Apo(a) stimulation of IL-8 mRNA and protein expression in U937 
macrophages is dependent on the KIV10 lysine-binding site 
 In order to confirm that the effect of Lp(a)/apo(a) on IL-8 expression we observed 
in THP-1 cells could also be shown using other macrophage-like cell lines, U937 
histiocytic lymphoma cells differentiated with PMA were assayed in the same manner as 
THP-1 macrophages. We found that 17K apo(a) and Lp(a) treatment of the U937 cells 
resulted in a 6.4-and 3.4-fold increase in IL-8 mRNA, respectively (Fig. 3.3A). Treatment 
of these cells with 17KΔLBS10 resulted in significantly less of an increase in IL-8 
expression compared to 17K-treated cells. In this cell line, 17KΔV treatment resulted in a 
significant increase in IL-8 mRNA compared to 17K (Fig. 3.3A). Similar trends were 
observed when secreted IL-8 protein was quantified after treatment with 17K, 
17KΔLBS10, 17KΔV and Lp(a) treatment, (Fig. 3.3B).  
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Figure	3.3	Apo(a)-induced	IL-8	mRNA	and	protein	expression	in	U937	macrophages	is	
dependent	on	the	KIV10	lysine-binding	site.	
A. Differentiated U937 macrophages were treated with 500 nM each of Lp(a), 17K, 
17KΔLBS10, or 17KΔV recombinant apo(a) in serum free medium for 12 hours. IL-8 
mRNA levels were quantified by real-time qRT-PCR using primers specific for IL-8 and 
GAPDH. IL-8 mRNA levels were normalized to GAPDH and the relative abundance of 
IL-8 mRNA was expressed relative to the untreated control. B. Conditioned medium 
harvested from treated cells in A was assayed for IL-8 protein expression using a human 
IL-8 ELISA kit. In all cases, the data represent the means ± s.e.m. of at least three 
independent experiments each conducted in triplicate. *: p < 0.05, **: p < 0.01 and ***: 
p < 0.001 versus Control; †: p < 0.05, ††: p < 0.01 and †††: p < 0.001 versus 17K. 
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3.4.4 Apo(a)-mediated stimulation of IL-8 expression is reduced by phospholipase 
A2, but not trypsin treatment 
 We sought to demonstrate a direct role for apo(a)-associated oxPL in mediating the 
stimulatory effect of apo(a) on IL-8 expression in THP-1 cells. Treatment of cells with 
apo(a) that had undergone trypsin treatment resulted in no significant difference in IL-8 
gene expression or protein production compared to undigested 17K (Fig. 3.4A, B). 
However, enzymatic removal of oxPL with PLA2 resulted in a significant decrease in IL-8 
mRNA expression of 53% compared to untreated 17K. (Fig. 3.4A). A similar result was 
seen when PLA2 treatment was followed by tryptic digestion of 17K; in this case a 67% 
decrease in IL-8 gene expression was observed compared to treatment with 17K that had 
been subjected to tryptic digestion alone (Fig. 3.4A). Comparable trends were seen with 
respect to IL-8 protein expression, wherein PLA2 treatment of apo(a) in the absence or 
presence of tryptic digestion resulted in 73% and 72% decreases in IL-8 protein levels, 
respectively, compared to the corresponding species not treated with PLA2 (Fig. 3.4B).  
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Figure	 3.4	 Apo(a)-mediated	 stimulation	 of	 IL-8	 expression	 is	 reduced	 by	
phospholipase	A2,	but	not	trypsin	treatment.	
A. THP-1 macrophages were treated with 500 nM 17K which was pretreated with either 
trypsin or PLA2 or by PLA2 followed by trypsin for 12 hours. IL-8 mRNA levels were 
quantified by real-time qRT-PCR using primers specific for IL-8 and GAPDH. IL-8 
mRNA levels were normalized to GAPDH and the relative abundance of IL-8 mRNA 
was expressed relative to the untreated control. B. Conditioned medium harvested from 
treated cells in A was assayed for IL-8 protein expression using a human IL-8 ELISA 
kit. The data represent the means ± s.e.m. of three independent experiments each 
conducted in triplicate. *: p < 0.05, **: p < 0.01 and ***: p < 0.001 versus no treatment 
(open bars); †: p < 0.05 and ††: p < 0.01 versus untreated17K. 
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3.4.5 Identification of THP-1 cell surface receptors involved in mediating apo(a) 
induced IL-8 expression 
 To identify potential cell surface receptor(s) involved in binding to apo(a) and 
facilitating IL-8 expression, a candidate receptor approach was taken. The expression of 
candidate receptors CD36 and TLR2 – either alone or in combination – was reduced using 
siRNA methodology, following which the cells were treated with 17K for 12 hours. 
Knockdown of both CD36 and TLR2 receptors individually as well as together resulted in 
an apparent blunting of the apo(a)-mediated increase in IL-8 mRNA levels compared to 
the apo(a)-treated control siRNA sample (Fig. 3.5A). When corresponding IL-8 protein 
levels were measured the apparent blunting of the apo(a)-stimulated increase was only seen 
under the conditions of the double knockdown (Fig. 3.5B). qRT-PCR analysis of siRNA 
treated samples revealed a relatively modest mRNA knockdown of 27% and 35% for CD36 
and TLR2 respectively (Fig. 3.5C). 
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Figure	 3.5	 The	 role	 of	 lipid-specific	 THP-1	 macrophage	 cell	 surface	 receptors	 on	
apo(a)-stimulated	IL-8	production.	
THP-1 macrophages were transfected with control siRNA (siControl) or siRNA 
corresponding to CD36, TLR2 or CD36 and TLR2 in combination. After 12 hours, cells 
were treated with 500 nM 17K for an additional 12 hours. A. Total cellular RNA was 
extracted and analyzed by real-time qRT-PCR, using primers specific for IL-8 and 
GAPDH. IL-8 mRNA levels were normalized to GAPDH and the abundance of IL-8 
mRNA was expressed relative to that in the cells not transfected with siRNA and not 
treated with 17K (Control). B. The amount of IL-8 protein secreted was measured in 
medium harvested from the cells treated with apo(a) in A using a human IL-8 ELISA. 
C. To determine receptor knockdown efficiency, real-time qRT-PCR was performed on 
RNA harvested from the cells in A using specific primer pairs for TLR2, CD36, and 
GAPDH. mRNA levels were normalized to GAPDH and expressed relative to those in 
cells transfected with the control siRNA. In all cases, data shown are the means ± s.e.m. 
of 2 – 4 independent experiments. 
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3.4.6 Characterization of the intracellular signaling pathways mediating apo(a)-
induced IL-8 expression 
 To examine the molecular mechanisms underlying the apo(a)-stimulated IL-8 gene 
expression in THP-1 macrophages, a series of inhibitors for signaling pathways and 
transcription factors that are known to act downstream of TLR2 and CD36 was used. 
Compared to control cells treated with 17K but no inhibitor, induction of IL-8 mRNA 
levels was found to be decreased between 40% and 85% using the ERK-specific MEK 
inhibitors PD98059 and PD0325901 and the c-Jun N-terminal kinase (JNK) inhibitor 
SP600125 (Fig. 3.6A). Inhibition of p38 kinase using the inhibitor SB203580 resulted in 
no change in the ability of apo(a) to induce IL-8 gene expression. Inhibition of transcription 
factor NF-κB by the inhibitor BAY-11-7082 resulted in a dramatic decrease 
(approximately 70%) in the ability of apo(a) to stimulate IL-8 expression. No effect on IL-
8 mRNA levels was observed upon inhibition of AP-1 with SR11302 (Fig. 3.6A). 
Measurement of IL-8 protein secretion in the corresponding samples showed similar trends 
to those observed for the mRNA abundance (Fig. 3.6B). Treatment with the inhibitors in 
the absence of 17K apo(a) did not result in an appreciable change in IL-8 expression (data 
not shown). 
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Figure	3.6	ERK1/2	and	JNK	signaling	and	activation	of	transcription	factor	NF-κB	are	
required	to	stimulate	IL-8	gene	expression.	
THP-1 macrophages were treated with 17K r-apo(a) alone or in combination with a 
variety of MAP Kinase pathway inhibitors (specific for ERK1/2 (PD98059, 
PD0325901), JNK (SP600125) or P38 (SB203580)), or inhibitors of downstream 
transcription factors NF-κB and AP1 (BAY-11-7082 or SR11302 inhibitors 
respectively). Conditions for inhibitor treatments were as outlined in Supplemental 
Table 1. A. IL-8 mRNA levels were quantified by real-time qRT-PCR, using primers 
specific for IL-8 and GAPDH. IL-8 mRNA levels were normalized to GAPDH and the 
abundance of IL-8 mRNA was expressed relative to the cells not treated with 17K or 
inhibitor (Control). B. The amount of IL-8 protein secreted was measured in medium 
harvested from the cells treated with apo(a) in A using a human IL-8 ELISA. The data 
represent the means ± s.e.m. of at least three independent experiments each conducted 
in triplicate. ***: p < 0.001 versus Control; ††: p < 0.01 and †††: p < 0.001 versus 17K 
alone. 
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3.4.7 Apo(a) stimulates transcription of the IL-8 promoter in THP-1 macrophages 
 In order to assess the ability of apo(a) to stimulate transcription of the human IL-8 
promoter, a firefly luciferase reporter plasmid was assembled containing a functional 216-
bp promoter fragment of the CXCL8 gene (between -162 and +54). After transfection of 
THP-1 monocytes with the reporter plasmid followed by differentiation into macrophages, 
treatment with 17K resulted in a more than 10-fold increase in relative luciferase activity, 
compared to that observed in control transfected cells not treated with 17K (Fig. 3.7A). In 
accordance with our findings with endogenous IL-8 mRNA, treatment of the transfected 
cells with 17KΔV resulted in a similar increase in luciferase activity to that observed with 
17K, while treatment with 17KΔLBS10 resulted in a significantly blunted increase (Fig. 
3.7A). Luciferase assays were also conducted using cells transfected with -162bp IL-8 
promoter constructs containing mutations in the NFκB and AP-1 transcription factor 
binding sites (Fig. 3.7B). The basal activities of both mutant promoters were reduced 
compared to the wild-type promoter, although they remained substantially higher than the 
activity observed from the promoterless control plasmid (pGL3 Basic) (Fig. 3.7B). The 
ability of 17K to enhance expression of the IL-8 promoter was almost abolished with either 
mutant (Fig. 3.7B).  
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Figure	3.7	Apo(a)-mediated	up-regulation	of	the	 IL-8	promoter	requires	the	apo(a)	
KIV10	domain	and	intact	NF-κB	and	AP-1	binding	sites.	
THP-1 monocytes were co-transfected with either the empty pGL3 Basic firefly 
luciferase reporter plasmid or the -162 IL-8 firefly luciferase reporter plasmid, together 
with the pRL-TK renilla luciferase internal control plasmid. Following transfection, cells 
were differentiated into THP-1 macrophages using PMA. A. Cells transfected with the 
IL-8 promoter construct were treated for 12 hours with 500 nM each of 17K, 
17KΔLBS10, or 17KΔV recombinant apo(a) proteins. Cellular lysates were then 
harvested and luciferase activity was quantified. Firefly luciferase activities were 
normalized to renilla luciferase activities, and expressed relative to that in cells 
transfected with -162 IL-8 but not treated with apo(a). The data represent the means ± 
s.e.m. of 3 – 7 independent experiments each conducted in triplicate. *: p < 0.05 and 
***: p < 0.001 versus -162 IL-8 Untreated; †: p < 0.05, ††: p < 0.01 and †††: p < 0.001 
versus 17K. B. THP-1 monocytes were transfected with the either the wild-type -162 IL-
8 reporter plasmid, or corresponding promoter constructs containing mutated NFκB or 
AP-1 sites (ΔNF-κB or ΔAP-1, respectively); transfected cells were treated with or 
without 500 nM 17K apo(a). Lysates were prepared and relative luciferase activities 
determined as described in A. The data represent the means ± s.e.m. of 3 – 7 independent 
experiments each conducted in triplicate. ***: p < 0.001 versus no 17K treatment. 
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3.5 Discussion 
 Despite its recognition as a causal risk factor for vascular disease, the nature of the 
contribution of lipoprotein(a) to atherogenesis remains poorly understood. It has been 
known for over 25 years that Lp(a) can accumulate at the sites of developing lesions.30 
Evidence has been generated to suggest that the pathogenicity of Lp(a) thus stems from its 
proatherogenic potential, owing to its LDL-like moiety, and from the ability of the unique 
apo(a) component of Lp(a) to attenuate the plasminogen activation system.31 In recent 
years, Lp(a) has been shown to preferentially associate with pro-inflammatory oxidized 
phospholipids which may underlie the risk associated with elevated plasma Lp(a) levels. It 
has been hypothesized that Lp(a) delivers oxidized phospholipids to the sites of 
atherosclerotic lesions, thereby contributing to chronic inflammation in this milieu.23  
 Atherogenesis is characterized by inflammation, mediated through the activity of a 
complex network of chemokines that play key roles throughout the process of lesion 
development. IL-8 (CXCL8) is a chemokine in the CXC subfamily that is expressed in 
macrophages present in atherosclerotic lesions.32 In addition to its role as a monocyte and 
neutrophil chemoattractant and activator, IL-8 promotes monocyte adhesion to arterial 
endothelial cells in the early stages of lesion formation33, 34, while contributing primarily 
to angiogenesis in the late stages of plaque formation.35  
 It was previously reported that Lp(a), through its apo(a) moiety, induces IL-8 gene 
expression in THP-1 macrophages.19 In this study, the apo(a) kringle V domain was 
proposed to be critical for the enhancment of IL-8 expression, perhaps through the presence 
of pro-inflammatory oxPL postulated to be present in this sequence.24 However, more 
recent findings from our group suggest that the strong LBS in KIV10 is required for 
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oxidized phospholipid modification of apo(a), and that removal of the KV domain does not 
affect oxPL addition.25 In the present study we addressed the mechanism by which apo(a) 
enhances IL-8 expression in THP-1 macrophages and the role of oxPL modification of 
apo(a) in this process. In initial experiments, we demonstrated that the apo(a) component 
of Lp(a), represented by a 17-kringle recombinant form of the protein, was able to induce 
IL-8 expression while LDL was not (Fig 1A,B). Dose-reponse curves indicate that IL-8 
expression is sensitive to apo(a) concentrations in the pathogenic range (> 75 nM) (Fig. 
1C,D). 
Once we established that use of a 17-kringle containing recombinant apo(a) was a 
suitable model to study apo(a)-mediated stimulation of IL-8 expression in THP-1 
macrophages, we began to probe the mechanism underlying this observation. A number of 
processes have been reported in which the lysine binding properties of apo(a) KIV10 is 
implicated, including the ability of apo(a) to inhibit pericellular plasminogen activation and 
to increase vascular endothelial cell permeability.13, 17 In these studies, the role of the lysine 
binding properties had been demonstrated using both the lysine analogue ε-ACA as well 
as an amino acid substitution in the apo(a) KIV10 domain that abolishes the lysine binding 
ability of this kringle. Interestingly, we have shown that the strong LBS in KIV10 is also 
required for oxPL modification of apo(a).25 The exact site of oxPL addition is unclear, 
although evidence from our laboratory demonstrates that the modification resides in apo(a) 
KIV1025, rather than in the KV domain as previously suggested.24  
In the current study, we first compared the ability of Lp(a), apo(a) and LDL, in 
equimolar concentrations, to stimulate IL-8 expression in THP-1 macrophages. 
Recombinant 17K apo(a) and plasma purified Lp(a) exhibited comparable effects of a 
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similar magnitude on both IL-8 mRNA and protein expression (Fig. 3.1A,B); no effect of 
plasma-derived LDL was observed relative to control conditions. This pointed to a role for 
the apo(a)-component of Lp(a), and suggested that apo(a) and Lp(a) are equally bioreactive 
in this system.  
We next addressed whether the lysine binding function of apo(a) KIV10 per se is 
critical for IL-8 upregulation. While addition of the lysine analogue ε-ACA had no effect 
on the ability of 17K r-apo(a) to induce IL-8 mRNA expression, mutation of the strong 
lysine binding site in KIV10 (17KΔLBS10 variant) resulted in a markedly decreased 
induction (Fig. 3.2A). At a concentration of 200 mM of the lysine analogue ε-ACA used 
in this study, the lysine binding sites on 17K apo(a) are blocked, and thus cannot participate 
in lysine-mediated binding interactions with cell surface receptors. However, mutation of 
the lysine binding site also eliminated oxPL addition to apo(a) , as assessed by western blot 
analysis with the E06 antibody (Fig. 3.2B) Our  findings thus point to a role for oxPL in 
mediating interactions with the cells that result in the stimulation of IL-8 expression. In 
support of a role for oxPL on apo(a), 17KΔV, which contains a comparable level of oxPL 
modification relative to 17K (Fig. 3.2B) stimulates IL-8 expression to a similar extent as 
the wild-type 17K (Fig. 3.2A). These key findings were recapitulated in the U937 human 
lymphocyte cell line following differentiation into a macrophage-like phenotype. We 
observed that Lp(a)/apo(a) retains the ability to induce both IL-8 gene and protein 
expression in this cell line. (Fig 3.3A,B) A comparable pattern of IL-8 stimulation was 
observed in U937 cells treated with the 17KΔLBS10, while the 17KΔV variant displayed 
an enhanced ability to stimulate IL-8 expression compared to that observed in THP-1 cells. 
(Fig. 3.3A, B).  
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Trypsin-degraded apo(a) stimulates mRNA production (and protein secretion) to a 
comparable extent as intact apo(a) protein (Fig. 3.4A,B). This provides indirect evidence 
for a role for the oxPL moiety of apo(a) since trypsin digestion would eliminate all 
functional protein-interacting domains in apo(a) while preserving the existence of the oxPL 
adduct capable of stimulating IL-8 expression. Pretreatment of 17K apo(a) with 
phospholipase A2 either in the absence or presence of trypsin digestion results in a 
substantial decrease in the ability of apo(a) to stimulate IL-8 mRNA and protein expression 
(Fig. 3.4A,B). PLA2 digestion results in release of a  lysoPC moiety from apo(a)24, thereby 
preventing delivery of the protein-bound oxPL to cell surface receptors. As such, the ability 
of PLA2 treatment of apo(a) to inhibit its stimulatory effect on IL-8 expression provides 
direct evidence for a role for oxPL modification of apo(a) in mediating this effect. 
Our identification of a critical role for the apo(a) KIV10 rather than the KV domain 
in stimulating IL-8 expression contradicts the earlier reports of Scanu and colleagues.19, 24 
In the first study a series of proteolytic fragments containing or lacking different kringles 
was used. While the F2 fragment (KIV5 – P) had similar IL-8-inducing activity as full-
length apo(a), none of the subfragments of F2 had comparable activity to F2, including the 
F7 fragment (KV-P) on which the conclusion for the role of KV rested. In the latter study, 
pointing to a role for the apo(a) kringle V domain in both binding to oxPL and up-regulating 
IL-8 expression, the rIII r-apo(a) variant did, in fact, contain both KIV10 and KV. 
Moreover, the observed lack of E06 reactivity (and hence oxPL content) of rhesus money 
apo(a), which lacks KV, can be explained by the fact that this species contains a 
Trp72→Arg mutation in KIV10 which renders its strong LBS inactive.36   
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 To identify THP-1 cell surface receptors that mediate the apo(a) up-regulation of 
IL-8 expression, we hypothesized a role for CD36 and TLR2. This is based on the study 
by Seimon and colleagues that demonstrated a role for activation of these receptors on 
macrophages via the oxPL component of apo(a)26, possibly through the sn1 saturated fatty 
acyl moiety in conjunction with the phosphocholine headgroup. In their study, activation 
of these receptors in turn led to stimulation of apoptosis in ER-stressd macrophages.26 
However, the downstream signalling pathway associated with activation of these receptors 
by oxPL was not determined. In the present study, a quite modest effect of  CD36 and 
TLR2 knockdown on apo(a)-mediated stimulation of IL-8 mRNA or protein in THP-1 
macrophages was observed (Fig. 3.5A,B). These experiments were hampered by the small 
extent of siRNA-mediated knockdown of these receptors, in keeping with the observations 
of others.37, 38 Thus, while our findings are not inconsistent with the notion that the oxPL 
modification of apo(a) allows it to induce IL-8 expression, further experiments will be 
required to conclusively demonstrate a role for these receptors, or others, in this effect. 
Regulation of IL-8 gene expression has been extensively studied in a variety of cell 
types.39 The most important factors mediating induction of IL-8 are NFκB and AP-1.39 A 
plausible link between TLR2/CD36 activation and regulation of IL-8 through these factors 
is supplied by the observations that activation of these receptors induces MAPK pathways 
that result in activation of the respective transcription factors.40 Interestingly, it has also 
been shown that NFκB activation accompanies Lp(a) stimulation of CCL1 expression in 
macrophages.41 On this basis, we hypothesized a role for NFκB and AP-1 in the 
enhancement of IL-8 expression in THP-1 cells downstream of MAPK signalling pathway 
activation in response to apo(a) treatment. Using specific inhibitors we demonstrated that 
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apo(a) mediated activation of MAP kinases JNK and ERK1/2 – but not p38 – signficantly 
lowered both apo(a)-induced IL-8 mRNA and protein expression (Fig. 3.6). JNK and 
ERK1/2 act through AP-1 and NFκB, respectively, to activate IL-8 transciption and have 
been shown to play a role in IL-8 induction by several factors including TNFα, whereas 
p38 regulates IL-8 mRNA abundance through modulation of the stability of its mRNA.42 
Accordingly, we found that both the 17K apo(a) and the variant lacking the kringle V 
domain – but not the 17KΔLBS10 variant – resulted in activation of the IL-8 promoter 
(Fig. 3.7A). These findings not only provide further evidence for the critical role of the 
oxPL moiety on apo(a) in its ability to up-regulate IL-8 expression, but also demonstrate 
that this effect is mediated at the level of transcription of the IL-8 promoter. A role for both 
NFκB and AP-1 sites on the IL-8 promoter were identified as essential for apo(a)-
stimulated IL-8 expression (Fig. 3.7B). These findings are consistent with previous data 
showing that both of these factors, which bind to adjacent sites on the IL-8 promoter 
(NFκB: -81 to -70; AP-1: -166 to -120)43, are required for induction of IL-8 by factors such 
as TNFα and interferon γ.39, 44, 45 On the other hand, our own inhibitor data indicate that the 
AP-1 inhibitor SR11302 had no effect on IL-8 induction by apo(a) (Fig. 3.6). The 
compound was incubated with the cells at its EC50 (1 µM), as recommended by the 
manufacturer, but this concentration has not always proved to be sufficient to abrogate the 
effects of AP-1.46, 47  
Very recently, quite a distinct effect of Lp(a)-associated oxPL on gene expression 
was reported.46 Specifically, it was found that Lp(a) upregulated ABCA1 expression in 
HepG2 (human hepatoma) cells in a manner associated with upregulation of LXRα and 
PPARγ. This effect was dependent on oxPL on Lp(a), but perhaps not oxPL covalently 
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associated with apo(a), as selective uptake of oxPL from Lp(a) by SR-B1 was implicated. 
Antibody blocking of the SR-B1 in our system did not, however, abrogate the stimulatory 
effect of apo(a) on IL-8 expression suggesting lack of a role for SR-B1 in this process (data 
not shown).  
In conclusion, we have shown that apo(a) induces IL-8 expression in THP-1 
macrophages through the oxPL modification of apo(a) that requires the presence of the 
strong lysine binding site in the kringle IV type 10 domain. The ability of the oxPL moiety 
on apo(a) to stimulate IL-8 expression occurs through a signalling pathway that may be 
initiated by oxPL-mediated toll-like receptor activation; this, in turn, up-regulates IL-8 
transcription through activation of NFκB and AP-1 via upsteam signalling through ERK1/2 
and JNK, respectively. This is a pivotal finding in the field in that it suggests an important 
dual role for the strong LBS in KIV10. One of these roles involves mediating key lysine-
dependent interactions involving the apo(a) component of Lp(a) that are critical to the 
inhibitory role of apo(a) in the plasminogen activation system.12, 13 On the other hand, the 
strong LBS in KIV10 is also critical for the oxPL modification of apo(a). This modification 
has been proposed to play a key role in the pathogencity of Lp(a) that underlines its risk21, 
22, with a direct role reported in the initiation of apopotosis in macrophages undergoing ER 
stress.26 The key role of the oxPL component of apo(a) in the activation of NFκB (and 
likely AP-1) may provide a common mechanistic basis for many of the observed effects of 
apo(a)/Lp(a) on induction of chemokines including CCL141, as well as adhesion molecules 
such as ICAM15, and VCAM and E-selectin.16 Caution must therefore be exercised in 
interpreting the results of experiments designed to elucidate the role of the apo(a) KIV10 
strong lysine binding site in the pro-atherogenic effects of Lp(a).47 Based on the present 
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study, the ability of KIV10 to mediate bona fide lysine-dependent interactions versus the 
importance of this kringle for the oxPL modification of apo(a) must be differentiated on a 
mechanistic basis going forward. 
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4.1 Summary 
 Lipoprotein(a) (Lp(a)) is a causal risk factor for a variety of cardiovascular diseases. 
Lp(a) is distinguishable from LDL by the presence of the glycoprotein apolipoprotein(a) 
(apo(a)). Apo(a) is structurally homologous to the fibrinolytic zymogen plasminogen 
which has led investigators to hypothesize that Lp(a) can interfere with the normal 
fibrinolytic functions of plasminogen. This, in turn, may have implications for the 
persistence of fibrin clots in the vasculature, thereby contributing to both thrombotic and 
atherothrombotic diseases. A single nucleotide polymorphism (rs3798220) in the LPA gene 
has been reported that results in a missense mutation of Ile4399 à Met in the protease-like 
domain of apo(a) (I3499M variant). In population studies, the I4399M variant has been 
correlated with elevated plasma Lp(a) levels and higher CHD risk, and carriers of the SNP 
enjoyed increased cardiovascular benefit from aspirin therapy. Additional evidence from 
in vitro studies suggested an antifibinolytic role for Lp(a) containing this variant.  In the 
present study, we performed a series of experiments to assess the effect of the Ile-Met 
substitution on fibrin clot formation and lysis as well as the architecture of the clots. We 
found that the Met variant decreased coagulation time and increased fibrin clot lysis time 
compared to wild-type apo(a). Further, we observed that the presence of the Met variant 
significantly increased fibrin fiber width, but not density, in plasma clots formed ex vivo. 
Mass spectrometry analysis of a recombinant apo(a) species containing the Met variant 
revealed sulfoxide modification of the methionine residue. Taken together, our data suggest 
that the I4399M variant differs structurally from wild-type apo(a), which may underlie key 
differences related to its effects on fibrin clot architecture and fibrinolysis. 
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4.2 Background 
Elevated lipoprotein(a) has been identified as a causal risk factor for cardiovascular 
diseases such as coronary heart disease (CHD).1 This complex lipoprotein consists of a low 
density lipoprotein (LDL) moiety covalently linked to the unique glycoprotein 
apolipoprotein(a) (apo(a)) by a single disulfide linkage.2 Apo(a) contains ten distinct 
plasminogen-like KIV domains, with all but KIV type 2 (KIV2) present as a single copy.3 
The KIV domains are immediately followed by sequences resembling plasminogen KV 
and the protease domain;  the protease-like domain in apo(a) is catalytically inactive .3 The 
KIV2 domain of apo(a) can be present from <3 to >30 copies, giving rise to extreme isoform 
size heterogeneity within the population.4  
It has long been hypothesized that, owing to the homology with plasminogen and 
lack of protease activity, the pathogenicity of Lp(a) may arise from its ability to interfere 
with the normal functions of plasminogen in the vasculature.  In this regard, binding of 
Lp(a)/apo(a) to fibrin is well documented, and it has been reported that apo(a) can compete 
with plasminogen for binding to lysine residues present on fibrin and partially degraded 
fibrin thereby decreasing plasmin formation and fibrin clot breakdown.5 An alternative 
mechanism has been proposed, whereby the apo(a) component of Lp(a) can form a 
quaternary complex with plasminogen, tPA and fibrin; this complex is catalytically 
inefficient with respect to plasmin formation compared to that observed in the absence of 
apo(a). Apo(a)/Lp(a) has also been shown to inhibit the conversion of Glu- to Lys-
plasminogen on the fibrin surface, hence attenuating this key positive feedback mechanism 
in fibrinolysis.6 In all of these studies, a role for the strong lysine binding site present in 
apo(a) KIV type 10 has been identified in mediating these effects.  
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Interestingly, it has been reported that apo(a) can promote thrombosis in a Plg-/- 
mouse model, suggesting a plasminogen-independent role for Lp(a).7 In keeping with a 
such a mechanism, apo(a) also has been reported to bind to fibrinogen in a lysine-
independent manner, with binding sites proposed on the αC region of fibrinogen through 
sites outside of the apo(a) KIV10 domain.8. The mechanism(s) by which Lp(a) can alter 
thrombotic processes in a plasminogen-independent context remains unclear.  However, 
owing to its ability to directly bind fibrin in both lysine-dependent and independent 
mechanisms, it is tempting to hypothesize that Lp(a) may directly contribute to the 
structure, formation and lysis of fibrin clots.  
 Several genetic studies have identified an association with two single nucleotide 
polymorphism (SNPs) within LPA, the gene encoding apo(a). These two SNPs (rs3798220 
and rs10455872) have been associated with increased plasma Lp(a) levels and increased 
risk for CHD.1 The rs3798220 SNP results in a Ile4399 → Met substitution in the inactive 
protease domain of apo(a).9 This variant of Lp(a) has been associated with a smaller 
number of KIV2 repeats and elevated plasma Lp(a) levels and increased CAD severity.9 
The low allele frequency of this variant (<4%; ref.) has posed challenges for human studies. 
Interestingly, however, in a randomized trial of low-dose aspirin therapy in women, it was 
observed that while carriers of the Met variant had significantly elevated Lp(a) levels and 
a two-fold increased risk for CVD, they also exhibited a greater than two-fold decrease in 
cardiovascular risk in response to low dose aspirin, an effect not observed in non-carriers. 
This may suggest that the I4399M variant of Lp(a) contribute to risk for CVD over and 
above that arising from Lp(a) levels. In a recent study, elevated Lp(a) levels were correlated 
with reduced clot permeability and increased clot lysis times in vitro.10 In a separate 
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investigation using similar in vitro methods, plasma from I4399M carriers showed ethnic-
dependent variations in plasma clot permeability and lysis times, with Caucasians 
exhibiting less permeable clots with a decreased rate of lysis than non-Caucasians11. In the 
current study, we have utilized both recombinant apo(a) and human Lp(a) to assess the 
ability of the I4399M polymorphism to affect fibrin clot formation and clot breakdown, as 
well as the structure of fibrin clots. Additionally, we have identified a possible mechanism 
through which the I4399M apo(a) variant can alter the prothrombotic/antifibrinolyic 
potential of Lp(a).  
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4.3 Experimental Methods  
 
4.3.1 Preparation of recombinant apo(a) and plasma-derived Lp(a) 
 Plasmids encoding a 17-kringle-containing form of recombinant apo(a) (17K r-
apo(a)), as well as KIV10-P (containing the KIV10, KV and protease-like domains of apo(a))  
were constructed and expressed in human embryonic kidney (HEK 293) cells as previously 
described.12-14  Plasmids encoding the 17K/I4399M and KIV10-P/I4399M variants 
corresponding to the rs3798220 SNP were generated by site directed mutagenesis using 
the QuikChange II-XL Site-Directed Mutagenesis Kit (Agilent Technologies) with the 
following mutagenic primer pair (mutagenic bases are boldface lowercase): sense 5’-CAT 
GTT CAG GAA ATg GAA GTG TCT AGG CTG-3’; antisense 5’-CAG CCT AGA CAC 
TTC cAT TTC CTG AAC ATG-3’. All r-apo(a) species were purified from the conditioned 
medium (CM) of stably-expressing cell lines by lysine–Sepharose (GE Healthcare) affinity 
chromatography as previously reported.12  
 Lp(a) was purified as previously described from the plasma of a healthy volunteer 
with an apo(a) isoform containing 16 KIV domains.15 Purified Lp(a) concentrations were 
determined by bicinchoninic acid assay (Pierce) using BSA as a standard. The integrity of 
the purified Lp(a) was assessed by SDS-PAGE (under either reducing or non-reducing 
conditions) followed by silver staining.  
 
4.3.2 In Vitro Fibrinolysis and Coagulation Assays 
Clot lysis assays were performed in similar manner to that previously reported with 
some modifications.16 Pooled, lipoprotein-deficient plasma (LPDP) was diluted 1:1 with 
TBST solution (0.02 M Tris pH 7.4, 0.15 M NaCl, 0.01% (v/v) Tween 20) and 
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supplemented with 3 different concentrations of 17K or 17K/I4399M. The reaction mixture 
was added to wells containing small, separated aliquots of CaCl2 and human thrombin 
(Haemotological Technologies Inc.) (final concentrations of 10 mM and 1 U/mL, 
respectively). Clot formation was monitored by measurement of absorbance at 405 nm at 
37°C in a plate-reading spectrophotometer (SpectraMax Plus 384; Molecular Devices). 
The time required to reach half-maximal absorbance (50% clot time) and the maximal 
change in absorbance (∆Abs) were determined from the resultant curves. For measurement 
of clot lysis, a similar protocol was followed except that the wells also contained a small, 
separated aliquot of tPA (Alteplase CathFlo®, Roche) (final concentration 3 nM). The time 
required to achieve the absorbance at 405 nm half-way between the maximum and 
minimum excursions (50% lysis time) was assessed turbidometrically as described above. 
 
4.3.3 Plasminogen activation assays 
Plasminogen activation in the presence of fibrin was measured as we have 
previously described.12 Briefly, recombinant plasminogen containing a serine to cysteine 
mutation in the active site (S741C) was expressed and purified from baby hamster kidney 
cells (BHK-21) and labeled with 5-iodoacetamidoflurocein.17 Reaction were assembled in 
a 96-well Microfluor2 black plates (Costar Inc.) pre-coated with HBS (150 mM NaCl, 20 
mM HEPES, pH 7.4) containing 1% (v/v) Tween-80. Fluorescently-labeled plasminogen 
(0.9 µM, final) was combined with human fibrinogen (1 mg/mL, final) in the presence or 
absence of 17K or 17K/I4399M (0.5, 1, or 1.5 µM, final) in HBS containing 0.02% (v/v) 
Tween 80. This mixture was then added to wells containing small aliquots of CaCl2, 
thrombin, and tPA, at final concentrations of 10 mM, 1U/mL, and 5 nM, respectively. The 
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quenching of fluorescence was monitored at 37°C in a SpectraMax M5e plate-reading 
fluorimeter (Molecular Devices) using the following settings: excitation wavelength: 
495nm; emission wavelength: 535nm; cutoff wavelength: 530nm; sensitivity: normal; 
PMT setting: low. Raw fluorescence measurements were corrected for the buffer blank and 
for internal filter effects. Linear regression was used to determine the initial rates of 
fluorescence decrease and the rate of plasmin formation was given by the equation: 𝑑[𝑃𝑛]𝑑𝑡 = 𝑑𝐼𝑑𝑡 × 1r ∙ I. × [𝑃].[𝐴].  
where d[Pn]/dt represents the rate of plasmin formation per mole of tPA (s-1), dI/dt is the 
initial rate of fluorescence decrease, r is the relative maximum change in fluorescence 
intensity (0.5 for fibrin surface)18, I0 is the initial fluorescence intensity, [P]0 is the initial 
fluorescently-labeled plasminogen concentration, and [A]0 is the initial tPA concentration. 
The rates of plasminogen activation are the average of triplicate measurements. 
 
4.3.4 Human subjects 
 Subjects were either healthy volunteers or were ascertained through a tertiary 
referral lipid clinic. There were no specific inclusion or exclusion criteria. Informed 
consent was obtained from subjects prior to DNA collection and analysis using a protocol 
approved by the University of Western Ontario Ethics Review Board (#07920E). Blood 
was collected into EDTA or citrate anticoagulant and plasma was prepared by 
centrifugation. Plasma was aliquoted and stored in cryovial tubes at -80 C. Genomic DNA 
was isolated from buffy coat and red cells of the remaining sample of each patient using 
the Puregene DNA isolation kit (Gentra Systems, QIAGEN Inc) or the GeneJET Whole 
Blood Genomic DNA Purification Mini Kit (Thermo Scientific). The rs3798220 variant in 
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LPA was genotyped using a validated TaqMan assay on a ViiA7 Real-Time PCR System 
and automated software (Applied Biosystems, Foster City, CA), or by direct sequencing of 
PCR products, at the London Regional Genomics Centre (www.lrgc.ca). For the latter, a 
427-base pair amplicon was produced using the following primers: 5'-GAA GGG GCT 
GGA CCA TAT TT-3' and 5'-CGG GTA ACA GGG TAT CTC TTT-3'.10 The PCR 
conditions used were:  at 98 °C followed by 36 cycles of 98 °C for 30 sec; 53 °C for 30 
sec; 72 °C for 40 sec, and a final extension for 10 min at 72 °C. The final reaction volume 
was 25 µL, and contained 10 ng genomic DNA, and was carried out using Q5® High-
Fidelity DNA Polymerase (New England Biolabs) as per the manufacturer’s instructions.  
Lp(a) isoform size was determined in plasma samples by SDS-agarose gel 
electrophoresis19, using an anti-apo(a) antibody raised against recombinant apo(a). Apo(a) 
isoform sizes were determined using a ladder of recombinant apo(a) isoform standards. 
Lp(a) plasma levels were determined using the Macra® Lp(a) Enzyme Linked 
Immunosorbent Assay (Mercodia, Uppsala, Sweden) as per manufacturer’s protocol. 
 
4.3.5 Assessment of plasma clot permeability 
 Fibrin clot permeability was determined using a pressure-driven system as 
previously described.20 Briefly, 20 mM (final) CaCl2 and 1 U/mL (final) human thrombin 
were added to 120 µL citrated plasma and the mixtures transferred to clear glass tubes to 
hold the clots. Following incubation for 2 h in a wet chamber, tubes containing the clots 
were connected via plastic tubing to a reservoir of a buffer (0.01 M Tris, 0.1 M NaCl, pH 
7.5) and the volumes flowing through the fibrin gels were measured over the course of 60 
mins. A permeation coefficient (Ks) was calculated using the following equation:  
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𝐾1 = 𝑄×𝐿×𝜂𝑡×𝐴×Δ𝑝 
where Q is the flow rate in time t; L, the length of a fibrin gel; η, the viscosity of liquid (in 
poise); A, the cross-sectional area (in cm2); and Δp, the pressure differential (in dyne/cm).  
 
4.3.6 Confocal and scanning electron microscopy of clots 
Clots for scanning electron microscopy were prepared and subjected to permeation 
as described in Section 5.3.5, and then were fixed for 30 min in 1.4% (v/v) glutaraldehyde. 
Clots were then washed 3 times with phosphate-buffered saline (PBS) for 30 mins, 
followed by 3 times with distilled, deionized H2O for a total of 30 mins. Images were 
acquired on a field-emission environmental scanning electron microscope (ESEM, FEI 
QUANTA-200 FEG type, Holland FEI Company). Acquisition conditions were as follows: 
pressure of 70 kPa; accelerating voltage of 10 kV; and a working distance of approximately 
10 mm. Fiber widths were measured using ImageJ software; a minimum of 30 fibers were 
measured per image. 
For confocal microscopy, clots were formed in a similar manner to that reported in 
Section 5.3.5, with the exception that the plasma was supplemented with 0.3 mg/mL Alexa 
Fluor® 568 labelled fibrinogen. The fibrinogen (Calbiochem, Mississauga, Canada) was 
labeled using an Alexa-568 Protein Labeling Kit (Invitrogen) according to the 
manufacturer’s protocol. The clots were allowed to mature for 3 h in a moist chamber at 
room temperature at which time they were washed with TBS to removed excess label. The 
resulting fluorescent clots were imaged on an Olympus FV1000 confocal microscope. 
Images were analyzed for fiber density using ImageJ software with a custom-designed 
plugin.20 In this method, a 10 × 10 grid is placed on individual images and the number of 
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ﬁbers intersecting the grid lines is computed. Fiber densities of four different micrographs 
per sample were averaged.  
 
4.3.7 Molecular dynamics simulations and protease domain modelling 
 The Molecular Operating Environment (MOE) software was used for model 
preparation, energy minimizations, and assessment of the generated trajectories. The 
molecular dynamics (MD) simulations were performed using the NAMD program21 All 
chemical models were derived from a previously-published model of the apo(a) protease 
domain.22 Water molecules present in the modelled structure were deleted. Hydrogen and 
proton atoms were then added to the model using the default method in MOE; water 
molecules were then added using the TIP3P water model.23 The latter added water 
molecules throughout the protein, where appropriate, and extending outwards from the 
edge of the protein to form a 6 Å layer of water molecules. The resulting solvated model 
was then minimized with the AMBER:12EHT force field until the root-mean-square 
gradient of the total energy was below 0.05 kcal mol–1 Å–1.24 The same procedure was used 
to generate both initial solvated structures of the wild-type apo(a) and the I4399M apo(a) 
variant. For all MD simulations the AMBER12:EHT force field was used as was the default 
velocity Verlet integration method to obtain the trajectories. The solvated systems were 
first equilibrated for 0.15 ns at 150 K, while the subsequent production MD simulations 
ran for 4.90 ns with a time step of 2 fs. 
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4.3.8 Mass spectrometry 
 15 µg of either KIV10-P or KIV10-P/I4399M protein was reduced with 16 mM DTT 
and labeled with 100 mM iodoacetamide (Sigma) for 60 min in the dark at room 
temperature with shaking. Samples were then subjected to a buffer exchange with ice cold 
trichloroacetic acid (15% v/v) followed by 20 min incubation at 4°C. After centrifugation, 
3 acetone washes of the pellet were performed. The pellet was resuspended in 4× reducing 
sample buffer. Samples were then subjected to SDS-PAGE followed by visualization of 
proteins by Imperial stain, as per manufacturer’s protocol (Thermo Scientific). Protein 
bands were then excised and subjected to a 16 h in-gel tryptic digest with a ratio of ~80:1 
apo(a):Trypsin Gold (Promega).25 Tryptic peptides were extracted, spotted in a 1:1 ratio 
with alpha-cyano-4-hydroxycinnamic acid and subjected to MALDI-TOF mass 
spectrometry using a Waters SYNAPT G2-Si instrument. The resulting spectra were 
analyzed using MassLynx Software (Waters). 
 
4.3.9 Statistical methods 
  Comparisons between samples were performed by one-way ANOVA using a 
Tukey post-hoc analysis using SPSS software, Version 22.0 (SPSS Inc.) or by a two tailed 
Student’s t-test using Microsoft Excel. Statistical significance was assumed at p < 0.05.  
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4.4 Results 
 
4.4.1 The effect of the I4399M apo(a) variant on clot formation 
  In preliminary experiments, we noticed that addition of 17K/14399M to a solution 
containing physiological concentrations of fibrinogen resulted in a cloudy solution, 
whereas addition of 17K had no such effect. We determined that this phenomenon was 
caused by the 17K/I4399M-mediated precipitation of fibrinogen, which did not occur with 
17K (Chapter 4 Supplementary Figure 1). This finding prompted us to investigate the 
effects of 17K/I4399M on plasma clot formation and lysis in lipoprotein-deficient plasma 
(LPDP).   
 
We titrated 17K and 17K I4399M (0.5, 1.0, and 1.5 µM) into LPDP and initiated 
coagulation by the addition of CaCl2 and thrombin. Addition of wild-type 17K had no 
effect on the maximum turbidity (change in absorbance) observed upon clot formation 
(Figure 4.1A). However, addition of 17K/I4399M resulted in a significant dose-dependent 
increase (17%, 21%, and 33%) in the maximum turbidity of the clots (Figure 4.1A). 
Supplementation of plasma with increasing concentrations of 17K resulted in a dose-
dependent decrease in the time to 50% clotting of 23%, 30%, and 34% compared to clots 
formed in the absence of apo(a) (Figure 4.1B). The 17K/I4399M variant had a significantly 
greater effect, with additional decreases in time to 50% clotting of 27%, 34%, and 36% 
compared to that observed with 17K (Figure 4.1B).  
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Figure	4.1	The	effect	of	17K	and	17K/I4399M	apo(a)	on	coagulation.	
LPDP was clotted with 1 U/mL thrombin and 20 mM CaCl2 in the absence and presence 
of the indicated concentrations of either wild-type 17K or 17K I4399M. Clot formation 
was monitored by the measurement of turbidity.  Panel A. The maximal change in 
absorbance (∆Abs) occurring upon clot formation. Panel B. Time to 50% clotting.  Data 
are results of at least three independent experiments, and were analyzed using Student’s 
t-test. Daggers: p < 0.05 versus 17K; asterisks: p < 0.05 versus no apo(a). 
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4.4.2 The I4399M apo(a) variant more potently inhibits fibrinolysis  
 We next compared the ability of 17K and 17K/I4399M to inhibit fibrinolysis, using 
a similar in vitro assay containing LPDP but with the addition of tPA. Compared to control 
samples lacking apo(a), clot lysis times were significantly decreased in the presence of 17K 
apo(a) (0.5, 1.0, and 1.5 µM), which extended lysis times by 2.9-, 5.6-, and 9.5-fold 
respectively (Figure 4.2A). The 17K I4399M variant (0.5, 1.0, and 1.5 µM) resulted in a 
significant additional 28%, 21%, and 11% increase in clot lysis times, respectively, 
compared to those observed with 17K (Figure 4.2A).  
We then assessed if differences between 17K and the I4399M variant in inhibition 
of clot lysis might be related to differences in their ability to inhibit plasminogen activation. 
To do this, we measured the effect of these variants on the activation of a fluorescently-
labelled plasminogen variant that is catalytically inactive upon cleavage by tPA (Figure 
4.2B). Both apo(a) variants yielded a dose-dependent decrease in plasminogen activation 
(between ~25% and ~45%), but there was no significant difference between 17K and 
17K/I4399M (Figure. 4.2B).  
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Figure	4.2	The	effect	of	17K	and	17K/I4399M	apo(a)	on	fibrinolysis.	
Panel A. Clots containing tPA were formed in the absence or presence of the indicated 
concentrations of either 17K or 17K/I4399M and clot lysis was monitored 
turbidometrically. The time to reach 50% clot lysis. A minimum of three experiments 
were conducted per treatment condition. Asterisks: p < 0.02 versus no apo(a); daggers: 
p < 0.05 versus 17K. Panel B. Plasminogen activation assays utilizing tPA and 
fluorescently-labeled recombinant plasminogen were conducted in the presence of fibrin 
and in the absence or presence of 17K or 17K/I4399M. The rate of plasminogen 
activation per mole of tPA is presented as a rate relative to that observed in the absence 
of apo(a). The data represent the means ± S.E.M. of three independent experiments each 
conducted in triplicate. Asterisks: p < 0.05 versus no apo(a); daggers: p < 0.02 versus 
0.5µM treatment. 
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4.4.3 The I4399M variant of apo(a) alters fibrin clot structure. 
 Fibrin clots were generated with purified components supplemented with 1.0 µM 
17K or 17K/I4399M. After glutaraldehyde fixation and extensive washes, fibrin clots were 
subjected to low vacuum scanning electron microscopy (SEM) to assess clot structure. 
Figure 4.3A shows representative secondary electron images taken at 30,000× 
magnification. While there was no difference in the width of fibrin fibers between clots 
lacking apo(a) and containing 17K, clot containing 17K/I4399M containing clots had fiber 
widths that were significantly (50% increase) greater (Figure 4.3). 
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Figure	4.3	The	effect	of	17K	and	17K/I4399M	on	fibrin	clot	structure.	
Panel A. Purified fibrinogen in the absence and presence of the respective apo(a) variants 
(1 µM) was clotted with thrombin and visualized using low vacuum scanning electron 
microscopy. Shown are representative images were taken at 30,000× magnification with 
a HFW of 6.67 µm. Panel B. Fiber widths were calculated using ImageJ, with a minimum 
of 30 fibers measured on at least 4 images. *: p < 0.0001 versus control lacking apo(a). 
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4.4.4 Clots formed from the plasma of individuals homozygous for the rs3798220 
SNP are structurally distinct  
 Clots formed in plasma from a total of four individuals with either high 
(>30mg/dL), or low (<10 mg/dL) plasma Lp(a), and homozygous for either the Met or Ile 
apo(a) variant were assessed for fibrin fiber density, plasma clot permeability, and average 
fibrin fiber width. Subjects of either genotype were matched for similar plasma Lp(a) 
concentration and apo(a) isoform size. Figure 4.4A shows representative plasma clots from 
each individual; clots were supplemented with 0.3mg/mL Alexa Fluor® 568 to label fibrin 
fibers and subjected to confocal microscopy to assess fiber density. Density was similar 
clot formed from the plasma of individuals of either genotype but with low Lp(a) levels 
(Figure 4.4B). Fiber density was significantly greater for the Ile/Ile homozygote with 
higher Lp(a) levels but not for the Met/Met homozygote with higher Lp(a) levels (Figure 
4.4B).  
Permeability of clots made from the plasma of each individual was assessed by a 
pressure-driven permeation method and measurements were reported by calculation of a 
permeability (Darcy) constant for the respective clots (Figure 4.4C). There was a 
significant decrease of approximately 30% in the Darcy constant of clots formed from the 
plasma of individuals with elevated plasma Lp(a) levels compared to those with low plasma 
Lp(a), irrespective of the genotype of the subject (Figure 4.4C). Plasma clots from each 
individual were also subjected to fixation and SEM imaging (Figure 4.4D) followed by 
determination of fibrin fiber width (Figure 4.4E). Fiber width was significantly greater for 
subjects with high Lp(a) levels; moreover, the Met/Met homozygotes had greater fiber 
width that Ile/Ile homozygotes for both ow and high Lp(a) levels.  
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Figure	4.4	Plasma	clots	from	individuals	homozygous	for	the	Met/Met	apo(a)	variant	
are	structurally	distinct.	
Individuals were genotyped for the rs3798220 LPA SNP; plasma Lp(a) concentrations 
were determined by ELISA. Panel A. Clots were formed in the presence of Alexa 568-
labeled fibrinogen using the plasma of individuals with either low or high Lp(a) levels 
who were either Ile/Ile or Met/Met homozygotes. The clots were subjected to confocal 
microscopy. Representative clot images are shown. Panel B. The number of fibrin fibers 
per 100 µm area was determined using ImageJ software.  The data represent the means 
± S.E.M. of analysis of at least 4 images from each individual. Asterisk: p < 0.05 
compared to individual of same genotype with low Lp(a) levels. Panel C. Clots prepared 
from individuals described in Panel A were subjected to a pressure-driven clot 
permeation assay. The data represent the means ± S.E.M. of analysis of at least 3 clots 
from each individual. Asterisk: p < 0.05 compared to individual of same genotype with 
low Lp(a) levels. Panel D. Plasma clots prepared as in Panel C were fixed and subjected 
to low vacuum SEM. Representative images, taken at 30,000× magnification, are shown. 
Panel E. Fibers from the clots shown in Panel D were assessed for average fiber width. 
Fibers were quantified by examining 30 different fibers from 4 - 5 different images for 
each individual. Asterisk: p < 0.05 versus individual with different Lp(a) levels but same 
genotype; dagger: p < 0.05 versus individual of same genotype but different Lp(a) level. 
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4.4.5 Modelling of the apo(a) protease domain containing the I4399M variant 
indicates structural differences compared to wild-type apo(a) 
 Using a model for the protease domain of apo(a)22, average occupancy images were 
taken for a native apo(a) protease domain and a simulation incorporating an induced 
I4399M substitution. Figure 4.5A shows a comparison between the simulated domains. 
The first coordination sphere (with respect to the Ile/Met residue) suggests that the 
substitution of the hydrophobic isoleucine residue to the more polar methionine residue 
induces a conformational change in the local environment of this amino acid. In the native 
structure, Ile4399 is shielded from the bulk solvent by the adjacent Arg4420.  When Met 
is in the 4399 position, however, the Arg4420 and Met4399 conform to a status where the 
Met is exposed to the solvent, and is no longer guarded by the neighbouring Arg. In Figure 
4.5 B, a root mean squared deviation analysis of the distance between the δ-carbon on Ile, 
or the sulfur on the alternate Met, with the guanidine nitrogen on the adjacent Arg was 
explored to examine the relationship between these moieties. The 5 ns simulation suggests 
that the Met has a shorter average distance to the Arg of 3.39 ± 0.03	Å, implying that the 
newly exposed Met4399 may be in a more coordinated state. Analysis of the Ile residue 
shows a greater and much more erratic average distance of 4.37 ± 0.12 Å. This suggests 
that the I4399M substitution results in a distinct alteration in the conformation of the apo(a) 
protease domain in this area. 
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Figure	4.5	The	I4399M	substitution	in	the	apo(a)	protease-like	domain	perturbs	the	
local	environment.	
Panel A. Average occupancy images of simulations of the Ile4399 (native structure) and 
Met4399 variants. The image on the left shows the Ile4399 residue buried underneath 
the adjacent Arg4420; this interaction is not observed in the simulation of the Met4399 
variant. Introduction of the methionine at position 4399 alters the conformation of the 
domain allowing the Arg residue to adopt a new position such that the Met residue can 
interact with the solvent around the molecule. Panel B. RMSD analysis of the distances 
between the Ile/Met and the adjacent Arg reports a greater average distance between the 
Ile and Arg residues, suggesting that the polymorphic Met variant is possibly in a more 
coordinated state and likely has a distinct conformation. 
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4.4.6 Identification of an oxidized methionine residue on the I4399M apo(a) variant. 
 KIV10-P and KIV10-P/I4399M were generated in order to assess the presence of 
oxidative modifications in the protease-like domain of apo(a) using mass spectrometry. 
The smaller size of these variants was expected to yield more easily interpreted spectra. 
MALDI-TOF mass spectrometry of KIV10-P tryptic peptides identified a peptide 
VILGAHQEVNLESHVQEIEVSR, which includes the Ile4399 residue, at the theoretical 
mass/charge ratio of 2487.3 m/z (data not shown). This indicates that this peptide is 
unmodified and present in its native form. Analysis of the corresponding peptide from the 
Met4399 variant was expected to be present at a mass of 2505.2 m/z (Figure 4.6A), but a 
peptide of this mass was not detected (Figure 4.6C). However, a peptide of an increased 
mass/charge ratio of 2521.2 m/z (Figure 4.6B), corresponding to the presence of an 
oxidized methionine residue in the peptide, was detected (Figure 4.6C). 
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Figure	4.6	Identification	of	an	oxidized	methionine	residue	on	the	I4399M	variant	of	
apo(a).	
Panels A and B. Theoretical MALDI-TOF mass fingerprints of the 
VILGAHQEVNLESHVQEMEVSR peptide and of the peptide containing the oxidized 
methionine residue. Panel C. The observed mass spectrum of KIV10-P/I4399M tryptic 
peptides is shown. 
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4.5 Discussion 
The rs3798220 in LPA which encodes an Ile to Met substitution in the protease 
domain of apo(a) has been associated with higher Lp(a) levels, smaller apo(a) isoforms, 
and greater risk of cardiovascular diseases.1, 9, 26 It remains unclear whether Lp(a) 
containing Met at position 4399 is inherently more pathogenic or whether this 
polymorphism is associated with some other genetic factor predisposing to disease. For 
example, some studies have shown that the effect of rs3798220 on disease disappears after 
adjustment for Lp(a) levels.1 On the other hand, it has been reported that that carriers of 
this SNP derive greater benefit from aspirin11; although it was found that there was no 
difference in event rate between carriers with high and low Lp(a) levels, possibly indicating 
a functional effect of the polymorphism, such a conclusion has to be tempered by the small 
number of events observed in the carrier group owing to the rarity of this SNP.11 We have 
decided to directly examine the effects of the Met substitution on the pathogenic potential 
of Lp(a) by expressing and functionally characterizing a recombinant form of the variant, 
in the context of a physiologically-relevant 17-kringle isoform. The focus of our work has 
been on the effect of this mutation on coagulation, fibrinolysis, and fibrin clot structure.  
It has been previously shown that Lp(a)/ apo(a) can inhibit fibrinolysis5, 14, inhibit 
tPA-mediated plasminogen activation on the surface of fibrin12, and inhibit the positive 
feedback step of plasmin-mediated conversion of Glu-plasminogen to Lys-plasminogen.6 
Inhibition of thrombolysis by apo(a) was also observed in a rabbit jugular vein model.27 
More recently, a report that apo(a) transgenic mice on a Plg-/- background had increased 
thrombotic potential when exposed to vascular injury lead to an alternative model for the 
effects of apo(a) on thrombolysis, possibly involving changes in clot structure.7 Indeed, 
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elevated Lp(a) levels have been previously associated with altered fibrin clot structure, 
reduced permeability of fibrin clots and prolonged lysis times.28, 29 Furthermore, human 
plasma from Caucasian patients carrying the rs3798220 SNP exhibited longer clot lysis 
times and increased clot permeability, compared to Caucasian patients who were not 
carriers.10 Curiously, however, these trends were not observed in non-Caucasian patients.  
 In this study, we have shown that (i) apo(a) decreases coagulation time of plasma 
clots in vitro and the Met4399 variant has a more potent effect; (ii) the Met4399 variant 
uniquely increases the maximum turbidity of plasma clots formed in vitro, suggesting an 
effect on fibrin structure; (iii) the Met4399 variant is a more potent inhibitor of fibrinolysis 
of plasma clots in vitro without being more effective at inhibiting plasminogen activation; 
(iv) the Met4399 variant causes the formation of more disorganized pure fibrin clots with 
thicker fibrils; and (v) plasma clots formed from patients homozygous for the Met4399-
encoding allele have an altered fibrin structure. Altogether, these data strongly suggest that 
the Met4399 variant has a greater prothrombotic/antifibrinolytic potential, at least in part 
through deleterious effects on fibrin structure. We present evidence from molecular 
modeling that the presence of Met at position 4399 alters the local structure of the protein, 
resulting in a more solvent-exposed and less mobile side chain. Indeed, we showed the Met 
residue to be oxidized by MALDI-TOF mass spectrometry, which provides a functional 
link to effects on fibrin structure (see below).  
 Given the association of rs3798220 with elevated plasma Lp(a) concentrations, we 
also took advantage of our recombinant expression system to directly address the 
proposition that the Ile to Met substitution increases the rate of apo(a) biosynthesis. Using 
a pulse chase secretion assay in HepG2 cells, we found no difference in the rate of secretion 
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of the Met variant compared to the Ile variant (Supplementary Figure 2). This result 
suggests that the association of the rs3798220 polymorphism and elevated Lp(a) levels 
may not be due to the SNP directly but likely due to the correlation of this variant with 
smaller apo(a) isoforms, which are more readily secreted.30 It cannot be excluded that the 
I4399M substitution affects other processes that impact plasma Lp(a) concentrations such 
as Lp(a) assembly or catabolism. It has not yet been directly investigated if the elevated 
Lp(a) levels in carriers of this polymorphism reflect linkage disequilibrium with smaller 
apo(a) isoforms or other genetic variants that directly impact Lp(a) levels.  
 The known causal relationship of elevated Lp(a) levels to cardiovascular diseases 
such as coronary heart disease and ischemic stroke could reflect the contribution of Lp(a) 
to atherosclerotic processes, thrombosis, or both. Indeed, evidence for both roles has 
emerged from in vitro and animal model studies.31 One approach to assessing if Lp(a) 
contributes to thrombosis has been to examine the relationship of Lp(a) to “pure” 
thrombotic disorders such as venous thromboembolism (VTE). The results of such studies 
have been controversial, however. Elevated plasma levels of Lp(a) have been correlated 
with idiopathic and recurrent VTE, and this was inversely correlated with the number of 
KIV2 repeats.32, 33 On the other hand, Mendelian randomization studies have suggested that 
Lp(a) is not a causal risk factor for venous thrombosis.34 A recent study reported an 
independent link between low KIV2 copy number and incidence of VTE.32 Four LPA SNPs, 
including rs3798220, were found to have no association with VTE when assessed 
individually, although certain LPA haplotypes influenced disease susceptibility. No 
haplotypes containing the minor allele of rs3798220 were shown to be associated with 
increased VTE risk, however.   
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We found that apo(a) decreased the clotting time of plasma clots in vitro with 
17KI4399M having the more potent effect (Figure 4.1A). In addition, this variant 
specifically increased the maximum turbidity of the clots (Figure 4.1B). Indeed, 
experiments in which purified apo(a) was combined with purified fibrin showed a marked 
effect of the Met4399 variant, but not the wild-type apo(a), on clot structure (Figure 4.3). 
Generally, increase in the turbidity of fibrin clots is strongly associated with changes in the 
structure of clots. More specifically, increased turbidity of a clot is indicative of thicker 
fibrin fibers and is generally associated with attenuation of prothrombin activation of 
thrombin activity35, although such an effect would not be occurring in our purified system. 
It is accepted that increased clot turbidity is associated with increased lysis times.36 
Detailed microscopic studies have revealed that thinner fibers may be more susceptible to 
lysis than thick fibers [reviewed in ref. 37].  
We also studied clot structure and permeability using, for the first time, plasma 
from individuals homozygous for the Met allele. Unlike previous studies10, we found no 
difference in clot permeability between Ile/Ile and Met/Met subjects with similar Lp(a) 
levels, although the subjects with higher Lp(a) did, as expected, have lower clot 
permeability (Figure 4.4C). rs3798220 genotype did affect plasma clot fiber density 
(Figure 4.4B), and amplified the ability of elevated Lp(a) to promote thicker fibrils (Figure 
4.4D,E). The latter result is in agreement with what we observed in a purified system using 
recombinant apo(a) of either genotype (Figure 4.3). It should be noted, however, that we 
were only able to obtain plasma from two subjects homozygous for Met at 4399, owing to 
the low frequency of this polymorphism. Nonetheless, our studies using purified 
components and naturally-occurring variants do support the idea that both Lp(a) levels and 
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rs3798220 influence fibrin clot structure, and hence the coagulability of plasma and its 
susceptibility to lysis. Accordingly, it is possible that the properties of the variant Lp(a) 
contribute to the increased risk for vascular disease in rs3798220 carriers through an effect 
on clot structure. 
To investigate a possible structural and biochemical rationale for the effects of the 
Ile/Met substitution, we used a molecular dynamic simulation approach. We modelled the 
inactive protease domain of apo(a) with either an isoleucine or methionine residue in the 
4399 position (Figure 4.5). In the native Ile containing domain, the Ile residue is kept in a 
buried orientation blocked from exposure to the protein-solution interface by adjacent 
Arg4420. Introducing the Met residue into the 4399 position results in a change in the 
orientation of the Arg residue such that the methionine can shift outward into a more 
exposed conformation, effectively altering the surface of the protease domain in this 
variant. Root mean squared deviation analysis between the Ile/Met and Arg residue show 
large fluctuations in the distance spanning the Ile-Arg residues, but a significantly more 
consistent distance measured between the Met-Arg suggesting that the Arg may stabilize 
the Met residue in its more solvent exposed conformation.  
A possible ramification of this putative conformational change is that it may expose 
the polymorphic methionine residue to oxidative molecules during apo(a) biosynthesis in 
hepatocytes or within the plasma. Indeed, using MALDI-TOF mass spectrometry we 
determined that the I4399M variant possesses an oxidized methionine residue in its native 
form. Met(O) moieties have been implicated in the dysfunction of several other plasma 
proteins, such as apoA-I and fibronectin.37, 38 The oxidation of Met on fibronectin was 
found to profoundly alter its ability to bind collagen, despite only a small conformational 
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change of the protein. Given that lysine-independent fibrinogen binding sites have been 
identified amongst the KV and protease domains of apo(a)8, 39, it is tempting to speculate 
that the presence of the Met residue resulting from the rs3798220 SNP may influence the 
ability of the variant apo(a) to bind to fibrin in a distinct way, altering clot structure and 
potentially augmenting the pathogenic effects of Lp(a) thrombosis and fibrinolysis. 
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4.7 Supplemental Data 
4.7.1 Experimental Methods 
4.7.1.1 SDS-PAGE analysis of apo(a)-fibrinogen interaction 
Fibrinogen (Calbiochem, Mississauga, ON, Canada) at a concentration of 3mg/mL 
was mixed together with the wild type and variant apo(a) to a final apo(a) concentration of 
500nM, vortexed, and incubated for 10 mins at room temperature. Where indicated, 
samples were further subjected to centrifugation at 1000 x g for 5 min followed by 
separation of the supernatant and pellet. The samples were then prepared with the addition 
of 4X SDS reducing sample buffer and boiled for 10 min at 90°C. Samples were analyzed 
on a 4-15% SDS-PAGE gel and stained using Imperial Stain (Thermo Scientific, Waltham, 
MA, USA) for visualization of proteins 
4.7.1.2 Pulse Chase Secretion Assay 
HepG2 cells were transiently transfected with an apo(a) expression construct 
(pRK5ha.17) encoding 17 KIV repeats with and without the I4399M SNP.13 The cells were 
grown to 90% confluency and split into a 6-well plate (Sarstedt) 16 hours prior to the 
experiment. Cells were then starved for 1h with methionine- and cysteine-free DMEM 
without serum, and pulse-labelled for 1h in the same media containing 200 µCi/mL 
[S35]methionine, and chased in complete DMEM media. Media and lysates were harvested 
at 0, 30, 60, 120, 240, and 480 min intervals, after PBS washes of the cells, using cold lysis 
buffer (100mM Tris, pH 8.0, 100mM NaCl, 10mM EDTA, 1% Triton X-100, 0.1% SDS, 
100mM ε-aminocaproic acid) containing protease inhibitors. Cellular debris was removed 
from media and lysates through centrifugation, and samples were pre-cleared by incubation 
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with gelatin-agarose (Sigma) for 2h at 4°C, followed by incubation with a monoclonal anti-
apo(a) antibody overnight at 4°C. The following day, r-protein G beads (Invitrogen) were 
added to the samples and incubated for another 2h at 4°C. Samples were pelleted and 
washed twice with RIPA buffer (50mM Tris, pH 7.4, 0.15M NaCl, 1% Nonidet P- 40, 1% 
Sodium Deoxycholate, 0.1% SDS, pH 7.5) and once in TE buffer (10mM Tris, 1mM 
EDTA, pH 7.0). The pellets were then boiled for 10mins in 2X Laemmli sample buffer 
(4% SDS, 20% glycerol, 0.001% bromophenol blue, 125mM Tris, 100mM dithiothreitol, 
pH 6.8). Immunoprecipitated samples were run on 7% SDS-PAGE gels, dried, and exposed 
using autoradiography (Fujifilm). After 4 days, the screen was then imaged using a 
Molecular Imager® FX (Bio-RAD). Protein secretion rates were determined by 
densitometric analysis using Alpha View software (AlphaInnotech), and presented as a 
percentage of the maximum intensity of the pRK5ha.17 transfected sample. 
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4.7.2 Supplemental Figures 
	
Supplemental	Figure	1.1	17K	I4399M	stimulates	aggregation	of	fibrinogen.	
Fibrinogen at 3.0 mg/mL, or apo(a) at 500nM was incubated for 10 minutes at room 
temperature alone or in combination. In the case of turbid samples, debris was isolated 
using centrifugation. Samples were subjected to SDS-PAGE analysis followed by 
Imperial staining to visualize protein bands. 
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Supplemental	 Figure	 1.2	 Apo(a)	 I4399M	 variant	 does	 not	 have	 a	 different	 rate	 of	
secretion	in	HepG2	cells.	
Pulse-Chase secretion assay was performed to determine the comparative secretion rate 
of 17K I4399M. A. Representative gel images for the anti-apo(a) immunoprecipitated 
samples for time points ranging from 0-480 min for both 17K and 17K I4399M 
transfected cells. B. Densitometric analysis of the immunoprecipitated bands represented 
as a fraction of the bands present for the equivalent time points in the 17K transfected 
samples, the data represent the means ± S.E.M of three independent experiments. No 
significant differences between protein secretion rates was determined.  
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General Discussion  
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Elevated levels of Lp(a) have been identified as a causal risk factor for calcific 
aortic valve stenosis (CAVS) and coronary heart disease (CHD).1 Plasma Lp(a) levels very 
widely in the population and are primarily genetically determined.2 The major genetic 
determinant of apo(a) production is the size of the LPA gene. However, there is evidence 
that single nucleotide polymorphisms may influence LPA levels as well, and additionally 
the extent of proinflammatory oxidative modification, and pathophysiology.3 Although 
there is compelling evidence for the proatherogenic roles for Lp(a), and several studies 
indicating roles in thrombotic processes; the mechanisms by which it elicits its effects on 
the vasculature remain to be fully understood. The aim of this study was to assess the 
impact of oxidative modifications on the apo(a) component of Lp(a). In this regard, we 
evaluated the roles of the covalent oxPC modification of apo(a) KIV10 and the potential 
methionine oxidation in the protease domain arising from an I4399M polymorphism.  
The location of the of the covalent oxidized phospholipid addition to the KIV10 
domain of apo(a) was studied using a site directed mutagenesis approach of candidate 
apo(a) variants. The proinflammatory effect of the oxPL moiety was assessed with respect 
to its effect on inflammatory responses in macrophages. Investigation into the relationship 
between the lysine binding potential of apo(a) molecules and the extent of oxPC 
modification was determined using several different strong lysine binding site (sLBS) 
destabilizing mutations. In addition, the I4399M polymorphism in apo(a) was studied with 
respect to its effect on fibrin clot structure and the time required for clot lysis.  
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5.1 Lp(a)/apo(a) possesses a proinflammatory oxidized phospholipid moiety 
 Previous studies have reported the association of oxidized phospholipids with the 
apoB100 -containing lipoproteins LDL and Lp(a).4 The early studies reported a strong 
correlation between oxPL:apoB100 with carotid and femoral atherosclerosis and with 
obstructive coronary artery disease.5, 6 Since Lp(a) contains an LDL-like moiety, it is 
intuitive to hypothesize that the oxPL detected in these studies is derived from Lp(a), 
though it was not until 2008 that specific apoB100 protein classes were differentiated with 
respect to oxPL:apoB100 levels.7 Lp(a) was found to contain approximately 85% of 
lipoprotein associated oxPL, thus represents almost the entire pool of oxPL:apoB100 
measured.7 Due to the proinflammatory properties of most oxPL species, this finding 
suggests that this may represent a mechanism for the proatherogenic effects of Lp(a).8, 9 It 
is important to note that all of the studies to date  reporting the quantification of 
oxPL:apoB100 have used the E06 antiphosphocholine antibody to detect oxPC. The E06 
mouse monoclonal IgM has been thoroughly investigated and has been proven to detect 
the phosphocholine (PC) head group of oxidized phospholipids, with high specificity.10, 11 
Thus the correlation between oxPL:apoB100 and vascular diseases can be interpreted as a 
correlation between E06-reactive oxidized phospholipid molecules and inflammatory 
processes. In fact, E06 has been used to stain atherosclerotic plaques based on its ability to 
bind to atherogenic lipoproteins and apoptotic cells within an atherosclerotic lesion, 
suggesting that the antibody could be used as a biomarker for proatherosclerotic epitopes 
in vivo.12 However, due to the ability of E06 to bind oxPC in a free and covalently 
conjugated form10, it is important to take into consideration the possibility of detecting both 
non-covalent and covalently bound oxPC molecules. In the early covalent oxPL epitope 
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mapping of Lp(a)/apo(a) by Edelstein and coworkers, it was determined that E06 could act 
as an indicator of the ability of apo(a) to elicit interleukin-8 (IL-8) mRNA and protein 
expression, in an oxPL-dependent manner.8 It was determined that only E06-reactive 
proteolytically cleaved fragments of apo(a) were able to stimulate IL-8 expression. This 
was the first indication that directly associated E06-reactive apo(a) fragments with the 
ability to enhance the pro-inflammatory potential and was later investigated in a follow up 
study, however it could only be inferred that this reflected a direct effect of the oxPL 
moiety.13 The data represented in Chapter 3 is the first to report a direct effect of the 
covalent oxPL moiety on IL-8 expression in macrophages, describing clear mechanistic 
links to inflammatory signaling pathways.  
In Chapter 2, we describe the use of E06 immunoblotting to detect specific 
sequences in apo(a) that are required for the addition of covalently-linked oxPC. Evidence 
from previous studies were able to identify the covalent attachment of an oxidized 
phospholipid modification on the apo(a) component of Lp(a), as seen by E06 
immunoblotting.8 Location of the apo(a) domain containing the covalent oxPL moiety was 
addressed in the studies of Leibundgut et al. where it was determined that the KIV10 domain 
houses the E06-reactive site in apo(a).14 The use of human recombinant 17-kringle-
containing apo(a) (17K) together with variants containing systematic deletions of the C-
terminal domains of apo(a) allowed for the description of important information in the 
development of the current study. Interestingly, primate apo(a) was not able to be detected 
by E06 and was able to give insight into the sequence requirements for covalent oxPL 
binding to apo(a). Sequence analysis of several species of primate apo(a) identifies the 
major differences between the human and primate KIV10 and KV domains (see Figure 2.6).  
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Using a recombinant, minimally small version of apo(a) – represented in a 
KIV10KV (dikringle) construct – the exact amino acid linkage to the oxPL moiety was able 
to be determined (Chapter 2). By generating mutants of the KIV10 amino acid differences 
between primate and human apo(a), we were able to verify the requirement for an intact 
strong lysine binding site (sLBS) in KIV10 in order to facilitate covalent oxPC addition. 
Using the Asp56 à Ala and Trp70 à Ala variants in KIV10, which are known to destabilize 
the sLBS15, 16, we have shown that inactivation of the LBS through two different mutations 
results in a loss of E06 immunoreactivity. This result is in agreement with the data 
previously published by our group using a 17KΔLBS10 variant (contains the Asp56 à Ala 
substitution), as well as from the assessment of primate species containing Asp56 
(gorilla/cynomologous) and Trp70 (chimpanzee/rhesus monkey) polymorphisms, which 
were also unable to be detected by E06.14 Assessment of KIV10KV containing a 
conservative Asp56 à Glu mutation, similar to that in the weak lysine binding KIV7, 
showed the retention of E06 reactivity, suggesting a decrease in the ability of this mutant 
to be covalently modified by oxPC. Prior characterization of this variant in the context of 
bacterially purified KIV10, showed that this mutation remains to permit lysine binding of 
this domain, but with a 10-fold decreased affinity.17 Thus, the decrease in E06 reactivity is 
likely caused by the decrease in LBS activity. This mutant represents a useful tool that 
could aid in the description of effects of the sLBS in KIV10 without the complexity for a 
possible role for the covalent oxPC moiety on apo(a). 
There is a population of individuals who possess a natural Trp70 à Arg 
polymorphism, giving rise to a pool of Lp(a) which is unable to bind lysine.15 It would be 
interesting to assess if these individuals have “E06-negative” Lp(a), and to see if Lp(a) 
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retains a causal relationship with CHD and CAVS in these individuals. It has been noted 
that transgenic mice overexpressing a Asp56 à Ala mutation in the KIV10 domain of an 
8-kringle construct were resistant to the formation of atherosclerotic lesions.18 The lack of 
disease progression in these animals was hypothesized to be due to the lack of ability of 
apo(a) to inhibit plasminogen activation due to the loss of the sLBS in KIV10, thus 
inhibiting TGF-β activation and subsequent smooth muscle cell (SMC) proliferation and 
migration.18 However, oxPLs have been documented to play a role in stimulating SMC 
proliferation by initiating phenotypic switching in vitro and in vivo.19 As such, it is also 
possible that the lack of oxPL on apo(a) transgenic animals lacking the sLBS in KIV10 
resulted in an inability to initiate phenotypic switching in SMCs and thus, mice did not 
have the usual accelerated effects of Lp(a) on the development of atherosclerosis. The 
assessment of key components of the atherosclerotic process, that can be modulated by 
oxPL, should also be assessed in similar in vivo models. A role for the oxPC modification 
of apo(a) should be assessed in endothelial dysfunction, permeability, and lesional 
macrophage deposition in relevant atherosclerotic mouse model, as these are all critical 
initial steps of atherogenesis. However, the role for the KIV10 LBS cannot be decoupled 
from a role for the covalent oxPC adduct without the use of a novel apo(a) transgenic mouse 
lacking a covalent oxPC modification (defined in Section 5.2).  
 
5.2 Differentiating roles for the KIV10 sLBS and covalent oxPL moiety on 
apo(a) 
There have been many studies that suggest roles for the KIV10 sLBS on the 
proatherosclerotic properties of apo(a)/Lp(a), such as endothelial cell (EC) migration and 
cytoskeletal remodelling.20, 21 However, it has not been clear whether this reflects a role for 
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the sLBS per se, or on the requirement of the sLBS for oxPL addition. In Chapter 3, we 
identified   a critical role for the activation of NF-κB in the signalling pathways initiated 
by the oxidized phospholipid moiety on apo(a). The activation of NF-κB is implicated in 
chronic inflammation seen within a developing atherosclerotic plaque [reviewed in Ref. 
22]. Previously described effects of apo(a) on vascular cell phenotype in vitro have linked 
a role for the intact sLBS in KIV10 to pathways that have been known to involve NF-κB. 
For example, ECs stimulated with 17K r-apo(a) have been shown to upregulate 
cyclooxygenase-2 (COX-2) and increase prostaglandin synthesis.21 This effect was 
abrogated when the apo(a) KIV10 sLBS was eliminated by site-directed mutagenesis. The 
expression of endothelial cell adhesion molecules ICAM1, VCAM1, and E-selectin can 
also be up-regulated by a similar signalling pathway stimulated by oxPL.23 Lp(a) and 
apo(a), but not LDL, are able to initiate an increase in mRNA of these inflammatory 
markers, although roles for the KIV10 sLBS or oxPL have not yet been explored.24, 25 With 
new knowledge about the requirement of the sLBS in apo(a) for covalent oxPL addition, 
caution must now be exercised when determining roles for the lysine binding potential of 
apo(a), as elucidated with sLBS deficient mutants. Since oxPLs have a wide range of 
proinflammatory functions they may be responsible for many of the proinflammatory 
effects attributed to Lp(a), and its lysine binding potential. In order to assess a role for the 
oxPL on apo(a), while at the same time accounting for a potential role for the sLBS in 
KIV10, a variant of apo(a) that lacks oxPL but maintains lysine binding ability is required. 
The use of a KIV10 Asp56 à Glu mutant can be used in this respect as well, as we have 
determined that it maintains the ability to be covalently modified by oxPC, but has impaired 
	
 
189 
 
lysine binding potential. We have gathered these essential tools using a targeted 
mutagenesis approach as described in Chapter 2.  
The determination of the specific amino acid residue that participates in the formation of 
the oxPL adduct has been of interest since the discovery of the covalent oxPL modification 
of apo(a). In the 2003 study by Edelstein et al. the possibility of Schiff base adducts on KV 
was explored using 2,4,6-trinitrobenzene sulfonic acid (TNBSA), which modifies exposed 
lysine residues.8 It was determined that two of the six KV lysine residues, Lys12 and Lys42, 
were not able to react with TNBSA, and therefore hypothesized to be blocked by oxPL 
adducts.  However, the study by Leibundgut et al. utilized a 17KΔLys12/42 double mutant, 
in addition to several recombinant apo(a) variants lacking the KV domain (17KΔV, 
17KΔVP, and KIV5-10) and found no requirement for the KV domain amino acids in the 
addition of oxPC to apo(a).14 We reported that all of these variants maintained E06 
immunoreactivity, thus suggesting that the site of covalent OxPL addition to apo(a) does 
not occur within the KV sequence. 14 We exploited known mechanisms of reactive 
aldehyde covalent bonding by amido- and thiol-containing amino acid side chains; Schiff 
base and Michael addition reactions to generate recombinant apo(a) molecules for this 
study. We constructed several candidate mutations corresponding to substitutions in His, 
Arg and Lys residues in the context of a minimally small KIV10KV.his apo(a) truncation, 
to aid in the identification of the site of oxPL addition. Similar to the previous results from 
our group on the 17KΔLys12/42 double mutant and KV lacking apo(a) truncations 
(17KΔV, 17KΔVP, and KIV5-10), we created KV lysine mutants in the context of 
KIV10KV, thus confirming the results seen using the corresponding 17K variants. As seen 
in Table 2.2, all mutations in lysine residues studied within KIV10KV were able to be 
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detected by E06. Candidates in the KIV10 domain consisted of His à Ala mutations and 
conservative Arg à Gln mutations that were considered appropriate due to the fact that 
Arg35 is a component of the cationic cluster in the sLBS. E06 screening of these KIV10 
variants identified KIV10KVΔH33A as the only variant that did not react with E06. Since 
this variant has not been previously studied, there was no prior knowledge as to the 
structural or functional effects of the His-Ala substitution. Molecular dynamic simulations 
of this mutant showed no significant changes in the overall structure of the KIV10 domain. 
In fact, assessment of the His33 residue in the modelling of KIV10 shows no likely 
intramolecular interactions of this amino acid at all, with the nearest potential interaction 
being over 3.0Å away. The function of this variant was determined by characterizing its 
ability to bind to lysine-Sepharose, compared to the wild-type KIV10KV. As seen in 
Chapter 2, there was no apparent difference in the ability of the His33 variant to bind to 
lysine-Sepharose compared to wildtype, making the H33A variant of KIV10KV the only 
E06 non-reactive KIV10 variant that possesses a fully functional strong lysine binding site. 
The ability to separate the lysine binding function of apo(a) KIV10 from its ability to 
covalently bind to oxPL will allow for mechanistic studies on the proatherogenic effects of 
Lp(a) in the vasculature. Using a full-length apo(a) variant containing the H33A mutation 
in KIV10, we can now assess the role of the oxPL moiety on vascular cell phenotype 
compared to wild-type apo(a). In a recent study, E06 was used to block the effects of the 
oxPL on 17K r-apo(a).26 Although E06 was able to block apo(a)-mediated IL-6 and TNFα 
secretion, it required the use of molar amounts of the antibody which may not be tolerated 
by all cell types [reviewed in Ref. 27]. ECs, SMCs, and monocytes express receptors 
capable of binding to immunoglobulins, thus stimulating inflammatory activation.27, 28 
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Solid-phase IgM incubation of U937 monocyte cells was recently shown to activate NF-
κB and stimulate H2O2 production in a scavenger receptor-A dependent manner, thus 
provoking proinflammatory macrophage phenotypes.28 There is also the concern that using 
a large IgM molecule (approximately 900 kDa) may sterically block apo(a)/Lp(a) from 
binding to cellular receptors via the sLBS, which is in close proximity to the E06 binding 
site on apo(a). While using E06 IgM as a tool to study the role of the oxPL modification of 
apo(a) may not be optimal, using H33A-containing apo(a) variants compared to wild-type 
apo(a) would provide the most direct assessment of the function of the covalent oxPC 
modification of apo(a).   
It would also be interesting to generate a humanized apoB100 transgenic mouse 
model that expresses wildtype apo(a), or variants containing KIV10D56E or KIV10H33A 
mutations. These animals could be used to determine the relative contributions of the oxPC 
moiety on apo(a) versus the sLBS. The use of the described set of transgenic animals would 
result in a bona fide Lp(a) particle lacking the sLBS but containing a covalent oxPC moiety, 
as well as the reverse situation where the LBS is intact but the proinflammatory oxPC 
moiety is not present. It has already been reported that mice expressing human apo(a) have 
significantly greater risk of developing atherosclerotic lesions compared to mice 
expressing an apo(a) with a defective sLBS.18 The specific role of the oxPC moiety on 
apo(a) cannot be discerned here, as apo(a) from these mice were also unable to bind lysine 
to the same degree as wildtype apo(a) mice. The generation of recombinant apo(a) variants 
or apo(a) transgenic animals with the H33A mutation or the D56E mutation will serve as 
our most powerful tool yet in the determination of the role for the oxidized phospholipid 
moiety in the atherogenic potential of Lp(a). Introducing these human apoB/apo(a) 
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transgenic mice, on an LDLR-/- or apoE-/-, background, will allow us to study the impact of 
the oxPC and sLBS on lesion development, lipid deposition, and recruitment of various 
vascular cells. We have reported evidence for a role for the oxPC moiety in monocyte 
recruitment (Chapter 3) and a role has been determined for the sLBS in EC29, thus it would 
be interesting to profile the lesion immunohistochemically for the proportion of each cell 
type (including VSMCs, macrophages and foam cells) in the different proposed mouse 
genotypes. 
The atherogenic potential of oxPLs has been shown to results from the stimulation 
of chronic inflammation.19, 30, 31 Chapter 3 reports the specific ability of the oxPL on apo(a) 
to induce interleukin-8 mRNA and protein expression in cultured macrophage cells. There 
have been few reports of functions confirmed to be elicited by the oxPL moiety on apo(a). 
Seimon and colleagues determined that the oxPL on apo(a) had the ability to induce 
apoptosis in ER-stressed macrophages, using the same phospholipase A2 digestion 
approach that we utilized in Chapter 3.32 A role for the oxPL was also described in the 
priming of human monocytes to elicit inflammatory reponses.26 The true scope of the effect 
of the covalent oxPC modification, as well as the non-covalent oxPLs on apo(a) on the 
functions of Lp(a) have not yet been defined. Though it seems from the studies by Seimon, 
van der Valk, and our group (Chapter 3), that the covalent oxPL moiety clearly plays a role 
in the chemotaxis, apoptosis and inflammatory signalling in monocyte/macrophage cells26, 
32; roles for the oxPL component of Lp(a) has not been studied in SMCs and endothelial 
cells. Work generated from our lab has shown clear effects for the KIV10 sLBS in EC 
proliferation and migration29, permeability and contractility20, and prostaglandin 
synthesis21. These processes all potentially could arise from responses of ECs to the oxPL 
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moiety on apo(a). The KIV10 sLBS has also been shown to be involved in the migration 
of SMCs in a RhoA/ROCK dependent manner.33 It should be noted that all cell signalling 
pathways reported from our lab in both ECs and SMCs are potential upstream affectors of 
NF-κB. It is possible that the cellular receptors triggered by the oxPL moiety on the apo(a) 
component of Lp(a) elicit a universal signalling cascade culminating in the activation of 
NF-κB (and likely AP-1), thus stimulating inflammatory phenotypes in vascular cells. As 
previously mentioned, the respective roles for the sLBS and oxPL on apo(a) have not been 
explored with respect to the reported increase in EC cell adhesion molecule expression 
observed upon apo(a)/Lp(a) treatment. 24, 25  
 
5.2 Future work on the characterization of oxidized phospholipids on 
Lp(a)/apo(a) 
The association of elevated Lp(a) levels and oxPL with the increased incidence of 
CAVD and CHD as determined by E06 ELISA, suggests great functional importance of 
the covalent oxPC on Lp(a) in initiating inflammatory processes in vivo [reviewed in ref. 
33]. The work presented in Chapters 2 and 3 clearly define the structural determinants 
required for covalent oxPL addition and a functional role for the oxPL moiety on apo(a). 
This work also illuminates key questions that have yet to be answered about the association 
of atherogenic oxPLs with the atherogenic potential of Lp(a). In addition to the potential 
pathophysiological processes that the covalent oxPL moiety on apo(a) may mediate  (see 
Section 5.1), there remain a number of basic questions regarding  i) role of a functional 
lysine binding site in oxPL addition (covalent or non-covalent); ii) the source of oxPL; a 
role for cellular receptors in the covalent oxPC modification of apo(a); iii) the role and 
significance of non-covalent oxPCs that are detected on the KIV10KV r-apo(a); and iv) the 
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role of the covalent oxPC moiety in other processes mediated by Lp(a)/apo(a), such as 
vascular cell migration or macrophage Lp(a) internalization.  
Chapter 2 illuminates the importance of an intact lysine binding site in the KIV10 
domain of apo(a) in covalent OxPC modification. This may provide insights into the 
regulation and mechanism of covalent oxPL addition to apo(a). The requirement of the 
lysine binding site in KIV10 raises the possibility that the addition of oxPL (both covalent 
and non-covalent) to apo(a) may require binding to exposed lysine residues on a cellular 
ligand. It has not been determined whether intracellular apo(a) has a covalent oxPC moiety. 
In this regard, it can be hypothesized that apo(a) requires molecular docking in close 
proximity to a cellular source of oxPL, such as a cell or microsomal membrane. Our group 
previously reported that recombinant apo(a) can bind to several distinct high and low 
affinity receptors on the surface of hepatocytes with the identity of the low affinity binding 
component being plasminogen receptors.34 Owing to the structure of free apo(a) and the 
presence of a covalent oxPC moiety on plasminogen35, it is tempting to speculate that the 
binding of apo(a)/plasminogen to a plasminogen receptor may be required for covalent 
oxPC addition to apo(a)/plasminogen, through lysine binding domains. It is also unclear if 
all secreted Lp(a) molecules have a covalent oxPC on apo(a) KIV10. Understanding the 
process by which apo(a) acquires the proinflammatory lipid moiety may give insight to the 
potential for therapeutic options aimed at decreasing the atherogenic potential of Lp(a) 
through blocking the covalent OxPL modification.  
Lp(a)/apo(a) has been documented to interact with a plethora of cellular receptors 
that may contribute to the pathophysiological functions of Lp(a). However, the nature of 
the interaction of apo(a) with several of these receptors is unclear. In Chapter 3 of this 
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thesis and in the work of Seimon et al., the effects of apo(a) on macrophage inflammation 
and apoptosis were proposed to be initiated by the binding of the covalent oxPC moiety to 
the lipid specific receptor CD36 and to toll-like receptors 2, 4, and 6.32 Each of these 
receptors are expressed at varying levels, and has the potential for different effects on 
different vascular cell types.36 An investigation into the major apo(a) oxPC receptor and 
the downstream effects on inflammatory processes is a vital step in determining the 
contribution of the covalent oxPC moiety on apo(a) to the role of Lp(a) in atherosclerosis. 
In the same way a role should be defined for the non-covalent oxPL species associated with 
KIV10KV that were observed by lipid extraction of apo(a) as reported in Chapter 2. To 
study potential roles for non-covalent oxPC in the inflammatory properties of apo(a), first 
the effect of the covalent oxPC must be defined using a H33A apo(a) variant. E06 
pretreatment of the H33A variant of apo(a) may give an additional decrease in the 
pathogenic potential of apo(a), this would infer proinflammatory roles for the non-covalent 
oxPC on apo(a). The initial study identifying Lp(a) as an E06-reactive lipoproteins (as 
quantified by sandwich ELISA) reported temporal changes in the amounts of oxPL 
detected as a function of the amount of time elapsed post-MI4; this trend was also reported 
with respect to plasminogen-associated oxPL.35 It has been proposed that Lp(a) might act 
as a scavenger of oxPL in these cases, picking up excess oxidized material generated as a 
product of the acute phase reactants PLA2 and platelet activating factor-acetylhydrolase.37 
It would be interesting to quantify and profile the different non-covalent oxPL species 
associated with Lp(a) from humans with different disease states (ie/ CAVS, myocardial 
infarction (MI), CHD, etc.). In this way we can further understand the roles for the non-
covalent oxPL associated with Lp(a) and potentially use these profiles to predict disease 
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risk. It was also recently reported that Lp(a) can transport autotaxin (ATX) and oxPL to 
mineralized aortic valves, thus contributing to the development of calcific aortic valve 
disease.38 It is possible that the affinity of ATX for the oxPL on Lp(a) facilitates the ATX-
Lp(a) interaction, this remains to be further investigated.  
Due to the proximity of the covalent oxPC moiety on Lp(a)/apo(a) to the sLBS, it 
would be interesting to see if loss of the oxPC on KIV10 could alter the function of 
Lp(a)/apo(a) in non-inflammatory processes. Roles for Lp(a) in the inhibition of 
fibrinolysis have been largely determined to be dependent on the lysine binding activity of 
apo(a).40-42 Since we currently do not know if 100% of plasma Lp(a) particles contain 
covalent oxPC, it is possible that there is a pool of Lp(a) that lacks covalent oxPC; this 
population may have an altered affinity for fibrin or plasmin modified fibrin. In a study on 
the covalent oxPC on plasminogen, it was determined that the oxPC on plasminogen was 
required for optimal clot lysis, as enzymatic removal of the oxPC resulted in a 30% 
decrease in clot lysis.35 It has yet to be determined, however,  if the oxPC on plasminogen 
has a role in fibrin binding in the context of plasminogen activation or in the proteolytic 
activity of plasmin.43 It can be hypothesized that if there is a pool of Lp(a) lacking a 
covalent oxPC modification, there may be a difference in the affinity of this Lp(a) for 
fibrin, thus potentially altering the effects of Lp(a) on the coagulation and/or fibrinolytic 
systems. Variants of apo(a) that possess lysine binding potential but lack an oxPC moiety 
might be interesting to assess in the context of plasminogen activation, binding, as well as 
the formation of the apo(a)/plasminogen/tPA/fibrin complex, in vitro. 
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5.4 Roles for Lp(a)/apo(a) in thrombotic and fibrinolytic processes 
 Due to the high degree of sequence similarity between apo(a) and plasminogen, and 
the lack of a functional serine protease domain (PD) in apo(a), it has been hypothesized 
that the pathogenicity of Lp(a) may stem from its ability to interfere with plasminogen in 
vivo. It has been previously reported that Lp(a)/apo(a) can bind to plasminogen41, fibrin 
and partially degraded fibrin.40 It has been shown that apo(a) can compete with 
plasminogen for the exposed lysine residues on fibrin, thus decreasing the ability of 
plasmin to be generated thereby reducing clot dissolution. Chapter 4 describes a role for 
the fibrin binding ability of a polymorphic form of apo(a) that results in alterations in the 
structure of clots, as well as a decrease in the ability of clots to be lysed.  
 The role for Lp(a)/apo(a) in thrombotic disorders has been thought to be largely 
dependent on the ability of Lp(a) to inhibit plasminogen activation and fibrinolysis. This 
work has been extensively investigated by our group in in vitro models, yielding the 
conclusion that apo(a) can inhibit plasminogen activation on the surface of fibrin and 
partially degraded fibrin.40, 44 It was further concluded that the robust inhibitory potential 
of apo(a) on plasminogen activation is due to the ability of apo(a) to participate with 
plasminogen, tPA, and fibrin in the formation of a quaternary complex that has a decreased 
turnover rate compared to complexes lacking apo(a).44 A later study concluded that apo(a) 
also inhibits this process by decreasing the extent of conversion of Glu-plasminogen to the 
more readily activatable Lys-plasminogen on the fibrin surface.45 However, there have 
been reports in vivo of apo(a) promoting coaguability in a plasminogen-independent 
manner. An increase in thrombotic potential was reported in a transgenic mouse model 
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overexpressing apo(a) on a Plg-/- background.46 This strongly suggests that apo(a) can have 
a direct effect on thrombotic processes.  
The role for Lp(a) in “purely thrombotic” disorders, such as venous 
thromboembolism (VTE), has been a controversial topic for many years [reviewed in ref. 
48].  There has been a significant body of in vitro data suggesting thrombotic roles for 
Lp(a). However, there has been limited progress on identifying a direct role for Lp(a) in 
thrombotic disorders within human population studies. A study from our group suggests 
roles for Lp(a)/apo(a) in platelet aggregation and granule release in the presence of the 
thrombin receptor activating peptide SFLLRN.49 Conversely, Lp(a) was shown to decrease 
the aggregation of platelets in the presence of platelet-activating factor50 and collagen; this 
may be due the ability of Lp(a) to directly bind to the latter two substrates.51, 52 The 
involvement of Lp(a) in platelet stimulation would occur in the context of the arterial 
system, where the prominent atherosclerotic potential of Lp(a) could be considered a major 
contributing factor to thrombotic disease progression, and thus may increase the 
atherogenic property of Lp(a). The roles for Lp(a) in thrombotic processes in the milieu of 
fibrin-rich and platelet poor venous blood are contradictory and inconclusive. Initial studies 
on the topic reported that Lp(a) is an independent risk factor for VTE.53-56 However, recent 
large population studies appear to show no causal relationship between Lp(a) and VTE.57, 
58  
Chapter 4 contains data showing that purified fibrin clots can form at an increased 
rate, and that the maximum turbidity of these clots containing 17K I4399M apo(a) is greater 
than that of clots formed in the absence of apo(a) or with 17K. It is generally accepted that 
more turbid clots (as measured by increased maximal absorbance) are associated with 
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thicker fibrin fibrils that result in an altered clot architecture [reviewed in ref. 46]. We 
report that clots with thicker fibrin fibers have prolonged lysis times. This contradicts the 
existing paradigm that thicker fibrin fibers result in a “loose” clot that is susceptible to 
lysis. However, assessment of clot structure and real-time lysis by microscopy has revealed 
that thinner fibers tend to lyse more rapidly, and this process may be obscured when 
assessing lysis by decreased turbidity at A405 nm; this may be attributable to the increased 
turbidity in the presence of thicker fibrin fibrils.47 It can also be noted that alterations in 
fiber thickness are associated with variations in the ability to generate thrombin, thus 
limiting the rate of clot formation, a factor not relevant in the context of our assays using 
purified components. The presence of thicker fibrils seen in the polymorphic clots in 
Chapter 4 using SEM assessment of plasma and especially purified fibrin clots, suggests 
that the increased fiber thickness is due to the I4399M polymorphism exclusively in the 
purified fibrin system and due to the presence of Lp(a) in the context of plasma, with 
additional increase in fiber thickness seen in plasma clots from a rs3798220 homozygote. 
The results suggest distinct and additive effects of this polymorphism on fibrin clots, above 
the effects of Lp(a) alone.  
It has been reported that the rs3798220 single nucleotide polymorphism is 
associated with increased plasma Lp(a) concentrations and increased levels of CHD.59 This 
variant results in a missense mutation in the inactive protease-like domain of apo(a), 
resulting in an Ile à Met substitution at the 4399 amino acid position. This variant has also 
been correlated with smaller apo(a) isoforms and increased CAD severity.60 The I4399M 
polymorphism has also been shown to be correlated with reduced clot permeability and 
increased clot lysis times in vitro.61 However, there was a significant influence of patient 
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ethnicity in the effect of the I4399M polymorphism on clot permeability and lysis which 
complicated the study.61 
Chapter 3 clearly identifies distinct properties of the I4399M polymorphism in 
assays using clots formed from purified components. In this context, 17K r-apo(a) 
containing the Met polymorphism (17K I4399M) had an increased ability to inhibit 
fibrinolysis compared to clots formed in the presence of wild-type 17K apo(a). Assessment 
of the ability of 17K and 17K I4399M to inhibit plasmin formation revealed no difference 
between their ability to inhibit this process. It is important to note that our plasmin 
generation assay looks directly at the cleavage of Glu-plasminogen to Glu-plasmin by tPA, 
and is not complicated by the positive feedback mechanism in which plasmin converts Glu-
plasminogen to Lys-plasminogen. Apo(a) has been shown to have a direct inhibitory effect 
on Glu- to Lys-plasminogen conversion on the fibrin surface, thus enhancing the 
antifibrinolytic role of apo(a) in systems that generate functional plasmin.45 Since we 
observed no distinct ability of the 17K I4399M variant to inhibit plasmin generation, but 
an increased ability to prolong fibrinolysis; it is possible that the conformational change in 
the protease domain to this SNP may have an effect on Glu- to Lys-plasminogen 
conversion. It has been proposed that the protease domain of apo(a) may influence the 
positive feedback mechanisms of plasminogen activation in the context of pericellular 
plasminogen activation62, but a specific role for the PD in this process has not yet been 
investigated. 
Apo(a) has also been shown to directly compete with plasminogen for the binding 
of fibrin and partially degraded fibrin.41 The effect of the I4399M polymorphism was not 
assessed on these processes. It is possible, however, that investigation of the affinity of the 
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apo(a) I4399M variant for fibrin surfaces compared to wild-type apo(a) or plasminogen 
might offer mechanistic information about the effect of the I4399M polymorphism on clot 
formation and lysis. Indeed, molecular dynamic simulation analysis indicates that 
introduction of Met4399 disrupts the native conformation of the inactive protease domain 
of apo(a). The shift in structure from a buried Ile residue to a solvent exposed Met residue 
illuminates a novel surface epitope on apo(a) that requires characterization in the context 
of the pathophysiological processes of Lp(a). A lysine- independent binding interface 
between apo(a) and fibrinogen has been previously described to be outside of the KIV10 
domain, likely in the region spanning KV-PD.63, 64 It should be investigated if apo(a) 
variants lacking the protease domain or containing the I4399M variant of apo(a) can 
interact with fibrinogen in this way. The identification of a methionine sulfoxide (Met(O)) 
residue at the Met4399 offers added complexity to this idea. Oxidation of methionine 
residues is currently under intense investigation as a mechanistic switch in many 
physiological processes involved in thrombosis and vascular function [reviewed in ref. 64]. 
Since there was no peptide detected in our mass spectrometric study with a native 
methionine residue it can be inferred that the Met4399 residue is irreversibly oxidized. 
However, this remains to be verified experimentally. Methionine sulfoxide reductases have 
been shown to reduce Met(O) residues on plasma Apo A-I, thrombomodulin and von 
Willebrand factor thereby modulating their functions in different disease states.65 
Fibronectin has been shown to exhibit a minute conformational change upon oxidation, 
although the oxidation of a specific methionine in this context can completely abolish the 
ability of fibronectin to bind to its ligand collagen.66 
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 The assessment of human plasma samples homozygous for the I4399M 
polymorphism revealed that this variant of apo(a) can cause increased fibrin fibril 
thickness, in agreement with results observed using clots formed from purified components 
in the absence or presence of apo(a) – additive to the effects observed by elevated plasma 
Lp(a) alone. This suggests independently that there may be a CVD risk for carriers of this 
polymorphism, regardless of their Lp(a) plasma levels.  
The implications of the I4399M variant on thrombotic disorders are difficult to 
assess in the human population owing to the low frequency of this variant. In order to 
understand the degree of CVD risk by the I4399M variant of apo(a) in disease, a much 
larger data set containing a greater subpopulation of rs3798220 carriers needs to be 
assessed, accounting for Lp(a) plasma concentrations and controlled for isoform size. In 
vitro studies looking at the role of the I4399M variant of apo(a) in clot formation and lysis 
can be expanded to explore the possibility of altered Glu- to Lys-plasminogen conversion 
or fibrin binding affinity associated with this variant.  Due to the ability of aspirin to have 
an effect on fibrin clot structure and lysis67, studies should include a determination to the 
potential benefits of aspirin therapy in a more diverse group of individuals with the I4399M 
polymorphism, that are not seen in those with elevated Lp(a) who lack this polymorphism. 
 
5.5 Closing remarks 
 This study outlines defined roles for oxidative modifications on apo(a) in the 
context of the prothrombotic and proatherogenic potential of Lp(a)/apo(a). Identification 
of Lp(a) as a causal risk factor for vascular diseases has sparked interest in the development 
for potential therapeutics that are directed at lowering plasma Lp(a) levels. The 
	
 
203 
 
development of therapeutic options that counteract the effects of the oxidative 
modifications on Lp(a) can potentially benefit those with elevated Lp(a). New therapeutic 
strategies aimed at lowering plasma Lp(a) levels through the use of PCSK9 monoclonal 
antibodies can lower Lp(a) levels by approximately 30%.68 There may be a benefit to 
additional aspirin therapy in individuals carrying the rs3798220 SNP, as some individuals 
will have clinically elevated Lp(a), despite anti-PCSK9 intervention. With the potential for 
oxidative modification of Lp(a) causing distinct effects on atherothrombotic processes, 
antioxidant therapy could be used prophylactically, to help abrogate the effects caused by 
other risk factors that can generate ROS. There have been reports of eicosapentaenoic acid 
having preventative effects on the oxidation of apoB-containing lipoprotein particles, when 
used in combination with triglyceride lowering therapies.69 Treatment options preventing 
the proinflammatory effects of Lp(a) on the vasculature should be explored in individuals 
with elevated plasma levels, especially when considering individuals who are prone to 
elevated levels of reactive oxygen species in the plasma, such as individuals who smoke or 
suffer from insulin resistance.  
The development of potent Lp(a) lowering agents, such as antisense 
oligonucleotides (ASOs) targeting apo(a), will be key to improving the outcome of 
individuals with elevated Lp(a). Apo(a)-ASO therapy has been shown to lower Lp(a) levels 
by >80%, in a Phase 1 clinical trial.70 Targeted anti-apo(a) ASO therapy will allow for the 
assessment of causal roles for Lp(a) in processes where is it difficult to determine if there 
is a causal role, as seen in the controversial studies on plasma Lp(a) levels and VTE. 
Ultimately, only by the robust lowering of plasma Lp(a), that has only been seen in the 
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early clinical trials of ASO therapy, can we begin to determine the true benefit of specific 
Lp(a) lowering on cardiovascular disease outcome.  
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Thank you for your time,
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---
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